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GloSSaRy
Acute infection: the period in which an individual becomes HIV-infected and before HIV 
antibodies can be detected by a serological assay (1). 
Analyte: a substance or chemical constituent that is analysed, generally referring to a 
component of blood or another bodily fluid. In the context of HIV, analytes include HIV p24 
antigen and HIV-1/2 antibodies.
Assay: a complete procedure for detecting the presence of or the concentration of an 
analyte, including all the components of a test kit used to identify HIV p24 antigen or 
HIV-1/2 antibodies.
Biological surveillance: the collection and use of biological markers to inform 
surveillance, in this context, HIV surveillance systems. This term is replacing the term 
serosurveillance because biological specimens other than serum are increasingly being 
collected routinely. 
Concentrated epidemic: HIV has spread rapidly in a defined subpopulation (such as men 
who have sex with men, sex workers, transgender people, people who use drugs or people 
in prison or other closed settings) but is not well established in the general population. 
This type of epidemic suggests that there are active networks of people with high risk 
behaviours within the subpopulation. The future course of the epidemic is determined by 
the nature of the links between subpopulations with a high HIV prevalence and the general 
population. Numerical proxy: HIV prevalence is consistently over 5% in at least one defined 
subpopulation but is below 1% in pregnant women attending antenatal clinics. 
Confirmed: to issue an HIV status, initially reactive test results need to be confirmed 
according to the national validated testing algorithm. 
Decentralization: the process of delegating or transferring significant authority and 
resources from the central ministry of health to other institutions or to field offices of the 
ministry at other levels of the health system (provincial, regional, district, subdistrict, 
primary health-care post and community). 
Early infant diagnosis: testing of infants to determine their HIV status, given that HIV 
can be acquired in utero (during pregnancy), peripartum (during delivery), postpartum 
(through breastfeeding) or via parenteral exposure (2).
Eclipse period: the period between HIV infection and detection of virological markers, 
such as HIV RNA/DNA or HIV p24 antigen (1).
External quality assessment (EQA): inter-laboratory comparison to determine if the HIV 
testing service can provide correct test results and diagnosis.
Generalized epidemic: HIV is firmly established in the general population. Although 
subpopulations at high risk may contribute disproportionately to the spread of HIV, sexual 
networking in the general population is sufficient to sustain the epidemic. Numerical 
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proxy: HIV prevalence is consistently over 1% in pregnant women attending antenatal 
clinics.
HIV status: a collection of results from one or more assays. An HIV status is similar to HIV 
diagnosis. It refers to reports of HIV-positive, HIV-negative or HIV-inconclusive, whereas 
HIV diagnosis generally refers to HIV-positive diagnoses and in some cases HIV-negative 
diagnoses.  
HIV test result: the result from a single test on a given assay. 
Index testing: a focused approach to HIV testing in which the household and family 
members (including children) of people diagnosed with HIV are offered HIV testing 
services; also referred to as index case HIV testing (3). 
Indicator condition-guided HIV testing: a focused approach to test people more likely 
to be infected with HIV who are identified through indicator conditions, such as STIs, 
lymphoma, cervical or anal neoplasia, herpes zoster and hepatitis B/C. These conditions 
occur more frequently in HIV-infected people than in uninfected people, either because 
they share a common mode of transmission with HIV or because their occurrence is 
facilitated by the characteristic immune deficiency associated with HIV infection (4).
Integration: the co-location and sharing of services and resources across different disease 
areas. In the context of HIV, this may include the provision of HIV testing, prevention, 
treatment and care services alongside other health services, such as TB, STI or viral 
hepatitis services, antenatal care (ANC), contraceptive and other family planning services 
and screening and care for other conditions, including noncommunicable diseases.
In vitro diagnostic (IVD) medical device: a medical device, used alone or in combination, 
intended by the manufacturer for the examination of specimens derived from the human 
body solely or principally to provide information for diagnostic, monitoring or compatibility 
purposes. For example, IVDs can be used for the following test purposes: diagnosis, 
screening, monitoring, predisposition, prognosis, prediction, determination of physiological 
status. Examples of IVDs include reagents, calibrators, control materials and specimen 
receptacles (5).
Key populations: Defined groups who, due to specific higher-risk behaviours, are at 
increased risk for HIV irrespective of the epidemic type or local context. These guidelines 
refer to the following groups as key populations: men who have sex with men, people who 
inject drugs, people in prisons and other closed settings, sex workers and transgender 
people. 
Lay provider: any person who performs functions related to health-care delivery and has 
been trained to deliver specific services but has not received a formal professional or 
paraprofessional certificate or tertiary education degree (6).
Multi-analyte testing: similar to multiplex testing (see “Multiplex testing”), the term 
refers to the use of the same platform to test for different analytes with different sets of 
reagents, typically using more than one specimen (7).
Multiplex testing: testing a single specimen with one test device for more than one 
analyte, for example, a single test device that detects HIV-1/2 antibodies and antibodies to 
Treponema pallidum (syphilis) (7).
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Negative predictive value: the probability that a person with a negative test result is 
not infected with HIV, that is, “true negative”(8).
Non-reactive test result: a test result that does not show a reaction indicating the 
presence of analyte. 
Nucleic acid testing (NAT): also referred to as molecular technology, for example, 
polymerase chain reaction (PCR) or nucleic acid sequence-based amplification (NASBA). 
This type of testing can detect very small quantities of viral nucleic acid, that is, RNA, DNA 
or TNA, qualitatively and quantitatively (9).
Pre-test information: a dialogue and the provision of accurate information by a trained 
lay provider or health worker before an HIV test is performed (10).
Positive predictive value: the probability that a person with a positive test result is 
infected with HIV, that is, “true positive”(8).
Quality assurance (QA): a part of quality management focused on providing confidence 
that quality requirements will be fulfilled (11).
Quality control (QC): a material or mechanism which, when used with or as part of a test 
system (assay), monitors the analytical performance of that test system (assay). It may 
monitor the entire test system (assay) or only one aspect of it (11).
Quality improvement (QI): a part of quality management focused on increasing the 
ability to fulfil quality requirements (11).
Quality management system: a system to direct and control an organization with 
regard to quality.
Reactive test result: a test result that shows a reaction to indicate the presence of 
analyte. 
Repeat testing: refers to a situation where additional testing is performed for an 
individual immediately following initial test results, within the same testing visit, using the 
same assays and, where possible, the same specimen (12).
Retesting: There are certain situations in which individuals should be retested after a 
defined period of time: (1) HIV-negative people with recent or on-going risk of exposure, 
(2) people with an HIV-inconclusive status and (3) HIV-positive people before they enrol in 
care or initiate treatment. Reasons for retesting before initiation of care or treatment 
include ruling out laboratory or transcription error and either ruling in or ruling out 
seroconversion (12, 13).
Rapid diagnostic test (RDT): in vitro diagnostic of immunochromatographic or 
immunofiltration format for, in the case of HIV diagnosis, the detection of HIV-1/2 
antibodies and/or HIV p24 antigen (8, 9).
Self-testing (HIVST): a process in which an individual who wants to know his or her HIV 
status collects a specimen, performs a test and interprets the result by him- or herself, often 
in private. Reactive test results must be followed by additional HIV testing services (14).
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Sensitivity: denotes the probability that an HIV assay will correctly identify all specimens 
that contain HIV-1/2 antibodies and/or HIV p24 antigen (12).
Sentinel surveillance: a type of surveillance that is conducted through selected sites 
among populations of particular interest or that may provide approximations of prevalence 
for a larger population, for example, in antenatal clinics (8, 15).
Seroconversion: when an individual first produces a quantity of HIV antibodies sufficient 
to be detectable on a given HIV serological assay (12). 
Serodiscordant couple: a couple in which one partner is HIV-positive and one partner is 
HIV-negative (16).
Serological assay: an assay that detects the presence of antibodies in human specimens, 
typically serum or plasma but also capillary/venous whole blood and oral fluid. RDTs, 
immunoassays (including EIAs, CLIAs, ECLs) and certain supplemental HIV assays are 
examples of serological assays (9).
Specificity: denotes the probability that the assay will correctly detect specimens that do 
not contain HIV-1/2 antibodies and/or HIV-1 p24 antigen.
Supplemental assay: an assay that provides additional information for specimens that a 
first-line assay has found to be reactive but may not be able to definitively confirm that 
reactivity.
Task sharing: the rational redistribution of tasks between cadres of health-care providers 
with longer training and other cadres with shorter training, such as trained lay providers 
(6, 17).
Test for triage: a community-based HIV testing approach involving trained and supported 
lay providers conducting a single HIV RDT. The lay providers then promptly link individuals 
with reactive test results to a facility for further HIV testing and to an assessment for 
treatment. Individuals with non-reactive test results are informed of their results, referred 
and linked for appropriate HIV prevention services and recommended for retesting 
according to recent or on-going HIV risk and national guidelines (18).
Testing algorithm: the combination and sequence of specific assays used within HIV 
testing strategies (12).
Testing strategy: generically describes a testing sequence for a specific objective, taking 
into consideration the presumed HIV prevalence in the population being tested (19).
Throughput: the number of specimens per hour per operator that can be tested by an 
assay; the volume of clients that come through a facility, laboratory or other community-
based settings.
Verified: people diagnosed HIV-positive are retested and their HIV diagnosis is verified 
before they initiate care or treatment.
Window period: the period between HIV infection and the detection of HIV-1/2 
antibodies using serological assays, which signals the end of the seroconversion period.
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ExECuTIVE SummaRy 
Purpose 
Countries, programme managers, health workers and other stakeholders have indicated 
the importance of consolidating World Health Organization (WHO) guidance for HIV 
testing services (HTS). Thus, this guidance brings together existing guidance relevant to 
the provision of HTS and addresses issues and elements for effective delivery of HTS that 
are common in a variety of settings, contexts and diverse populations. In addition, this 
document provides a new recommendation to support HTS by trained lay providers, 
considers the potential of HIV self-testing to increase access to and coverage of HIV 
testing, and outlines focused and strategic approaches to HTS that are needed to 
support the new UN 90–90–90 global HIV targets – the first target being diagnosis of 
90% of people with HIV (20). Moreover, this guidance will assist national programme 
managers and service providers, including those from community-based programmes, in 
planning for and implementing HTS. 
These guidelines aim to: 
•	 provide comprehensive evidence-based recommendations for HTS; 
•	 support testing by trained lay providers to increase access to HTS through community-
based approaches; 
•	 offer guidance to countries to deliver a mix of HTS approaches appropriate to their 
epidemic context, focusing on HTS for groups most affected and currently undiagnosed 
and underserved; 
•	 provide guidance to ensure the accuracy of test results and support improvement of the 
quality of HTS; 
•	 catalyse greater national and global commitment to the provision of effective HTS as a 
key element of comprehensive HIV programmes, with better linkage to prevention, 
treatment and care, to reduce HIV incidence, morbidity and mortality.
These guidelines discuss issues relating to HTS and highlight the need for tailored HTS 
approaches to the following population groups:
•	 key populations1 
•	 infants 
•	 children 
•	 adolescents (10–19 years old) 
•	 pregnant and postpartum women
•	 couples and partners.
1 In this document key populations are defined as the following groups: men who have sex with men, people in prison or other closed 
settings, people who inject drugs, sex workers and transgender people. For further guidance on key populations, see Consolidated 
guidelines on HIV prevention, diagnosis, treatment and care for key populations (http://www.who.int/hiv/pub/guidelines/keypopulations).
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During global meetings and consultations in 2015, stakeholders advised WHO to 
consider developing a term, in place of “HIV testing and counselling”, that encompasses 
the full range of services available. The Guideline Development Group discussed this and 
agreed that HIV testing services should be used.  
definition: HIV testing services
Throughout these guidelines the term HIV testing services (HTS) is used to 
embrace the full range of services that should be provided together with HIV 
testing – counselling (pre-test information and post-test counselling); linkage 
to appropriate HIV prevention, treatment and care services and other clinical and 
support services; and coordination with laboratory services to support quality 
assurance and the delivery of correct results. The WHO 5 Cs are principles that 
apply to all models of HTS and in all circumstances (see section 1.7).
Guideline development methodology
The WHO HIV Department led the development of these guidelines along with a WHO 
Guideline Steering Group and a Guideline Development Group of external experts. 
The WHO Guideline Steering Group proposed that the consolidated HTS guidelines provide 
a synthesis of current recommendations on approaches to delivering HTS, including 
pre-test and post-test services and messaging, HIV diagnosis, quality assurance of HIV 
testing, HIV diagnosis in the context of surveillance and the monitoring and evaluation of 
HTS. The Group determined that guidelines on HTS developed prior to WHO's adoption of 
the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 
process were still valid, as these were supported by evidence and widely implemented. For 
example, although provider-initiated testing and counselling (PITC) was recommended in 
2007, the Group determined that this widespread and evidence-based intervention (21, 22) 
did not require additional review or revisions. However, the Group did propose that the 
guidelines create a framework to assist countries in selecting a mix of HTS approaches and 
include a new recommendation for trained lay providers to conduct HIV testing services, 
using rapid diagnostic tests (RDTs). 
In late 2014 the WHO Guideline Steering Group formed a Guideline Development Group 
comprising a geographically and gender-balanced group of academics, researchers, 
programme managers, implementers and people from community networks and 
organizations. From January through March 2015, WHO convened a series of virtual 
guideline development meetings to review the compilation of previous WHO guidelines 
related to HTS, appraise the evidence for formulating a new recommendation on HIV 
testing by lay providers using RDTs and to review all sections of the consolidated 
guidelines. Following these meetings external peer reviewers, UN agency reviewers and 
WHO staff members from the Department of HIV as well as other WHO departments and 
regional teams reviewed the draft consolidated HTS guidelines.
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Recommendations 
Table 1 summarizes the recommendations presented in this document. All 
recommendations and guidance in the document derive from existing WHO guidance, 
with the exception of the new recommendation on HIV testing by trained lay providers. 
The new recommendation on HIV testing by trained lay providers is in line with existing 
WHO recommendations that support task sharing in the health sector. The Guideline 
Development Group, using the GRADE process, assessed the quality of the available 
evidence as moderate. Based on this evidence the group made a strong recommendation 
that trained lay providers, using RDTs, can perform HIV testing.
Guidance from the WHO/UNAIDS Working Group on Global HIV/AIDS and STI 
Surveillance is included in this document (Chapter 9). This guidance suggests that 
countries and programmes use the currently recommended diagnostic testing strategy 
for HIV surveillance, make use of programmatic data for surveillance when possible – 
particularly in prevention of mother-to-child transmission programmes – and that 
programmes should encourage and move toward the return of test results to participants 
in surveillance studies.
Implications for programming
Public health considerations underlie the need to prioritize and improve access to 
accurate, high-quality HTS for diverse populations and settings. These guidelines aim to 
support countries to provide more effective and acceptable HTS as part of their HIV 
programmes. They also aim to expand coverage strategically in areas and among 
populations in greatest need, to increase access to services, to improve the quality of 
testing services and to help to achieve global targets – particularly the new UNAIDS 
target of diagnosing 90% of all people with HIV by 2020. To accomplish this, countries 
will need to assess their specific situations and take into account their epidemiological 
context and the populations most in need in their settings. It is also important to assess 
and, as much as possible, to address social and legal barriers to access as well as issues 
concerning the quality of health services. 
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Table 1. Summary of wHo recommendations on HIV testing services
Approach Recommendations
Chapter 2 and Chapter 4: New recommendation
HIV testing by trained 
lay providers using rapid 
diagnostic tests (RDTs)
Lay providers who are trained and supervised can 
independently conduct safe and effective HIV testing 
using RDTs (strong recommendation, moderate quality of 
evidence).
Chapter 3: Pre-test and post-test services
Disclosure
WHO (2010). Guideline on 
HIV disclosure counselling for 
children up to 12 years of age 
(http://www.who.int/hiv/pub/
hiv_disclosure/en/).
Initiatives should be put in place to enforce privacy 
protection and institute policy, laws and norms that 
prevent discrimination and promote tolerance and 
acceptance of people living with HIV. This can help create 
environments where disclosure of HIV status is easier (strong 
recommendation, low quality of evidence).
Retesting
WHO (2010). Delivering HIV 
test results and messages for 
re-testing and counselling in 
adults
(http://www.who.int/hiv/pub/
vct/hiv_re_testing/en/index.
htm).
All settings
It is recommended to offer retesting at least annually to 
people from key populations and to HIV-negative partners in 
serodiscordant couples. Depending on client risk behaviours, 
more frequent voluntary retesting should be offered and 
available.
Generalized HIV epidemic
Retest all HIV-negative pregnant women in the 3rd trimester, 
postpartum or during labour because of the high risk of 
acquiring HIV infection during pregnancy.
Concentrated HIV epidemic
Retest HIV-negative pregnant women who are in 
serodiscordant couples or are from a key population group.
Retesting before ART 
initiation
WHO (2014). WHO reminds 
national programmes to retest 
all newly diagnosed people 
with HIV
(http://www.who.int/hiv/pub/
vct/retest-newly-diagnosed-
plhiv-full/en/).
National programmes should retest all people newly and 
previously diagnosed with HIV before they enrol in care and 
initiate ART.
Retesting people on ART is not recommended, as there are 
potential risks of incorrect diagnosis, particularly for in vitro 
diagnostics (IVDs) that use oral fluid specimens.
Chapter 4: Service delivery
Provider-initiated testing 
and counselling (PITC)
WHO (2007). Guidance on 
provider-initiated HIV testing 
and counselling in health 
facilities
(http://www.who.int/hiv/pub/
vct/pitc/en/index.html).
Generalized HIV epidemic
PITC should be offered for: all clients and in all services 
(including services for sexually transmitted infection (STI), 
viral hepatitis, tuberculosis (TB), children under age five, 
immunization, malnutrition, antenatal care and all services 
for key populations) as an efficient and effective way to 
identify people with HIV.
Concentrated HIV epidemic 
PITC should be offered for clients (adults, adolescents and 
children) in clinical settings who present with symptoms 
or medical conditions that could indicate HIV infection, 
including presumed and confirmed TB cases.
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Approach Recommendations
Provider-initated testing 
and counselling (continued)
Regardless of epidemic type
PITC should be considered for malnutrition clinics, STI, 
hepatitis and TB services, ANC settings and health services 
for key populations. 
For TB settings: routine HIV testing should be offered to 
all clients with presumptive and diagnosed TB; partners of 
known HIV-positive TB patients should be offered HTS with 
mutual disclosure (strong recommendation for all people 
with HIV in all general HIV epidemic settings); and TB-control 
programmes should mainstream provision of HTS in their 
operations and routine services.
Community-based HIV 
testing services
WHO (2013). Consolidated 
guidelines on the use of 
antiretroviral drugs for 
treating and preventing HIV 
infection 
(http://www.who.int/hiv/pub/
guidelines/arv2013/download/
en/index.html).
Generalized HIV epidemic
WHO recommends community-based HIV testing services, 
with linkage to prevention, treatment and care services, 
in addition to routinely offering PITC for all populations, 
particularly key populations (strong recommendation, low 
quality of evidence).
Concentrated HIV epidemic
WHO recommends community-based HIV testing services, 
with linkage to prevention, treatment and care, in addition 
to PITC, for key populations (strong recommendation, low 
quality of evidence).
Chapter 5: Priority populations
Infants and children 
WHO (2010). WHO 
recommendations on the 
diagnosis of HIV infection in 
infants and children
(http://www.who.int/hiv/pub/
paediatric/diagnosis/en/). 
WHO (2011). Guideline on 
HIV disclosure counselling for 
children up to 12 years of age 
(http://www.who.int/hiv/pub/
hiv_disclosure/en/).
•	HIV-exposed infants and children younger than 18 months 
with unknown or uncertain HIV exposure should be tested 
(with a virological assay) within 4–6 weeks of birth so that 
those presumptively diagnosed with HIV can start ART 
(strong recommendation, high quality of evidence).
•	HIV-exposed infants with non-detectable NAT at 4–6 
weeks should undergo HIV serological testing at 
around nine months of age (or at the time of the last 
immunization visit) to rule out HIV infection. Infants whose 
serological assays are reactive at nine months should 
undergo virological testing to rule in HIV infection (strong 
recommendation, low quality of evidence).
•	Children of school age (6–12) should be told their HIV-
positive status and their parent’s or caregiver’s status; 
younger children should be told their status incrementally 
to accommodate their cognitive skills and abilities (strong 
recommendation, low quality of evidence).
Adolescents 
WHO (2013). Guidelines on 
HIV testing and counselling 
for adolescents and care for 
adolescents with HIV 
(http://www.who.int/hiv/pub/
guidelines/adolescents/en/).
HIV testing services, with linkages to prevention, treatment 
and care, should be offered for adolescents from key 
populations in all settings (strong recommendation, very low 
quality of evidence).
Adolescents with HIV should be counselled about the 
potential benefits and risks of disclosure of their HIV status 
and empowered and supported to determine if, when, how 
and to whom to disclose (conditional recommendation, very 
low quality of evidence).
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Adolescents (continued) Generalized HIV epidemic
HIV testing services, with linkage to prevention, treatment 
and care, should be offered to all adolescents in generalized 
epidemics (strong recommendation, very low quality of 
evidence).
Concentrated HIV epidemic
HIV testing services, with linkage to prevention, treatment 
and care, should be accessible to adolescents in low-level 
and concentrated epidemics (conditional recommendation, 
very low quality of evidence).
Pregnant and postpartum 
women
WHO (2013). Consolidated 
guidelines on the use of 
antiretroviral drugs for 
treating and preventing HIV 
infection
(http://www.who.int/hiv/pub/
guidelines/arv2013/download/
en/index.html).
High prevalence settings
PITC for women should be considered a routine component 
of the package of care in all antenatal, childbirth, 
postpartum and paediatric care settings. In such settings, 
where breastfeeding is the norm, lactating mothers who 
are HIV-negative should be retested periodically throughout 
the period of breastfeeding.
Low prevalence settings
PITC can be considered for pregnant women in antenatal 
care as a key component of the effort to: 
•	 eliminate mother-to-child transmission of HIV 
•	 integrate HIV testing with testing for syphilis and viral or 
other key tests as relevant to the setting 
•	 strengthen the underlying maternal and child health 
systems.
Couples and partner testing services are recommended in 
antenatal care settings, facilitating provision of interventions, 
including ART for prevention in serodiscordant couples in 
all settings (strong recommendation, very low quality of 
evidence).
Couples and partner HIV 
testing and counselling 
WHO (2012). Guidance 
on couples HIV testing 
and counselling, including 
antiretroviral therapy for 
treatment and prevention in 
serodiscordant couples 
(http://www.who.int/hiv/pub/
guidelines/9789241501972/
en/index.html).
•	Couples and partners should be offered voluntary HIV 
testing services with support for mutual disclosure (strong 
recommendation, low quality of evidence).
•	 In antenatal care settings couples and partners should 
be offered voluntary HIV testing services with support for 
mutual disclosure (strong recommendation, low quality of 
evidence).
•	HIV testing services for couples and partners, with 
support for mutual disclosure, should be offered to 
individuals with known HIV status and their partners 
(strong recommendation, low quality of evidence for 
all people with HIV in all epidemic settings; conditional 
recommendation, low quality of evidence for HIV-negative 
people depending on the country-specific HIV prevalence).
Key populations
WHO (2014). Consolidated 
guidelines on HIV prevention, 
diagnosis, treatment and care 
for key populations 
(http://www.who.int/hiv/pub/
guidelines/keypopulations/
en/).
•	HIV testing services should be routinely offered to all key 
populations in the community, in closed settings such as 
prisons and in facility-based settings. 
•	Community-based HIV testing services for key populations 
linked to prevention, treatment and care services are 
recommended, in addition to routine facility-based HIV 
testing services, in all settings (strong recommendation, 
low quality of evidence). 
•	Couples and partners should be offered HIV testing 
services with support for mutual disclosure. This applies 
also to couples and partners from key populations. 
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Approach Recommendations
Chapter 7: Testing strategies
Testing strategies for 
high and low prevalence 
settings 
WHO (2012). Service delivery 
approaches to HIV testing and 
counselling (HTC): a strategic 
policy framework 
(http://www.who.int/hiv/pub/
vct/htc_framework/en/).
High prevalence 
In settings with greater than 5% HIV prevalence in the 
population tested, a diagnosis of HIV-positive should be 
issued to people with two sequential reactive tests. 
•	 For individuals with A1+; A2−; A3+, an HIV-inconclusive 
status is reported, and the client should be asked to return 
in 14 days for retesting. 
•	 For individuals with discrepant test results where the A1 is 
reactive, the A2 is non-reactive and the A3 is non-reactive 
(that is, A1+, then A2−, then A3−), the final result should 
be considered HIV-negative.
Low prevalence 
In settings with less than 5% HIV prevalence in the 
population tested, a diagnosis of HIV-positive should be 
issued to people with three sequential reactive tests. 
•	 For individuals with A1+; A2−, the final result should 
be considered HIV-negative. However, if A1 is a fourth 
generation assay (Ab/Ag) and A2 is an Ab-only assay, 
when A1+; A2−, the result should be considered HIV-
inconclusive and the person should be retested after 14 
days.
•	 For individuals with A1+; A2+; A3−, an HIV-inconclusive 
status is reported, and the client should be asked to return 
in 14 days for retesting.
•	HIV testing services may use combinations of RDTs or 
combinations of RDTs/EIAs/supplemental assays rather 
than EIA/Western blot combinations.
Chapter 9: HIV testing in the context of surveillance
HIV testing in the 
context of surveillance
(http://www.who.int/hiv/
strategic/surveillance/
workinggroup/en/).
•	 For surveillance, use a testing strategy and national 
validated testing algorithm that is suitable for HIV 
diagnosis.
•	Use programmatic data, when possible, for HIV 
surveillance; particularly for prevention of mother-to-child 
transmission programmes.
•	Routinely return HIV diagnoses to participants in the 
context of surveillance.
•	Use HIV incidence assays for population-level incidence 
estimates and not for individual disease staging; 
returning these test results to study participants is not 
recommended.
•	Use linked HIV testing for biological surveillance that 
is either confidential (using personally identifiable 
information) or anonymous (using unique study codes).
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1 INTRoduCTIoN
1.1 Progress and challenges 
HIV testing is the gateway to HIV prevention, treatment, care and other support services. 
People’s knowledge of their HIV status through HIV testing services (HTS) is crucial to the 
success of the HIV response. The Joint United Nations Programme on HIV/AIDS (UNAIDS) 
and the World Health Organization (WHO) have endorsed global goals to achieve “zero 
new HIV infections, zero discrimination and zero AIDS-related deaths”. Because of the 
potential serious medical, social and psychological consequences of misdiagnosis of HIV 
(either false-positive or false-negative), all programmes and people providing HIV testing 
must strive also for zero misdiagnoses. 
The new global 90–90–90 targets call for 90% of all people with HIV to be diagnosed, 
90% of people with HIV diagnosed to receive ART and 90% of those on ART to have a 
suppressed viral load by 2020 (20). The first 90 – diagnosis of HIV – is essential to the 
second 90 – initiation of ART among people with HIV – and the ultimate outcome of the 
third 90 – viral load suppression among people on ART, which improves client outcomes 
and prevents HIV-1 transmission (23).
The challenge is to increase 
access to and uptake of HTS for 
those who remain undiagnosed 
and for those at greatest ongoing 
risk for HIV infection.
Significant increases in access to HTS
Approximately 150 million children and adults in 
129 low- and middle-income countries received HIV 
testing services in 2014.1 In the 77 countries that 
reported for both years, 33% more people were 
1 Global AIDS Response Progress Reporting (WHO, UNAIDS, UNICEF), 6 July 2015.
The overarching goals of HIV testing services are to: 
•	 identify people with HIV through the provision of quality services for individuals, 
couples and families;
•	 effectively link individuals and their families to appropriate HIV treatment, care 
and support, as well as HIV prevention services, based upon their status; and
•	 support the scale-up of high impact interventions to reduce HIV transmission and 
HIV-related morbidity and mortality, that is, antiretroviral therapy (ART), 
voluntary medical male circumcision (VMMC), prevention of mother-to-child 
transmission (PMTCT), pre-exposure prophylaxis (PrEP) and post-exposure 
prophylaxis (PEP).
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tested in 2013 than in 2009 (24, 25). Much of this growth stems from the expansion of 
provider-initiated testing and counselling (PITC) in clinical settings, the introduction of 
more community-based HTS and the ability to provide same-day test results, and often 
diagnosis, using rapid diagnostic tests (RDTs). While significant progress has been made, 
in 2013 it was estimated that 55% of people with HIV remain unaware of their status, 
and testing continues to be delivered without specifically aiming to reach those most at 
risk and as yet undiagnosed (26).
In high prevalence settings men lag behind
In countries with high HIV prevalence, HIV testing rates for men are generally lower than 
for women, as Fig. 1.1 illustrates. Global reporting suggests that this is because in these 
settings HTS is conducted mainly in reproductive health services, including antenatal 
care (ANC), where the routine offer of HIV testing is generally the norm. Additional 
approaches are needed to increase uptake of HTS among men, including the provision of 
HTS in settings that are more appropriate and acceptable to men, and to devise ways to 
encourage testing of male partners in high prevalence settings and of couples and male 
partners of women with HIV in all settings (24).
Provider-initiated HIV testing services need to be expanded
PITC, often referred to as routine HIV testing, can be expanded in more settings and more 
regions. According to Global AIDS Response Progress Reporting (WHO, UNICEF, UNAIDS), 
at the end of 2014, 76% of 117 reporting low- and middle-income countries had a policy of 
recommending PITC during all client encounters, and 90% of 39 reporting countries in the 
WHO African region recommended PITC in ANC settings. However, in other African 
countries and in Asia, HIV testing coverage of pregnant women is less than 40% (24).
Approaches are needed to 
increase early infant diagnosis 
and timely referral of infants 
diagnosed as HIV-positive to 
treatment and care.
HIV testing coverage among children is low also. 
Although HIV testing coverage in PMTCT programmes 
has improved significantly over the past decade, rates 
of early infant diagnosis remain far from optimal. 
Among reporting countries in 2012, only one-third of 
infants born to HIV-infected mothers received a 
virological HIV test within the first two months of life 
(24). Moreover, despite reports of a high proportion of HIV cases detected among 
children tested in clinical settings in countries with generalized epidemics (27–29) , in 
many settings PITC is still rarely offered to children in TB and malnutrition clinics (30, 31). 
Such low HIV testing coverage for infants and children also is a missed opportunity to 
offer HTS to parents, caregivers and family members of children attending facility-based 
health services. Barriers to HIV testing among infants and children include mothers 
moving back to their home villages after delivery in a faraway facility, fear of disclosure 
of HIV status, fear of stigma and discrimination and parents’ lack of knowledge of the 
need to enrol children in infant care, as well as impediments such as lack of 
transportation, inconvenient service hours and long waits at health facilities (30, 31). 
Approaches are needed to increase early infant diagnosis and timely referral of infants 
diagnosed as HIV-positive to care and treatment. Both are key to improving health 
outcomes and child survival.
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fig. 1.1. Percentage of men and women ages 15–49 years who were ever tested 
for HIV and received their results in 15 selected countries in the wHo african 
Region, 2003–2011
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adolescents, too, are underserved
While most infants with undiagnosed HIV infection will die before their fifth birthday, 
some long-term survivors will continue to remain unidentified as HIV-infected into 
adolescence. Adolescents, particularly girls, are also at risk for acquiring HIV through 
sexual transmission. In sub-Saharan Africa adolescents (10–19 years of age) are less 
likely than adults to be tested, to obtain care, to remain in care and to achieve viral 
suppression (13). Between 2005 and 2012 the number of HIV-related deaths among 
adolescents increased by 50% (32). Based on Demographic and Health Surveys and 
Multiple Indicator Cluster Surveys from 2008 to 2012 in the WHO African Region, fewer 
than one of every five girls ages 15–19 years were aware of their HIV status (24). 
Because uptake of HIV testing among adolescents is low and services for adolescents are 
of poor quality or in many settings have not yet been developed, there is often little 
support for adolescents to overcome barriers, adhere to treatment and stay in care. 
Therefore, high levels of HIV-related morbidity and mortality are becoming more 
common among adolescents (33). 
access for key populations should be prioritized
Key populations continue to be disproportionately affected by HIV in all settings. In 2013 
there were an estimated 2 million new HIV infections worldwide. Of these, an estimated 
40% occurred among key populations (10, 34). Within key populations adolescents 
(10–19 years old) and young people (15–24 years old) are at greater risk for acquiring 
HIV than older people (10). In countries with low HIV prevalence, HIV testing often takes 
place primarily in ANC services and does not reach key populations. The estimated HIV 
testing coverage among key populations in many countries remains low (34) , and even 
these reports may be overestimates. In many countries data on HIV testing coverage 
collected for key populations are based on small samples from a limited number of 
settings and, therefore, may overestimate overall coverage in these populations. 
Countries and programmes must 
prioritize and focus on tailored 
HTS approaches for key 
populations in all settings.
Also, in all settings people from key populations are 
less likely than the general population to link to HIV 
services in a timely manner because their behaviour 
is criminalized and they experience stigma and 
discrimination (10). For instance, in Bangkok 25% of 
drug users report that they avoid health services 
because they are afraid of compulsory treatment (35) , and uptake of HIV services 
remains low. Likewise, globally, men who have sex with men report that the experience 
of homophobia is the most important deterrent to their use of health services (36). 
To reduce HIV burden, countries and programmes must prioritize and focus on tailored 
HTS approaches for key populations in all settings. 
late or delayed linkage to prevention, treatment, care and support is common 
Globally, many people diagnosed with HIV infection are not linked to treatment and 
care(13). In resource-limited settings, primarily sub-Saharan Africa, it is estimated that as 
much as 40% of people who are diagnosed through HIV testing services are not linked 
to care (25, 37, 38). Barriers that hinder or delay linkage to HIV treatment and care 
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persist, including transportation costs and distance to the facility, stigma, fear of 
disclosure, staff shortages and long waiting times (37) , as well as policy and legal 
barriers that may hinder access particularly for adolescents and key populations. 
Ultimately, many people with HIV are diagnosed late and start ART late, with CD4 
counts below 200 cells/μL (39). Such late initiation has not decreased significantly over 
the past decade (39). A combination of interventions is needed to improve linkages to 
prevention, treatment and care and to reduce loss to follow-up between HIV testing and 
treatment and care, especially for key populations.
Challenges of quality HIV testing are evident
It is important that all clients 
who undergo HIV testing receive 
the correct HIV diagnosis. 
In addition to strategically expanding HTS, it is 
equally important that all clients who undergo HIV 
testing receive the correct HIV diagnosis. Recent 
reports suggest that misdiagnosis of HIV status is 
occurring in resource-limited settings (40). Recent 
policy analysis also suggests that only 20% of national HIV testing strategies align with 
WHO recommendations (41) (see Annex 2). An audit in three countries conducted by 
Médecins Sans Frontières found significant rates of false-positive diagnoses reported to 
individuals (2.6%–4.8%) (42). Retesting all individuals diagnosed HIV-positive found 
that 10.3% had been misdiagnosed HIV-positive in the Democratic Republic of Congo 
and 7.1% in Ethiopia (42). In Malawi, during a three-month period in 2014, 7% of people 
previously diagnosed HIV-positive who were retested did not have a concordant HIV-
positive status and may have been misdiagnosed. Following quality improvement (QI) 
and re-training, during another three-month period in 2014, only 4% of the people 
previously diagnosed HIV-positive who were retested before ART initiation did not have 
concordant results (43). The rate of false-negative HIV statuses reported (people infected 
with HIV who are told they are not infected) remains unknown and is difficult to assess, 
as there is not routine follow-up for people who receive an HIV-negative status. 
Poor quality HIV testing is multifaceted; it results from a number of factors, sometimes 
in combination, including poor product performance, improper storage of test kits and 
supplies, clerical or transcription errors, user errors in performing the test and/or 
interpreting the test result, lack of training, improper use of the testing strategy and/or 
algorithm, lack of supportive supervision and training, lack of standard operating 
procedures (SOPs) and poor documentation and record-keeping practices. To address 
these problems, effective quality assurance systems must expand along with the 
expanded delivery of HTS. 
To close these various gaps in coverage and quality, more proactive, rights-based HIV 
testing approaches are needed. This includes more emphasis on quality assurance, more 
focused promotion of testing in geographical areas of high HIV prevalence and incidence 
and among key populations, and strategic investment in multiple efforts to increase 
demand for testing services. Also critical to closing gaps are use of a broader array of 
approaches to HIV testing, including couples and partner HIV testing, routine facility-
based HTS in clinical settings beyond ANC and TB, community-based HTS and, 
potentially, HIV self-testing (HIVST) (14, 24).
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1.2 Rationale 
These guidelines aim to address gaps and limitations in current approaches to HTS. 
Countries and other programme managers and health workers have indicated the 
importance of consolidating WHO’s guidance on HTS to aid national programme 
managers and service providers, including those from community-based and community-
led programmes, in planning for and implementing services. 
1.3 Scope of guidelines
These guidelines outline a public health approach to strengthening and expanding HTS. 
They present and discuss a new recommendation to allow trained lay providers to 
perform HTS, and they compile a range of existing WHO guidelines into one consolidated 
document. 
Summary of chapters
Chapter 2 details the methodology for development of these guidelines. 
Chapter 3 describes pre-test and post-test services, including linkage to 
prevention, treatment and care services. 
Chapter 4 provides general service delivery recommendations. 
Chapter 5 addresses HTS for specific populations – infants and children, 
adolescents, pregnant women, couples and partners (including serodiscordant 
couples), men, key populations and other vulnerable populations. 
Chapter 6 presents and discusses a framework for focusing HTS approaches in 
different epidemic and population contexts. 
Chapters 7 and 8 describe help with how to conduct and assure the quality of 
HIV testing. 
Chapter 9 discusses HIV testing and diagnosis in the context of surveillance.
Chapter 10 outlines core monitoring and evaluation considerations for HIV 
testing. 
1.4 using these guidelines
Like the Consolidated guidelines on the use of antiretroviral drugs for treating and 
preventing HIV infection (13) and the Consolidated guidelines on HIV prevention, 
diagnosis, treatment and care for key populations (10) , these guidelines address issues 
across the continuum of HIV prevention, diagnosis, care, treatment and support (Fig. 
1.2). These consolidated guidelines aim to cover all aspects of HTS. Each chapter 
contains information for specialists and includes information on specific HTS topics so 
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that sections and chapters can be read alone. Information from other chapters is 
included and cross-referenced where appropriate. In addition, some chapters will be 
particularly useful to specific audiences, for example, those responsible for developing 
HIV testing strategies and selecting HIV assays (Chapter 7), quality assurance (QA) 
(Chapter 8), surveillance (Chapter 9) and monitoring and evaluation of HTS (Chapter 
10).
fig. 1.2. Continuum of linkage to care and prevention
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Background documents developed to support these guidelines and the systematic 
reviews and GRADE (Grading of Recommendations, Assessment, Development and 
Evaluation)1 tables for new recommendations appear in Annex 1, published on the WHO 
website at http://www.who.int/hiv/pub/guidelines/.
1.5 Goal and objectives 
The primary goal of these guidelines is to provide consolidated guidance for national 
programme managers and other decision-makers to consider in the design and 
management of their HIV response and particularly their approach to HIV testing 
services. Specific objectives in support of this goal include the following:
•	 consolidate existing and new guidance for HTS for all populations and settings and 
for various approaches so that it is easily accessible and user-friendly;
•	 present a new recommendation to support trained lay health providers conducting 
HIV testing, using RDTs, in order to increase access to testing, particularly through 
community-based HTS;
•	 consider issues relating to HIVST, including approaches to introducing and monitoring 
the acceptability, uptake and effectiveness of HIVST;
•	 update and clarify existing service delivery guidance as needed;
1 Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA et al. GRADE guidelines: 15. Going from evidence to 
recommendations: determinants of a recommendation’s direction and strength. J Clin Epidemiol. 2013;66:726–35.
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•	 provide guidance to inform strategic decision-making regarding the mix of 
approaches to delivering HTS that will maximize impact;
•	 provide specific guidance on how to implement WHO recommended testing 
strategies, how to validate testing algorithms, and how to better select assays to 
assure and improve the quality of HIV testing;
•	 provide guidance on HIV testing and diagnosis in the context of surveillance, 
emphasizing the routine return of HIV status to individuals. 
1.6 Target audience
These guidelines address national HIV programme managers and other decision-makers, 
particularly within ministries of health. Such managers are responsible for the national 
health sector response to HIV, including HIV testing, as well as prevention, treatment 
and care services for the entire populations of Member States. These managers also play 
a key role in ensuring the availability of a continuum of prevention, treatment and care 
services for key populations. 
These guidelines will also be of use to officers at the national level responsible for other 
communicable diseases, especially other forms of sexually transmitted infections (STIs), 
tuberculosis (TB) and viral hepatitis (HBV and HCV). These guidelines also will assist 
national and subnational programme managers responsible for the provision of HTS and 
a comprehensive range of integrated services.
Finally, these guidelines will be helpful to other implementers of HTS, including 
international and national nongovernmental organizations and community-based 
organizations. They will serve as the normative guidance to support effective funding, 
planning, implementation, and monitoring and evaluation of HTS for donors such as the 
Global Fund to Fight AIDS, Tuberculosis and Malaria.
1.7 Guiding principles
A public health and human rights-based approach is important to delivering HTS. A 
human rights-based approach gives priority to such concerns as universal health 
coverage, gender equality and health-related rights such as accessibility, availability, 
acceptability and quality of services. For all HTS, regardless of approach, the actual 
public health benefits must always outweigh the potential harm or risk. Moreover, the 
chief reason for testing must always be both to benefit the individuals tested and to 
improve health outcomes at the population level. HTS should be expanded not merely to 
achieve high testing uptake or to meet HIV testing targets, but primarily to provide 
access for all people in need to appropriate, quality HTS that are linked to prevention, 
treatment, care and support services. Thus, HIV testing for diagnosis must always be 
voluntary, consent must be informed by pre-test information, and testing must be linked 
to prevention, treatment, care and support services to maximize both individual and 
public health benefits. 
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All forms of HIV testing should adhere to the WHO 5 Cs: Consent, Confidentiality, 
Counselling, Correct test results and Connection (linkage to prevention, treatment and 
care services) (44). Coerced testing is never appropriate, whether that coercion comes 
from a health-care provider, an employer, authorities (such as immigration services) or a 
partner or family member. 
The 5 Cs are principles that apply to all HTS and in all circumstances
•	 Consent: People receiving HTS must give informed consent to be tested and counselled. 
(Verbal consent is sufficient; written consent is not required.) They should be informed 
of the process for HIV testing and counselling and of their right to decline testing.
•	 Confidentiality: HTS must be confidential, meaning that what the HTS provider and 
the client discuss will not be disclosed to anyone else without the expressed consent of 
the person being tested. Confidentiality should be respected, but it should not be 
allowed to reinforce secrecy, stigma or shame. Counsellors should discuss, among other 
issues, whom the person may wish to inform and how they would like this to be done. 
Shared confidentiality with a partner or family members – trusted others – and health-
care providers is often highly beneficial.
•	 Counselling: Pre-test information can be provided in a group setting, but all people 
should have the opportunity to ask questions in a private setting if they request it. All 
HIV testing must be accompanied by appropriate and high-quality post-test counselling, 
based on the specific HIV test result and HIV status reported. Quality assurance (QA) 
mechanisms as well as supportive supervision and mentoring systems should be in place 
to ensure the provision of high-quality counselling.
•	 Correct: Providers of HIV testing should strive to provide high-quality testing services, 
and QA mechanisms should ensure that people receive a correct diagnosis. QA may 
include both internal and external measures and should receive support from the 
national reference laboratory. All people who receive a positive HIV diagnosis should be 
retested to verify their diagnosis before initiation of HIV care or treatment. 
•	 Connection: Linkage to prevention, treatment and care services should include 
effective and appropriate follow-up, including long-term prevention and treatment 
support. Providing HTS where there is no access to care, or poor linkage to care, 
including ART, has limited benefit for those with HIV. 
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2 mETHodoloGy
2.1 overview
The WHO HIV Department led the development of these guidelines in accordance with 
procedures and reporting standards laid out in the WHO handbook for guideline 
development (45), using the GRADE process. These consolidated guidelines on HTS 
combine existing WHO recommendations which had previously been developed through 
the GRADE process, guidance published by WHO together with UN partners and one new 
WHO recommendation. All current WHO recommendations that pertain to HTS are 
included. 
2.2 Establishing the Guideline development Group
The WHO HIV Department set up three groups to perform specific guideline development 
functions: (1) an internal WHO HTS Guideline Steering Group to lead the process, (2) a 
Guideline Development Group comprising 19 external experts responsible for the 
formulation of the new WHO recommendation, service delivery guidance and selection of 
case examples and for review and approval of the final content of the guidelines 
document, and (3) 120 external peer reviewers. Members of the groups were selected 
so as to ensure a range of expertise and experience, including appropriate geographical, 
gender and community representation. (See Acknowledgements for lists of participants.)
Involvement of key stakeholders
An important element of this work was engaging with a diverse set of stakeholders to 
update and synthesize key messages across existing WHO guidance on HTS. These 
stakeholders included countries (ministries of health and laboratory services), researchers, 
international and national implementing agencies, community networks and implementers, 
WHO regional and country offices and other UN agencies. Also, to maximize stakeholder 
engagement and ensure the relevance of the guidelines to countries, WHO solicited case 
examples from civil society, community-based organizations and networks, including key 
populations and people living with HIV, and additional experts in the field. 
declarations of interest
All Guideline Development Group participants and external peer reviewers submitted 
declarations of interest to the WHO secretariat. The WHO secretariat and the Guidelines 
Development Group reviewed all declarations and found no conflicts of interest sufficient 
to preclude anyone from participating in the development of the guidelines. A full 
compilation and summary of the declarations are available in Annex 15; see http://www.
who.int/hiv/pub/guidelines/.
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2.3 defining the scope of the guidelines
To develop these guidelines, the WHO Guideline Steering Group mapped all existing WHO 
guidance specifically concerned with HTS (see Table 1, page xix). Then, the Group reviewed 
these and other materials to identify areas requiring updating, gaps, overlaps and 
inconsistencies. The outcome of the mapping exercise was presented to the Guidelines 
Development Group at several virtual scoping meetings during November and December 
2014. The group reviewed the mapping, advised on the scope of the guidelines and noted 
areas that did not need updating and areas requiring new guidance – specifically, HIV 
testing, using RDTs, by trained lay providers. 
2.4 Review of the evidence 
These guidelines include one new recommendation, on HIV testing by trained lay providers, 
as well as existing recommendations. Development of the new recommendation began 
with a systematic review of the evidence. The Guidelines Development Group 
recommended commissioning new literature reviews and appraisal of existing reviews to 
investigate values and preferences, along with reviews of the costs and feasibility of 
implementation (see Annex 1). Also, WHO commissioned a new descriptive review of 
current national policies on trained lay providers’ involvement in HIV testing to inform 
consideration of the feasibility of the new recommendation (see Annex 2). 
2.5 development of the recommendation on HIV testing, using RdTs, 
by trained lay providers
As noted, the scoping exercise identified a need for evidence-based recommendations 
concerning trained lay providers performing HIV testing with RDTs. The question was 
framed in the PICO (Population, Intervention, Comparator, Outcome) format. The WHO 
Guideline Steering Group drafted the PICO question. The question was circulated to the 
members of the Guideline Development Group, who selected and ranked the importance of 
a range of outcomes and gave comments. Once the PICO question was completed and 
agreed, external researchers used it to develop search protocols and perform a systematic 
review of the available scientific evidence, as described below. See Annex 1 for details. 
PICO question: Should trained lay providers, using HIV rapid diagnostic tests (RDTs), 
perform HIV testing?
P: People who receive HTS 
I: HIV testing, using HIV RDTs, performed by trained lay providers
C: HIV testing, using HIV RDTs, performed by trained health professionals (for example, 
nurses or doctors), or no intervention
O: Primary: (1) Measures of testing quality (quality assurance) (for example, lost or 
damaged/uninterpretable specimens); (2) accurate test results (sensitivity and specificity); 
(3) adverse events (for example, coercion, inter-partner violence, psychosocial events and/
or self-harm, stigma, discrimination); (4) uptake of HTS. Secondary: (5) Rate of CD4 
measurement (among all participants found to have HIV, the percentage who reach this 
next stage of triage); (6) linkage to medical visit after diagnosis; and (7) initiation of ART 
(among participants eligible per national guidelines).
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2.5.1 Systematic review of values and preferences 
Researchers used the same search strategies to identify studies presenting information on 
end-users’ values and preferences related to the PICO question. Researchers included 
studies in the values and preferences review if the studies presented primary data 
examining people’s preferences regarding different cadres of health providers and HIV 
testing. These studies could be qualitative or quantitative in nature but had to present 
primary data; opinion pieces and review articles were not included. Researchers 
qualitatively summarized the values and preferences literature; this summary is presented 
in Annex 1.  
2.5.2 Policy analysis
WHO conducted a separate analysis of national HIV testing policies to assess the overall 
feasibility of HIV testing provided by trained lay providers. Two researchers searched, 
reviewed and analysed national HIV testing policies from the Americas, Africa, Asia and 
Europe. From 1 November 2014 through 21 December 2014, the researchers conducted 
electronic searches for national HIV testing policies, using Google, governmental and 
nongovernmental websites and WHO databases. They also contacted WHO and UNAIDS 
regional technical advisors and key experts in the field. This report is presented in Annex 2.
2.6 developing the recommendation
From January through March 2015, WHO convened 12 virtual guideline development 
meetings (two parallel morning and afternoon meetings on six separate occasions to allow 
participation from all time zones) and nine WHO Steering Group meetings. During these 
meetings participants considered the evidence for formulating a new recommendation and 
reviewed all relevant sections of the consolidated guidelines. 
2.7 Review of service delivery, implementation approaches and case 
examples 
In addition to the systematic review on trained lay providers conducting HIV testing and 
the review of 48 countries’ policies on HIV testing (see Annex 2), two other literature 
reviews were conducted. Both were on community-based HTS: one among key populations 
and the other among the general population. Both inform the discussion of HTS 
approaches described in Chapter 4 and strategic decision-making described in Chapter 6. 
WHO also identified examples of HTS practices in the field. These case examples offer 
insights into implementation of HTS, including services for key population groups. They 
explain why and how programmes have worked and the types of challenges faced during 
implementation. Case examples were solicited and collected specifically to illustrate 
effective and acceptable ways to deliver community-based HTS among key populations. 
The WHO Steering Group and Guideline Development Group then reviewed the case 
examples and selected the most relevant for inclusion in the guidelines. See Annex 3 for all 
case examples collected and more details. 
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2.8 additional background work
As part of the guideline development process, WHO commissioned three other literature 
searches and mathematical modelling to provide the most up-to-date information. They 
include: 
•	 Attitudes, values and preferences on HIV self-testing among key populations. 
This review informs Chapter 4 and discussion on HIV self-testing (see Annex 4).
•	 Review of the cost of different HIV testing approaches. The review informs 
Chapter 6 on the strategic selection of HTS approaches (see Annex 5).
•	 Mathematical model on the cost of testing pregnant women in high and very 
low prevalence settings. This model informs Chapter 6 on the strategic selection of 
HTS approaches  (see Annex 6).
•	 Review of misdiagnosis of HIV status. This review informs Chapters 7 and 8 on HIV 
diagnosis and the quality of services (see Annex 14).
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       Key PoINTS 
•	The 5 Cs are essential for all HTS: consent, confidentiality, counselling, correct test 
results and connection to HIV prevention, treatment and care (see section 1.7).
•	HTS should be prioritized for and promoted to those who are at high risk and have 
not been tested recently.
•	Verbal consent is usually adequate, but all individuals should have a private opportunity 
to refuse testing. Mandatory testing is never warranted.
•	HTS must ensure that all tests results and client information are confidential. Although 
disclosure to sexual partners, supportive family members and health workers is often 
beneficial, this must be done only by or with the consent of the person being tested. 
•	Retesting for individuals thought to be in the window period is needed only for 
those who report specific recent risk.
•	 It is the ethical and professional responsibility of the person providing HIV test results to 
adhere to international and national guidelines to ensure correct test results.
•	People who test HIV-negative will usually need only brief health information about 
their HIV status report, how to prevent acquisition of HIV in the future and where and 
how to link to HIV prevention services, as appropriate. People with significant ongoing 
risk may need more active support and linkage to HIV prevention services. Everyone who 
is diagnosed HIV-positive should receive post-test counselling, including couples where 
one or both are diagnosed HIV-positive. 
•	People whose test results are not yet confirmed or whose HIV status is reported as 
inconclusive need follow-up services to ensure that they receive an HIV diagnosis. 
•	Key populations need tailored approaches and messages. 
•	Connection to prevention, treatment and care is an essential component of HTS.
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3 PRE-TEST aNd PoST-TEST SERVICES
3.1 Introduction
Linkage to appropriate services 
following diagnosis should be 
regarded as a key component of 
effective and comprehensive HTS.
Attaining the UN 90–90–90 targets depends on the 
first 90 – diagnosing 90% of people with an HIV 
infection. Many people with HIV have already been 
diagnosed, as evidenced by such achievements as the 
estimated 13 million people on ART worldwide. Many 
people needing care and treatment remain 
undiagnosed, however. Successful linkage from diagnosis to prevention, treatment and 
care services is also essential to reach the second and third 90s – that 90% of HIV-positive 
people who have been diagnosed are on ART and that 90% of people with HIV receiving 
ART have achieved viral suppression (20). 
Receipt of an HIV diagnosis empowers individuals to make informed decisions about HIV 
prevention, treatment and care that will affect both HIV transmission and an individual’s 
health and survival. Therefore, linkage to appropriate services following diagnosis should 
be regarded as a key component of effective and comprehensive HTS (see Fig. 1.2, page 8). 
This chapter discusses essential services prior to HIV testing as well as post-test messages 
and counselling services. Post-test services are described specifically for individuals who 
test HIV-negative, individuals who are diagnosed HIV-positive, individuals who receive a 
reactive test result but need further testing and individuals who have an inconclusive HIV 
status. The importance of linkages to prevention, treatment and care is explained, and 
innovative approaches to improve successful linkages are explored.
3.2 Services prior to HIV testing
Certain basic services should be provided prior to testing in all settings, regardless of the 
approach used to deliver HTS (see Chapter 4 for description of various approaches). These 
services apply to all adults, couples or partners, and adolescents. Specific pre-test services 
for testing of children are described in Operational guidelines on HIV testing and 
counselling of infants, children and adolescents for service providers in the African region 
(http://tinyurl.com/hivtestguideafro) (46). 
3.2.1 Promoting HTS
Many countries and programmes have vigorously promoted HTS through mass media, 
including radio, television, billboards and posters, the Internet and electronic social media. 
The use of the mass media has been shown to increase the uptake of HTS in the short term 
(47). In both high and low HIV prevalence countries, as a result of campaigns and 
promotional activities, there is widespread knowledge that HTS are available and where 
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they are available. For example, among countries with generalized epidemics, recent 
Demographic and Health Surveys indicate that in Zambia (2014) 96% and in Tanzania 
(2011–2012) 91% of both men and women know where to receive an HIV test. Knowledge 
of where to receive HIV testing in countries with concentrated epidemics is lower but still 
widespread. For example, among both men and women, 69% in Cambodia (2010) and 
71% in Sierra Leone (2013), know where to receive a test. Some countries report gender 
differences. For example, in the Dominican Republic (2010) 96% of women and 85% of 
men knew where to receive a test, and in Ethiopia (2011) 66% of women and 82% of men 
knew where to receive one. 
Since knowledge of HIV testing and of where it is available is widespread, the continued 
need for promotion addressing the general population should be assessed. Depending on 
the goals of the HTS programme, general promotion and awareness campaigns for HTS 
may no longer be necessary. Even in countries with generally widespread knowledge of 
HIV testing, however, promotional activities may need to focus on populations where HIV 
testing rates remain suboptimal, including key populations and adolescent groups, which 
will likely require tailored messages and approaches – for example, via social media. 
Case examples: Promoting HIV testing services 
•	 In China a 24-hour online HIV test scheduler and “Easy Tell”, an anonymous 
partner notification system, supported HIV self-testing.
•	 In Macedonia members of parliament received HIV testing through mobile 
services; this event publicized the benefits of HIV testing.
•	 In Kenya a professionally designed four-phase mass media campaign significantly 
increased testing when it directly mentioned HIV and the personal, family and 
prevention benefits of testing (48). 
•	 In Lebanon activities including word-of-mouth, outreach campaigns, referrals 
from health-care providers and social media promoted a specialized medical 
centre offering sexual health services for men who have sex with men, sex 
workers and transgender people.
•	 In Lithuania an association of women affected by HIV and their families 
organized a mobile HIV testing tour. To promote uptake, city mayors, other 
municipal leaders, public health and prison authorities, and local media were 
informed about the programme, and newspapers, radio and television presented 
over 80 communications about the mobile services.
Sources: Marum et al., 2008 (48); Annex 3.
In addition to outreach and promotion, clear signs that direct prospective clients to testing 
are important. This applies to testing in health facilities, in the community and through 
mobile services. In certain clinic settings, where HIV testing is routinely offered, such as 
ANC, STI clinics and TB services, signs, printed information and posters and group health 
education sessions can efficiently inform pregnant women, other clients and family 
members that testing is offered.
20 Consolidated guidelines on HIV testing services
3.2.2 Creating an enabling environment
Critical enablers are elements outside of health sector interventions that allow health 
interventions and services to be provided effectively and safely. Examples range from 
tolerance among the larger population toward people from key populations to laws and 
policies that enable young people to be tested without parental consent. While these 
factors are not directly the responsibility of the health sector, health-care providers and 
organizations delivering HTS should work with community-based organizations, legal 
authorities and advocacy organizations to ensure that the environment supports and 
enables people to learn their HIV status. For a description of critical enablers, see Chapter 
4 and the Consolidated guidelines on diagnosis, prevention, care and treatment for key 
populations (http://www.who.int/hiv/pub/guidelines/keypopulations/en/) (10). 
wHo recommendation  
Initiatives should be put in place to enforce privacy protection and institute 
policy, laws and norms that prevent discrimination and promote tolerance and 
acceptance of people living with HIV. This can help create environments where 
disclosure of HIV status is easier (strong recommendation, low quality of 
evidence).
Source: WHO, 2011 (49).
3.2.3 Ensuring a confidential setting and preserving confidentiality
All HTS providers must remain committed to preserving confidentiality, one of the 5 Cs of 
HTS (see Section 1.7). Confidentiality applies not only to the test results and reports of HIV 
status but also to any personal information, such as information concerning sexual 
behaviour and the use of illegal drugs. HTS should avoid practices that can inadvertently 
reveal a client’s test results, or HIV status, to others in the waiting room or in the health 
facility. Such practices might include counselling all people diagnosed HIV-positive in a 
special room or by a specific provider or making it obvious to others which clients will need 
or is receiving additional testing or lengthy post-test counselling. Lack of confidentiality 
discourages people from using HTS. For example, in Cambodia some sex workers refused 
HIV testing because the outreach setting where peer educators were providing counselling 
was not perceived as private (50). Health workers and others who provide HIV testing may 
need special training and sensitization regarding the confidentiality of medical records, 
particularly where key populations are concerned.
3.2.4 Providing pre-test information
Historically, HIV counselling has been provided both before and after HIV testing. Before 
the introduction of RDTs, same-day results were not feasible, so counsellors included 
comprehensive information in the pre-test session in case the client did not return for their 
test results. Moreover, in the pre-treatment era pre-test counselling often focused on 
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providing a risk assessment, preparing clients to cope with an HIV-positive diagnosis in the 
absence of treatment and encouraging clients to return to receive their test results. 
With the widespread use of HIV RDTs, most people receive their HIV test results – at least 
results of the first test – and often a diagnosis on the same day. Therefore, intensive 
pre-test counselling is no longer needed and may create barriers to service delivery (51, 52). 
Individual risk assessment and individualized counselling during the pre-test 
information session is no longer recommended. Depending on local conditions and 
resources, programmes may provide pre-test information through individual or group 
information sessions and through media such as posters, brochures, websites and short 
video clips shown in waiting rooms. When children and adolescents are receiving HTS, 
information should be presented in an age-appropriate way to ensure comprehension. 
Offering or recommending HIV testing to a client or a group of clients includes providing 
clear and concise information on:
•	 the benefits of HIV testing
•	 the meaning of an HIV-positive and an HIV-negative diagnosis
•	 the services available in the case of an HIV-positive diagnosis, including where ART is 
provided
•	 the potential for incorrect results if a person already on ART is tested 
•	 a brief description of prevention options and encouragement of partner testing
•	 the fact that the test result and any information shared by the client is confidential
•	 the fact that the client has the right to refuse to be tested and that declining testing will 
not affect the client's access to HIV-related services or general medical care
•	 potential risks of testing to the client in settings where there are legal implications for 
those who test positive and/or for those whose sexual or other behaviour is stigmatized
•	 an opportunity to ask the provider questions.
Special considerations for pregnant or postpartum women 
Pre-test information or health education for women who are or may become pregnant or 
are postpartum should also include:
•	 the potential risk of transmitting HIV to the infant
•	 measures that can be taken to reduce mother-to-child transmission, including the 
provision of ART to benefit the mother and prevent HIV transmission to the infant
•	 counselling on infant feeding practices to reduce the risk of HIV transmission
•	 the benefits of early HIV diagnosis for mothers and infants
•	 encouragement for partner testing.
Supporting intensified tuberculosis case finding at HIV testing facilities
Tuberculosis (TB) is the most common presenting illness among people with HIV. It is fatal 
if undetected or untreated and is the leading cause of death among people with HIV, 
responsible for about one of every four HIV-associated deaths. Early detection of TB and 
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prompt linkage to TB treatment along with ART can prevent these deaths. HTS provides an 
important opportunity for intensified TB case finding and, thus, early detection and 
treatment of TB.
HTS should integrate screening for 
TB symptoms into the information 
session before HIV testing, both at 
health facilities and in community-
based testing.
HTS should integrate screening for TB symptoms into 
the information session before HIV testing, both at 
health facilities and in community-based testing. All 
clients with TB symptoms should be thoroughly 
investigated, and post-test counselling should 
discuss the outcome of this investigation. All clients 
diagnosed with TB should be promptly registered 
with the national TB programme and started on anti-TB treatment. HIV-positive clients 
diagnosed with active TB should be urgently started on ART, regardless of CD4 count, 
while those not having TB should consider TB preventive therapy (for example, isoniazid 
preventive therapy) as indicated in the schema in Fig. 3.1.
fig. 3.1. HIV/TB testing and screening algorithm to increase TB case finding in HTS
Clients attending HIV testing services 
(facility or community settings)
Pre-test information & counselling
HIV testing & TB symptom screening/
investigation*
HIV-positive HIV-negative
TB-positive No TB TB-positive No TB
Prompt TB 
treatment & 
ART
Consider TB 
preventive 
therapy (IPT) 
and ART
Prompt 
referral for TB 
treatment
Post-test 
information & 
counselling if 
requested
*Per national guidelines.
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Case example: In India intensified TB case finding is systematic at all HIV 
testing facilities 
Health workers or trained lay providers at HIV testing facilities screen each client 
for the presence of cough for two weeks, fever, weight loss and night sweats or 
other symptoms suggestive of pulmonary or extra-pulmonary TB. This screening is 
an integral part of pre-test information. All symptomatic clients are systematically 
referred and enrolled for investigations in the same facility. This activity is 
routinely reported to the district, state and national levels. The following table 
summarizes the data for four recent years.
Year Total clients 
attending HIV 
testing centres 
(excluding 
pregnant women)
Presumptive TB 
cases identified
Total TB cases 
diagnosed among 
presumptive
Proportion of 
HIV-positive TB 
patients started 
on ART
2010 7 678 746 484 617 51 412 57%
2011 9 774 581 580 695 55 572 59%
2012 9 193 113 552 350 46 863 59%
2013 7 264 722 620 539 64 506 88%
Source: TB India, 2014 (53).
Special considerations for couples or partners who ask to be tested together
An increasing number of countries offer couples counselling and partner testing, which 
promotes mutual disclosure of HIV status and increases adoption of prevention measures, 
especially in the case of discordant couples (one HIV-positive partner and one HIV-negative 
partner). The pre-test information session for couples should not ask about past sexual 
behaviour or risks, as this is unnecessary and may create problems for the couple. The 
person conducting a pre-test information session should make clear that both testing and 
post-test counselling can be provided individually, if either partner prefers, and that 
disclosure of HIV status to the other person is not required. For more information on 
couples testing, see Guidance on couples HIV testing and counselling including 
antiretroviral therapy for treatment and prevention in serodiscordant couples (http://apps.
who.int/iris/bitstream/10665/44646/1/9789241501972_eng.pdf) (16).
Special considerations for key populations
There are many reports of discrimination and stigma against people from key populations 
in health-care settings. In many settings health workers lack experience, knowledge or 
training on how to provide inclusive and non-judgemental HTS for key populations. 
Countries should prioritize the training of health workers so that they can provide 
acceptable services, better understand the needs of key populations and be familiar with 
local support and prevention services (10). Links with key population networks and 
community-based organizations to support or provide HTS, including services delivered by 
peers, may increase reach, uptake and acceptability. 
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Consent by adults
Informed consent remains one of the essential 5Cs of testing services. It should 
always be obtained individually and in private by an HTS provider. In most settings 
verbal consent for HIV testing is sufficient. The provider must ensure that the client has 
learned enough about testing to give informed consent. HTS may provide information 
about testing and the need for consent in a group setting, such as group health education, 
but clients should give consent in an individual and private manner. In settings such as 
ANC or TB clinics, where HIV testing is routine, health workers should carefully explain 
how a client can decline testing and ensure that each person has a private opportunity to 
opt out of testing. People who are under the influence of drugs or alcohol or otherwise 
mentally impaired should not be tested, as they are not able to give informed consent. HTS 
should ensure that no one coerces clients into being tested.
Consent by adolescents
Policies related to age of consent for testing can pose barriers to adolescents’ access to 
HIV testing and other health services. While policies on age of consent for HIV testing vary 
among countries, ministries of health are encouraged to review these policies in light of 
the need to uphold adolescents’ rights to make choices about their own health and 
well-being (with consideration for different levels of maturity and understanding). All 
training materials should address applicable laws and regulations regarding age of consent 
for HIV testing and situations in which minors may consent for themselves. All staff involved 
in HTS should be aware of their countries' laws and regulations. For more information see 
HIV and adolescents: guidance for HIV testing and counselling and care for adolescents 
living with HIV (http://www.who.int/hiv/pub/guidelines/adolescents/en/) (54) and 
Adolescent HIV testing, counselling and care: implementation for health providers and 
planners (http://apps.who.int/adolescent/hiv-testing-treatment/page/Informed_consent_
and_HIV_testing) (55). 
3.3 Services for those who test HIV-negative
Individuals who test HIV-negative should receive brief health information about their test 
results. Research to date has not demonstrated that a lengthy counselling session is 
needed or is beneficial. Further, lengthy post-test counselling for people testing negative 
may divert counselling resources that are needed by those who test HIV-positive, those 
whose results are inconclusive and those who are found to be in a serodiscordant 
relationship (52, 56). 
Counselling for those who test HIV-negative should include the following:
•	 an explanation of the test result and reported HIV status;
•	 education on methods to prevent HIV acquisition and provision of male or female 
condoms, lubricant and guidance on their use;
•	 emphasis on the importance of knowing the status of sexual partner(s) and information 
about the availability of partner and couples testing services;
•	 referral and linkage to relevant HIV prevention services, including voluntary male 
medical circumcision (VMMC) for HIV-negative men, PEP, PrEP for people at substantial 
ongoing HIV risk;
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•	 a recommendation on retesting based on the client’s level of recent exposure and/or 
ongoing risk of exposure (see next section);
•	 an opportunity for the client to ask questions and request counselling.
3.3.1 Retesting during the window period 
In many settings post-test counselling messages recommend that all people who have a 
non-reactive (HIV-negative) test result should return for retesting to rule out acute 
infection that is too early for the test to detect – in other words, in the window period. 
However, retesting is needed only for HIV-negative individuals who report recent 
or ongoing risk of exposure. For most people who test HIV-negative, additional 
retesting to rule out being in the window period is not necessary and may waste 
resources. 
For most people who test 
HIV-negative, additional retesting 
to rule out being in the window 
period is not necessary.
The routine and widely reiterated advice to everyone 
with a negative test result to retest after a “three-
month window period” is not appropriate. This is 
because most people who receive HIV testing and 
test HIV-negative, particularly where HIV testing is 
offered routinely in clinical settings, will not be at 
risk from recent infection. For a small minority who identify a specific recent suspected 
exposure, retesting after four to six weeks can be advised. 
See Table 3.1, page 31, and Delivering HIV test results and messages for retesting and 
counselling in adults (http://www.who.int/hiv/pub/vct/hiv_re_testing/en/) (12) for detailed 
and specific guidance on messages concerning retesting. 
3.3.2 Retesting for those who remain at high risk of HIV acquisition
People who are diagnosed HIV-negative but remain at high risk, such as some people from 
key populations, may benefit from regular retesting. Retesting gives these people both the 
opportunity to ensure early HIV diagnosis and to receive ongoing health education on HIV 
prevention. WHO recommends that people in high-risk categories retest at least 
annually (12). 
3.3.3 Services for adolescents who test HIV-negative
Particularly in high prevalence settings, adolescents who test HIV-negative need information 
and education about healthy behaviours, such as correct and consistent condom use, 
reduction of risk-associated behaviours and prevention of HIV and unwanted pregnancy 
and about the need for retesting if they have new sexual partners. Those testing negative 
also need referral to appropriate prevention services, such as VMMC, contraception and 
harm reduction (54). For more information see HIV and adolescents: guidance for HIV 
testing and counselling and care for adolescents living with HIV (http://apps.who.int/iris/
bitstream/10665/94334/1/9789241506168_eng.pdf) (55).
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3.3.4 Services for partners who both test HIV-negative
Particularly in high prevalence settings, couples and others who test for HIV with a sexual 
partner and are both diagnosed HIV-negative can benefit from the standard health 
information and prevention education given to individuals who test negative. In addition, 
the counsellor or health worker may offer further counselling at the couple’s or a partner’s 
request. 
3.4 Services for those whose HIV status is inconclusive or test 
results are not yet confirmed
An HIV-inconclusive status means, in high prevalence settings, that the first reactive 
test result was not confirmed by additional testing using subsequent HIV assays or that, 
in low prevalence settings, the first two test results were reactive but the third assay was 
non-reactive (see Chapter 7). All clients with an HIV-inconclusive status should be 
encouraged to return in 14 days for additional testing to confirm their diagnosis.
Receiving an HIV-inconclusive status may be confusing and stressful for the individual or 
couple and may be difficult for the provider to explain. As with many other tests for 
medical conditions, resolving the discrepancy with a third test is not useful, given the high 
probability that it may equally produce a false-reactive result. Most, if not all, HIV-
inconclusive statuses can be resolved with retesting 14 days later. (For a full discussion of 
discrepant test results and resolving an HIV-inconclusive status, see Chapter 7.) Clients 
with an HIV-inconclusive status should be told that a definitive diagnosis cannot be 
provided that day and that immediate referral to HIV care or ART initiation is not 
appropriate. They should be given a clear plan for follow-up testing.
Unconfirmed results occur when clients who have an initially reactive HIV test result do 
not receive additional testing in the same visit to confirm their HIV diagnosis. This may 
occur in community settings where only one assay is performed, an approach known as 
test for triage (see Chapter 4). It is the responsibility of providers and counsellors to 
explain that this initial result is not an HIV diagnosis and needs confirmation and to 
refer clients with a reactive test result to a site where they can receive an HIV diagnosis. 
These providers should encourage clients to go as soon as possible to a facility, such as a 
clinic or laboratory, for additional HIV testing and a diagnosis. It is not necessary for these 
clients to wait 14 days to go to the facility. After the test result is confirmed and an HIV 
diagnosis is given, HIV-positive clients should receive post-test counselling. In particular, 
every effort is needed to reduce loss to follow-up between a test for triage and 
additional testing and HIV diagnosis.
3.5 Services for those whose test results are HIV-positive
An HIV-positive diagnosis is a life-changing event. Before giving HIV-positive test results, 
the health worker, trained lay provider, or counsellor should keep in mind the 5 Cs of HTS, 
as recommended by WHO and UNAIDS, in particular correct test results (see section 
1.7). It is the professional and ethical duty of the person providing the HIV diagnosis to 
ensure that testing procedures follow WHO-recommended testing strategies as described 
in Chapter 7.
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A diagnosis of HIV infection is a 
life-changing event. Before giving 
these results, the provider should 
keep in mind the 5 Cs of HTS.
Once health workers or lay providers are confident of 
adherence to all measures to ensure correct test 
results, they should provide post-test health 
education and counselling. All post-test counselling 
should be “client-centred”, which means avoiding 
formulaic messages that are the same for everyone 
regardless of their personal needs and circumstances. Instead, counselling should always 
be responsive to and tailored to the unique situation of each individual or couple. Health 
workers, professional counsellors, social workers and trained lay providers can provide 
counselling. People with HIV who are trained in counselling may be particularly under-
standing of the needs and concerns of those who receive an HIV-positive diagnosis. 
wHo good practice recommendation  
To ensure that clients who are misdiagnosed are not needlessly placed on life- 
long ART (with potential side-effects, waste of resources and psychosocial and 
emotional implications), WHO recommends that all clients be retested to verify 
their HIV diagnosis prior to enrolling in care and/or starting ART.
Source: WHO, 2012 (44); WHO, 2014 (57).
The information and counselling that health workers, or others, should provide to HIV-
positive clients is listed below. Absorbing all of this information in one session may be 
very challenging, and a follow-up counselling session may be required. Indeed, the shock 
of learning of an HIV-positive diagnosis may make it difficult for a person to take in further 
information immediately. 
•	 Explain the test results and diagnosis.
•	 Give the client time to consider the results and help the client cope with emotions 
arising from the diagnosis of HIV infection.
•	 Discuss immediate concerns and help the client decide who in her or his social 
network may be available to provide immediate support.
•	 Provide clear information on ART and its benefits for maintaining health and reducing 
the risk of HIV transmission, as well as where and how to obtain ART.
•	 Make an active referral for a specific time and date. (An active referral is one in which 
the tester makes an appointment for the client or accompanies the client to an 
appointment, including an appointment for co-located services, and enrolment into HIV 
clinical care.) Discuss barriers to linkage to care, same-day enrolment and ART eligibility 
assessment. Arrange for follow-up of clients who are unable to enrol in HIV care on the 
day of diagnosis. 
•	 Provide information on how to prevent transmission of HIV, including information of 
the reduced transmission risk when virally suppressed on ART; provide male or female 
condoms and lubricants and guidance on their use.
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•	 Discuss possible disclosure of the result and the risks and benefits of disclosure, 
particularly among couples and partners. Offer couples counselling to support mutual 
disclosure.
•	 Encourage and offer HIV testing for sexual partners, children and other family 
members of the client. This can be done individually, through couples testing, index 
testing or partner notification.
•	 Assess the risk of intimate partner violence and discuss possible steps to ensure the 
physical safety of clients, particularly women, who are diagnosed HIV-positive.1 
•	 Assess the risk of suicide, depression and other mental health consequences of a 
diagnosis of HIV infection.
•	 Provide additional referrals for prevention, counselling, support and other 
services as appropriate (for example, TB diagnosis and treatment, prophylaxis for 
opportunistic infections, STI screening and treatment, contraception, ANC, opioid 
substitution therapy (OST), and access to sterile needles and syringes, and brief 
sexuality counselling (58) ).
•	 Encourage and provide time for the client to ask additional questions.
Case example: adhara HIV/aIdS association, Spain  
In Seville a community-based outreach programme of the Adhara HIV/AIDS 
Association (http://www.adharasevilla.org) makes sure that the partner of 
someone testing HIV-positive is promptly linked to a consultation with an HIV 
specialist. They have compared this strategy with voluntary HIV testing at 
community centres and found that the number of newly diagnosed HIV-positive 
cases at the detached community centre was was lower compared with using the 
index partner testing strategy.
Source: Annex 3.
3.5.1 Special considerations concerning disclosure
People who test HIV-negative rarely need assistance or support with disclosing their HIV 
status to others. In contrast, maintaining privacy about testing HIV-positive and deciding 
about disclosure are serious concerns for many who are diagnosed HIV-positive. 
There are three forms of disclosure relevant and appropriate to HIV testing:
•	 Disclosure by the individual to a sexual partner, family member or friend. Such 
disclosure can have considerable benefits, particularly for couples and sexual partners. 
However, many clients who learn that they are HIV-positive need time to absorb the 
diagnosis before they are ready to disclose and may benefit from additional counselling. 
Research findings on the consequences of disclosure, especially disclosure by women to 
their male partners, are mixed. Women who have experienced intimate partner violence 
1 Training in assessment of intimate partner violence and knowledge of referral sources is helpful.
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prior to testing may experience violence from their partner after disclosing their HIV 
status. Providers and counsellors should assess the risk of intimate partner violence in 
the individuals they serve (59, 60) and make referrals as needed.
•	 Disclosure by a health worker to a sexual partner of the individual. In some 
settings laws or regulations require the disclosure of HIV-positive status to sexual 
and/or drug-injecting partners. Where this is the case, providers should discuss this with 
clients before asking for informed consent for testing. Providers need to be sensitive to 
clients who may be more susceptible to adverse outcomes of disclosure, such as 
discrimination, violence, abandonment or incarceration and to adapt counselling 
accordingly. Such clients may need additional counselling both before and after testing. 
•	 Disclosure by a health worker to other health workers involved in the client’s care. 
Providers need to inform people who test positive that, in order to assure appropriate 
medical care, the diagnosis will be shared with other medical workers as needed. Such 
disclosure should respect the client’s basic right to privacy and confidentiality of all 
medical information.
Disclosure by a health worker to the police or other legal authorities is not considered 
ethical in the context of HTS unless the client has consented to this disclosure. In this case 
HTS providers should obtain written consent to disclose a client’s HIV status to legal 
authorities. 
3.5.2 Post-test counselling for special populations
Key populations. Intensified post-test counselling combined with follow-up counselling 
by community health workers significantly increases the proportion of people with HIV 
from key populations who enrol in HIV care (61). Also, people who inject drugs are more 
likely to start and stay in HIV treatment if they are participating in OST programmes (62). 
Therefore, referral to community health workers and to other services such as OST should 
be included in post-test counselling for people from key populations. Some people from 
key populations who test HIV-positive may lack social networks and/or a supportive family 
to help them deal with their diagnosis. These people may need additional counselling as 
well as peer support services to cope with this diagnosis. A peer counsellor may 
particularly help people understand and cope with the diagnosis and support linkage to 
care and treatment by serving as a “peer navigator”, who assists with finding, choosing 
and obtaining a full range of services. 
The 2014 WHO Consolidated guidelines on HIV prevention, diagnosis, treatment and care 
for key populations (http://www.who.int/hiv/pub/guidelines/keypopulations/en/) (10) 
describes essential services for key populations. In terms of HTS these guidelines describe 
interventions to reduce barriers to testing and to linkage to care after testing.
Couples and partner HIV testing services. Couples counselling requires additional 
training and enhanced counselling skills. Post-test counselling for serodiscordant couples 
may be especially challenging, as these results may be hard for the provider to explain and 
difficult for the couple to accept. For more guidance on post-test counselling and services 
for discordant couples, see Guidance on couples HIV testing and counselling including 
antiretroviral therapy for treatment and prevention in serodiscordant couples (http://apps.
who.int/iris/bitstream/10665/44646/1/9789241501972_eng.pdf) (16).
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Pregnant women. Post-test counselling for pregnant women who are diagnosed with an 
HIV infection should include the following, in addition to the standard messages described 
above for all people diagnosed with HIV infection:
•	 childbirth plans: providers should encourage HIV-positive pregnant women to deliver in 
a health facility for their own well-being as well as to ensure access to PMTCT services;
•	 use of ARVs for the client’s health, when indicated and available, as well as the use 
of ARVs to prevent transmission to the infant;
•	 the importance of partner testing and information on the availability of couples 
testing services;
•	 ensuring screening for TB and testing for other infections such as syphilis;
•	 counselling on adequate maternal nutrition, including iron and folic acid;
•	 advice on infant feeding options and support to carry out the mother’s infant feeding 
choice;
•	 HIV testing for the infant and needed follow-up for HIV-exposed infants.
Adolescents. Along with standard messages for all those diagnosed with an HIV 
infection, post-test counselling for adolescents with HIV should include (54) :
•	 tailored help with linkage to HIV care and treatment;
•	 counselling, referral and linkage to specific psychosocial and mental health services 
tailored to both the situation in which infection happened and the developmental age of 
the individual;
•	 information on adolescents’ rights and responsibilities, especially their right to 
confidentiality; 
•	 an opportunity to ask questions and discuss issues related to sexuality and the 
challenges they may encounter in relationships, marriage and childbearing;
•	 individualized planning on how, when and to whom to disclose HIV status and 
engage families and peers in providing support;1
•	 referral for small-group counselling and structured peer support groups, which 
may particularly benefit adolescents with HIV.
Children. Informing children of their HIV diagnosis is complex, and the approach depends 
on the child’s age and the counselling skills of the health-care provider. For information on 
disclosure to children, see Guidance on HIV disclosure counselling for children 12 years of 
age and younger (http://www.who.int/hiv/pub/hiv_disclosure/en/) (49). 
3.6 linkage to care
Without linkage to treatment and care, testing and learning one’s HIV-positive status have 
limited value. Also, those who test HIV-negative, if at continuing high risk, as well as those 
who test HIV-positive, need linkage to prevention services. Table 3.1 classifies the variety 
of services that may be appropriate links for people with HIV and for people who test 
HIV-negative. WHO provides guidance on the HIV care and prevention services that may be 
offered according to client needs and overall context (13). 
1 Additional WHO guidance on disclosure to and by adolescents appears at: http://apps.who.int/adolescent/hiv-testing-treatment/page/
disclosure.
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Table 3.1. HIV care and prevention services by test status
HIV-positive HIV-negative
Treatment Antiretroviral therapy
Prevention Male and female condoms and condom-compatible lubricants
PrEP for people at substantial ongoing 
risk of HIV-infection
PEP following suspected exposure
VMMC (in 14 priority countries)
Harm reduction for people who use drugs (needle and syringe programmes, OST, 
other drug-dependence treatment and opioid overdose prevention and management)
Behavioural interventions to support risk reduction, particularly for people with HIV 
and key populations
Sexual and 
reproductive 
health
Contraception
Brief sexuality counselling
PMTCT
Cervical cancer screening
Anal cancer screening (for men who have sex with men)
STI screening STI screening for those with ongoing risk, 
including key populations
HIV testing for 
partners and 
family members
For all partners and family members 
(includes partner notification and index 
case testing)
For partners of people from key 
populations, where appropriate
Retesting and 
confirmatory 
testing
Retest before ART initiation or when 
linked to care from community-based 
testing
Retest at least every 12 months if at high 
ongoing risk, particularly key populations
Other clinical 
services
Assessment and provision of vaccinations, such as HBV for key populations, pregnant 
women and infants, tetanus vaccination for adolescent boys and men receiving 
VMMC where appropriate
HBV and HCV testing and treatment HBV and HCV testing particularly for key 
populations, according to epidemiology, 
and treatment
Co-trimoxazole chemoprophylaxis
Intensified TB case finding and linkage to TB treatment
Provision of isoniazid preventive therapy 
if person does not have TB
Malaria prevention (such as bed nets and prophylaxis), depending on epidemiology
Other support 
services
Mental health services
Psychosocial counselling, support and 
treatment adherence counselling
Support for disclosure and partner 
notification
Legal services
Sources: WHO, 2013 (13); WHO, 2012 (41); WHO, 2008 (59).
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key messages about linkages and connections to prevention, treatment 
and care 
•	 There appear to be good practices that support linkage to prevention, treatment 
and care (see box, next page). However, evidence is limited. 
•	 All people who test HIV-positive need immediate linkage to care to maximize the 
benefits of ART. 
•	 Special efforts will be needed to link people who have a reactive test result in a 
community setting to facility-based services for additional testing and an HIV 
diagnosis. For those diagnosed HIV-positive, retesting to verify diagnosis is 
critical before care or treatment is initiated. 
•	 People diagnosed HIV-positive and those testing HIV-negative with ongoing HIV 
risk need to be linked to prevention services.
•	 National policies and strategic planning are needed to improve access to and 
uptake of HIV testing as well as linkage from testing to prevention, treatment 
and care.
3.6.1 linkage to treatment and care
Linkage is defined as a process of 
actions and activities that support 
people testing for HIV and people 
diagnosed with HIV to engage with 
prevention, treatment and care 
services as appropriate for their HIV 
status. For people with HIV, it refers 
to the period beginning with HIV 
diagnosis and ending with enrolment 
in care or treatment (64).
Linkage to care after receiving an HIV-positive 
diagnosis remains challenging. In resource-
limited settings, primarily sub-Saharan Africa, it 
is estimated that as much as 40% of people 
who are diagnosed through HTS are not linked 
to care (25, 37, 38), and late initiation of ART 
continues to be common (39). Factors that may 
contribute to poor linkage and particularly to 
poor rates of enrolment in care and treatment 
following HIV testing range from client 
factors, such as feeling healthy, depression, 
lack of social or family support and fear of 
disclosure, to social or cultural factors, such 
as stigma and discrimination, structural or economic factors, including legal issues and 
lack of transportation, and health system barriers, such as poor referrals, stigmatizing or 
unfriendly services and long waiting times in facilities (65, 66). 
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Good practices to increase linkage  
Providers of HTS have a crucial role in ensuring linkage to care for people diagnosed 
with an HIV infection, whether that linkage is quick or delayed. Prompt linkage to 
HIV care and treatment is ideal and should be encouraged. However, many people 
do not link to care and treatment immediately. Often, people need time to accept 
the diagnosis and seek support from partners and families before linking to care 
(67), and others cycle in and out of care (37). Systematic reviews and several studies 
describe practices, listed below, that may improve linkage to care and treatment of 
people who have received an HIV-positive diagnosis. 
Good practices include:
•	 Comprehensive home-based HIV testing, which includes offering home 
assessment and home-based ART initiation (52, 68–70) ; 
•	 Integrated services, where HIV testing, HIV prevention, treatment and care, TB 
and STI screening and other relevant services are provided together at a single 
facility or site (34) ;
•	 Providing on-site or immediate CD4 testing with same-day results (37, 
70–74) ;
•	 Providing assistance with transport, such as transportation vouchers, if the 
ART site is far from the HTS site (37, 75) ;
•	 Decentralized ART provision and community-based distribution of ART (76) ; 
•	 Support and involvement of trained lay providers who are peers and act as 
peer navigators, expert patients/clients and community outreach workers to 
provide support and to identify and reach people lost to follow-up (76–78) ; 
•	 Intensified post-test counselling by community health workers (79) ;
•	 Using communication technologies, such as mobile phones and text 
messaging, which may help with disclosure, adherence and retention (80–82), 
particularly for adolescents and young people (54) ;
•	 Providing brief strengths-based case management, which emphasizes 
people's self-determination and strengths, is client-led and focuses on future 
outcomes, helps clients set and accomplish goals, establishes good working 
relationships among the client, the health worker and other sources of support in 
the community, and provides services outside of office settings (52, 83, 84) ;
•	 Promoting partner testing may increase rates of HIV testing and linkage to 
care, as may approaches in PMTCT settings that encourage male involvement 
(85, 86).
•	 Intimate partner notification by the provider, with permission, is feasible in 
some settings; it identifies more HIV-positive people and promotes their early 
referral to care (87–90).
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Case examples: “Test, treat and retain” – continuum of care and 
assessment tool in the Eastern mediterranean
In an effort to improve linkage to services, the WHO Regional Office for the 
Eastern Mediterranean developed a tool to assess the barriers to HIV testing, 
treatment and care. As a result of this assessment, Egypt, Iran, Pakistan and 
Sudan all were able to identify programmatic weaknesses that caused poor 
linkage rates. 
•	 In Egypt the assessment identified client factors as the key barriers to linking to 
HIV treatment. Clients fear disclosure and lack of confidentiality along the 
continuum of care. 
•	 In Iran the assessment showed that loss to follow-up is highest among people 
who inject drugs; 62% of people who inject drugs who had an initial reactive 
RDT did not link to laboratory-based confirmatory testing. 
•	 In Pakistan also, it was difficult to link people who inject drugs to confirmatory 
testing and, as appropriate, to HIV care and treatment. In fact, many people who 
inject drugs in Pakistan refused services, often due to fear of stigma and 
discrimination. 
•	 In Sudan efforts are underway to improve linkage to care from outreach mobile 
testing, which has had poor linkage rates, by introducing peer navigators to help 
and support clients in linking to services.
Sources: EMRO, 2014 (91); Annex 3.
3.6.2 linkage to HIV prevention services 
A range of HIV prevention services should be available for those with HIV, in addition to 
timely initiation of ART (92), and for those who are HIV-negative, (see Table 3.1). 
Linkage to prevention services for people who test HIV-negative is not well-documented or 
studied. It is important to support linkage to prevention services for those with the 
greatest ongoing risk, for example, people in settings of high HIV incidence, people from 
key populations and others at high risk of HIV, such as serodiscordant couples. In VMMC-
priority countries, linking HIV-negative men to VMMC services is important. Although 
linkage of men and boys eligible for VMMC from HIV testing to VMMC services can be 
challenging, it can succeed when linkage is prioritized. For example, in a Mozambique 
programme where lay providers’ HTS was performed, 68% of HIV-negative males were 
linked to VMMC services (93). 
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Case example: Government of mozambique and Jhpiego VmmC programme
The Government of Mozambique and Jhpiego provide a voluntary medical male 
circumcision (VMMC) programme and a related home- and community-based HTS 
programme. The HTS programme uses lay providers employed by local community 
and faith-based groups; they are known as community counsellors. Home-based 
HTS has been very acceptable to Mozambican communities, with more than one 
million clients tested between 2007 and 2014. Over the years the role of the 
community counsellors has expanded to include additional health screening and 
education. 
The Mozambican VMMC programme began in November 2009 and had reached 
322 129 men as of February 2015. In 2012, as the number and capacity of VMMC 
sites expanded, a decision was taken to train the community counsellors to refer 
men testing HIV-negative at home or at other community settings to VMMC 
services. Considerable effort was made to ensure that the community counsellors 
would be perceived as credible sources of information about VMMC. First, they 
attended a VMMC counselling training, followed by a two-week internship at a 
VMMC site. During their internship, they provided HTS for VMMC clients and had 
the opportunity to observe client flow from group education to post-operative 
follow-up. Two-thirds of men linked to the VMMC site received circumcisions.
Source: Annex 3.
3.6.3 linkage policy 
Countries should consider policies and strategies to improve and prioritize linkage between 
HTS and prevention, treatment and care services. 
For example, in 2009 the Ethiopia Ministry of Health developed its National Referral and 
Linkage Strategy (94). Key aspects of this strategy include activities to:
•	 strengthen the community environment to reduce stigma and increase community-
based support for treatment adherence and retention 
•	 improve service delivery, reporting and feedback mechanisms
•	 reduce barriers to care, such as administrative processes and the requirement for 
identification cards for enrolment in HIV care (94).
Monitoring people’s linkage following HIV testing is critical to strengthening treatment and 
prevention cascades. For additional guidance on the monitoring and evaluation of linkage 
to prevention, treatment and care services, see: 
•	 Consolidated strategic information guide for HIV in the health sector (http://www.who.
int/hiv/pub/guidelines/strategic-information-guidelines/en/) (95). 
•	 Metrics for monitoring the cascade of HIV testing, care and treatment services in Asia 
and the Pacific (http://www.wpro.who.int/hiv/documents/Metrics_to_Mmnitor_and_
evaluate_the_Impact_of_ART/en/) (96). 
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       Key PoINTS 
•	There are many facility-based and community-based approaches to delivering 
HTS. Selecting approaches strategically and applying effective programming practices are 
critical.
•	There are many advantages to integrating HIV testing with testing for HBV and 
HCV and with screening and testing for TB and STIs. 
•	Trained lay providers using RDTs should be authorized to perform HIV testing 
and provide pre-test information and post-test counselling. This will increase 
access to HTS, particularly to community-based services. 
•	The routine offer of HTS in clinical settings (PITC) has been widely implemented 
in antenatal and TB clinics in high HIV burden settings but often not in other facility 
settings, including paediatric clinics; this is a missed opportunity. 
•	WHO proposes a new approach for testing in community settings – “test for 
triage”, in which a single RDT is offered in the community with linkage to further testing 
in a facility to confirm an HIV-positive diagnosis and start clinical care when needed.
•	HIV self-testing (HIVST) is increasingly available, both informally and in a regulated 
manner, in some countries. The potential benefits of HIVST, related issues and potential 
cautions should be weighed and considered.  
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4.1 Principles and approaches to service delivery
HTS can be delivered in different ways and to different people. Services can be offered in 
a variety of settings, both in health facilities and in the community. HTS can be offered 
in facilities such as primary care clinics, inpatient wards and outpatient clinics, including 
specialist clinics such as STI and TB clinics, in district and provincial or regional hospitals 
and their laboratories and in private clinical services. In the community HTS can be 
offered through home-based index testing or door-to-door outreach, in schools and 
other educational establishments and in workplaces, places of worship, parks, bars and 
other venues. In addition, HIV self-testing (HIVST), a process in which an individual who 
wants to know his or her HIV status collects a specimen, performs a test and interprets the 
result by him or herself, often in private, is an emerging approach that can extend HTS to 
people who may be unable or reluctant to attend existing HTS as well as to people who 
frequently retest (14). 
assess the situation 
To identify approaches with the greatest public health benefit and impact, a situational 
assessment should be undertaken. This assessment should consider HTS coverage, gaps in 
coverage in geographic areas with high levels of undiagnosed HIV infection and among 
populations at high risk of HIV infection, the social and epidemiological context and the 
available financial and human resources.
a strategic mix of HTS approaches 
A strategic mix of HTS approaches 
facilitates diagnosis of as many 
people as early as possible, with 
linkage to prevention, treatment, 
care and support for those testing 
HIV-positive and to prevention 
services for those who test 
HIV-negative.
Countries need to consider a strategic mix of 
approaches to deliver HTS. The mix should facilitate 
the diagnosis of as many people with HIV as early as 
possible. In diagnosing as many people as possible, 
the mix should aim to maximize yield, efficiency, 
cost-effectiveness and equity. Equity does not mean 
that HTS should be provided equally across a 
country or population; rather it should focus HTS on 
populations at greatest risk for HIV and who are 
undeserved. Also, the mix should support timely and 
complete linkage to prevention, treatment, care and support services for those testing 
HIV-positive. Those who test HIV-negative, particularly those at ongoing risk, need linkage 
to prevention services as well as to learn where and when to retest. The organization of 
the health system, local context, epidemiology, current testing coverage and available 
financial and human resources and what the intended clients want, will determine the 
appropriate mix of HTS approaches to reach populations at high risk and geographic areas 
with largely undiagnosed HIV infection (44). 
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Provide a supportive environment with critical enablers
Critical enablers are key to the success of health sector HIV interventions. Critical enablers 
are conditions, to some extent outside the purview of the health sector, that facilitate the 
accessibility, acceptability, uptake, equitable coverage, quality, effectiveness and efficiency 
of HIV interventions and services. These critical enablers support the uptake of HIV testing 
and linkages to prevention, treatment and care, especially for groups that are reluctant to 
use or have limited access to current HTS, such as men, adolescents, key populations and 
other vulnerable groups. Collaborating with other ministries, NGOs and faith-based 
organizations is crucial to develop the necessary strategies, activities and approaches that 
address critical enablers (Fig. 4.1).
fig. 4.1. addressing critical enablers for HTS programmes 
* Includes decriminalization and age of consent.
1
Reviewing laws, 
policies and practices* 
Reducing stigma and 
discrimination
2
empowering  
the community
4
Preventing  
violence
3
Critical 
enablers
Source: WHO, 2014 (10).
all HTS must meet standards
HTS must emphasize the WHO 5 Cs (see section 1.7). All people being tested for HIV must 
give informed verbal consent to be tested and be made aware of their right to 
refuse testing. Mandatory, compulsory or coercive HIV testing is never appropriate (44). 
HTS should always be provided in a respectful, non-discriminatory and ethical manner, 
reflecting the professional integrity of the provider and respecting the human rights of the 
person being tested. 
All sites that provide HTS should have SOPs and ethical codes of conduct. They should 
protect client information and confidentiality and should employ appropriately trained and 
supervised health workers (including lay providers) (97). 
All HIV testing should follow a validated national testing algorithm and WHO-
recommended testing strategies.1 This approach should include retesting all people 
previously diagnosed HIV-positive before they enrol in care or initiate 
treatment (57). 
All HTS should have appropriate quality assurance (QA) and quality improvement (QI) 
mechanisms in place (44, 95). 
1 A testing strategy refers to the sequence in which diagnostic tests are used for a specific objective, taking into consideration the presumed 
HIV prevalence in the population tested. A testing algorithm refers to a defined combination of specific assays within a testing strategy.
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4.2 Good practices for effective HTS programming
Several WHO-recommended effective health programming practices can improve the 
quality and efficiency of HTS in some settings. These practices include: 
•	 integration of HTS with other health services 
•	 decentralization of HTS to primary health-care facilities and outside the health system 
(for example, workplaces, schools, places of worship)
•	 task sharing of HTS responsibilities to increase the role of trained lay providers (10, 13). 
definitions
Integration: the co-location and sharing of services and resources across 
different disease areas. In the context of HIV, this may include the provision of 
HIV testing, prevention, treatment and care services alongside other health 
services, such as TB, STI, HBV and HCV services, antenatal care, contraceptive 
and other family planning services, and screening and care for other conditions, 
including noncommunicable diseases.
Decentralization: the process of delegating or transferring significant authority 
and resources from the central ministry of health to other institutions or to field 
offices of the ministry at other levels of the health system (provincial, regional, 
district, subdistrict, primary health-care post and community).  
Task sharing: the rational redistribution of tasks between cadres of health-care 
providers with longer training and other cadres with shorter training, such as 
trained lay providers.
4.2.1 Integration of HIV testing with other services
Integration involves not only providing related services in a single setting, but also linking 
recording and reporting systems to share information, with the consent of the client, and 
to provide referrals between settings and providers. WHO recommends the integration 
of HIV services, including HTS, with a range of other relevant clinical services, 
such as those for TB, maternal and child health, sexual and reproductive health, harm 
reduction programmes for people who inject drugs and, in priority countries, VMMC 
programmes (13). The primary purpose of such integration is to make HTS more convenient 
for people coming to health facilities largely for other reasons, and to increase the uptake 
of HIV testing. Also, certain other services, such as TB, STI and harm-reduction services, 
attract a clientele that is generally at high risk for HIV infection. Thus, integration with HTS 
and other HIV services creates the opportunity to diagnose coinfections and to start care and 
treatment services for all conditions at the same time and in the same place. Integration is 
appropriate in all epidemic settings and particularly important where HIV prevalence is high. 
For clients the integration of HTS into other health services may facilitate taking care of 
various health needs at the same time and in the same location, saving time and money. It 
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will likely facilitate linkage to complementary prevention or treatment and care services 
and expand the reach of HIV testing to people seeking other health services. For the health 
system, integration may reduce duplication of services and improve coordination – for 
example, in stock management (98). 
The goal of programme 
collaboration should be to 
create integrated delivery 
systems that best facilitate 
access and increase impact.
Collaboration among programmes at every level of the 
health system is important to the success of HIV 
services and related health and social services. Aspects 
of coordination that need consideration include 
mobilizing, allocating and sharing resources (including 
multi-tasking and task sharing; see section 4.2.3); 
training, mentoring and supervising health workers; 
procuring and managing medicines, test kits and other medical supplies; maintaining the 
quality of HIV testing; and reducing stigma and discrimination in health-care settings. The 
goal of programme collaboration should be to create integrated delivery systems that best 
facilitate access to and increase the impact of HTS, HIV treatment and other health 
services. 
Case example: Integration of services 
In Myanmar, in an effort to reduce harm associated with unsafe sexual practices 
among female sex workers, men who have sex with men and transgender people, 
Médecins du Monde provides HIV and sexual health services and psychosocial 
support in a friendly setting that offers various activities. Users are free to access 
medical care or just relax, with social activities and services offered such as 
meditation in dedicated areas, games, hair dressing or manicures.
Source: Annex 3.
4.2.2 decentralization of services
In HTS decentralization refers to providing HTS in peripheral health facilities, community-
based venues and other locations other than sites performing confirmatory HIV testing and 
related services. Decentralization of services may be appropriate in both high 
prevalence and low prevalence settings. For example, providing HIV testing in places 
closer to people’s homes may reduce transportation costs and waiting times experienced in 
central hospitals and, therefore, increase uptake. Task sharing, and particularly the greater 
involvement of trained lay providers, can facilitate efforts to decentralize health services, 
including HTS.
Decentralization of services, however, may not always be appropriate or acceptable to 
potential users. In some settings centralized HIV services may provide greater anonymity 
than neighbourhood services for key populations or others who fear stigma and discrimina-
tion. Also, in some low prevalence settings, decentralizing HTS may be inefficient and 
costly. Context, needs, service gaps and overall costs and benefits should be weighed to 
decide where HTS should be decentralized. 
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4.2.3 Task sharing of HTS: increasing the scope of work of lay providers
Task sharing: background and rationale
Many countries continue to face shortages of trained health workers. Task sharing – that 
is, the rational redistribution of tasks between cadres of health-care providers with longer 
training with cadres with shorter training – is a pragmatic response to health workforce 
shortages. It seeks to increase the effectiveness and efficiency of available personnel and 
so to enable the existing workforce to provide HTS to more people. 
Task sharing to trained lay 
providers seeks to enable the 
existing workforce to provide HTS 
to more people.
In particular, task sharing to staff that works in the 
community may help to address the needs of key 
populations and other priority groups that may be 
reluctant or unable to access HTS in health facilities, 
including linking them to services and providing 
ongoing care and support. Services led by trained lay 
providers, including peer-based interventions, can be a welcome and thus important 
means of delivering services, providing information and teaching skills that promote safer 
behaviours. Beyond providing services, lay workers who are their clients’ peers can act as 
role models and offer non-judgemental and respectful support that can help reduce 
stigma, facilitate access to services and improving their uptake (10, 99).
By itself, increasing task sharing and broadening the scope of responsibilities of trained lay 
providers will not fully rectify staff shortages and poor quality services. Task sharing is not 
simply a means to save resources but rather one potentially valuable tool to improve both 
access to and coverage of services and the quality of services. 
WHO has previously recommended the use of lay providers to perform certain 
clinical services, including counselling and referrals, and has particularly recommended 
task sharing in the delivery of some HIV clinical services (17, 151), including in mother, 
newborn and child health services and promotion of HIV testing in pregnancy and 
prescription of ART by nurses (6). Task sharing to expand HTS has taken place for over a 
decade in many countries across the Americas (100), Europe (101, 102), sub-Saharan Africa 
(103–109) and Asia (110). Several systematic reviews, from various domains of health care, 
support the general conclusion that good health outcomes can be achieved by devolving 
tasks to nurses and lay or community health workers (111–114). 
definition
Lay provider: any person who performs functions related to health-care delivery 
and has been trained to deliver specific services but has received no formal 
professional or paraprofessional certificate or tertiary education degree. 
Source: WHO, 2014 (6).
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Review of the evidence regarding task shifting to lay providers 
In this guideline WHO issues a new recommendation endorsing the provision of HTS by lay 
providers (see definition in box) using RDTs. A summary of the results of a systematic 
review of the relevant evidence and a discussion of the guidance follow. Annexes 1 and 2 
provide details.
The uptake of HTS can increase when trained lay providers deliver services. In a 
randomized trial in an emergency department in the United States of America, the rate of 
uptake of HTS was higher in the trained lay providers arm than in the trained health-care 
professionals arm – 57% (1382/2446) versus 27% (643/2409; p<.001) (100). Similarly, a 
pre/post study in rural Malawi reported that, after HTS was delegated from health workers 
with longer training to lay providers with shorter training, the uptake of HIV testing 
increased from 1300 to 6500 tests per month (104). 
HIV testing conducted by trained lay providers is accurate and equivalent to testing 
by laboratory staff and health-care providers with longer training, as three studies have 
shown (103, 105, 110). In the Sisonke District of South Africa, of 3986 samples tested both 
by trained lay providers and by laboratory staff, all but 23 results matched (105). Of these 
23, only two cases were deemed “critical errors”: the trained lay providers found HIV-
positive test results whereas the laboratory reported HIV-negative test results. The 
remainder were cases in which at least one result was inconclusive. Most of these were 
considered cases in which a trained lay provider was extra cautious and waiting for 
laboratory confirmation before providing the client with an HIV status. Overall, sensitivity 
was calculated at 98.0% (95% CI: 96.3–98.9%) and specificity at 99.6% (95% CI: 
99.4–99.7%). In Malawi HIV testing performed by trained lay providers had a sensitivity of 
99.6% and a specificity of 100%. Of 2911 specimens sent for laboratory confirmation, only 
four results did not match the results found by lay providers. Three of these four were 
classified as “sample peculiarities” because the results from several parallel testing 
strategies continued to be discordant (103). In Cambodia, of 563 specimens, trained lay 
providers’ and laboratory staff’s test results matched in all but four cases (110). Further 
investigation found that all test results reported by trained lay providers were correct; 
errors in writing reports in the laboratory explained the discrepant findings.
Values and preference
Six additional studies reported on some aspect of the values and preferences of clients 
concerning trained lay providers conducting HTS (two in the USA (115, 116) and four in 
sub-Saharan Africa (108, 117–119). In a randomized controlled trial in the USA that included 
a client satisfaction survey, clients reported greater overall satisfaction with the HTS 
provided by trained lay providers than with HTS provided by trained health professionals 
(OR: 1.50; 95% CI: 1.00–2.24) (115). In Botswana 46 of 47 clients who received HTS from a 
trained lay provider and participated in exit interviews expressed a high level of satisfac-
tion with services and felt comfortable about returning for services in the future (119). 
Overall, studies found support among clients for trained lay providers performing HTS, 
particularly in the most rigorous study, the randomized controlled trial in the USA (100).
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The systematic review and the values and preference search identified other benefits of 
trained lay providers offering testing and counselling. These include:
•	 Opportunities for delivering a range of services. Trained lay providers can deliver 
various health services within and beyond HIV prevention, treatment and care, including 
vaccination, TB and STI screening and testing and bed net distribution for malaria 
prevention.
•	 Cost-saving. Task sharing involving lay providers with shorter training may cost less 
than using health workers with longer training to perform the same tasks. Trained lay 
providers generally receive lower wages than health professionals. However, full 
programme costs, cost-effectiveness and affordability vary across settings. 
•	 Feasible and currently supported by national policy. An analysis of national HIV 
testing policies in 48 countries found that trained lay providers are permitted to perform 
HIV testing with RDTs in 40% of countries overall and in over 60% of the 25 countries in 
the WHO African region. Even greater numbers of countries allow lay providers to 
perform pre-test information and post-test counselling (60% of the 48 countries and 
80% in the WHO African region) (41) (see Annex 2). A number of countries, however, 
still limit these functions to health professionals with longer training. 
•	 Social and cultural context. Task sharing with trained lay providers may increase the 
likelihood that services will be sensitive to the culture of the community (120, 121). In 
particular, trained lay providers may reach more people because they often are culturally 
competent at talking with their peers, particularly people from key populations and 
adolescents (10, 54, 122).
wHo recommendation
Lay providers who are trained and supervised to use rapid diagnostic tests 
(RDTs) can independently conduct safe and effective HIV testing services 
(strong recommendation, moderate quality of evidence). 
additional considerations
Selection. Selection of lay providers is important. For example, in Zambia clients wanted 
providers they could trust; such trust was based on providers’ professional conduct, 
knowledge, politeness, adeptness in dealing with sensitive issues and ability to listen (108). 
Training, mentoring and ongoing support. Like other health-care providers and 
laboratory technicians, lay providers need training, mentoring and supervision by on-site 
supervisors, ideally including someone trained in laboratory procedures. National 
competency standards can help to ensure that lay providers are offering high quality HTS. 
Standardized training should cover how to conduct full HTS procedures, including 
collecting specimens, performing RDTs following the validated national testing algorithm 
and testing strategy, providing counselling and issuing test reports as well as record-
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keeping and reporting. Lay providers also should be trained in medical ethics so that they 
are fully aware of their duties to obtain consent and to maintain confidentiality regarding 
the client and the client’s test results and HIV status. As with any other health workers 
providing HTS, ongoing supportive supervision and mentoring of lay providers should cover 
both the testing and counselling aspects of their work, provide up-to-date job aides and 
SOPs, and involve regular external quality assessment (EQA). A system for quality 
assurances (QA) will need to be in place for HTS provided by trained lay 
providers, as it should be for HTS conducted by health professionals. See Chapter 8 
for additional information on QA systems. 
Remuneration. Trained lay providers may cost less than health workers with longer 
training. However, it is important that programmes compensate trained lay providers 
appropriately for their work. Otherwise, high turnover is likely. These workers should 
receive adequate wages and/or other appropriate incentives. The main reason for involving 
lay workers is to increase access to HTS and not to reduce costs.
Policy and regulations. Task sharing requires government leadership, to emphasize its 
importance, to give priority to its implementation and to ensure an enabling regulatory 
framework. National policies need to establish a role for trained lay providers with special 
skills to perform HTS and include their terms of reference in the national salary grid (see 
box). Some countries may need to change regulations and policies so as to enable nurses, 
other non-physician health professionals and trained lay providers to offer HTS. Support 
from the national medical, nursing and medical technologist councils will facilitate the 
necessary policy changes. 
key steps for introducing HTS by lay providers
Countries should review and revise national policies to:
•	 permit trained lay providers to provide all testing services, including collecting 
specimens, performing HIV rapid diagnostic tests, interpreting test results and 
reporting HIV status; to give pre-test information and post-test counselling; and 
to support linkages to prevention, treatment and care services;
•	 acknowledge and adequately remunerate trained lay providers for performing 
HTS, in keeping with their specialized skills; 
•	 address the roles of trained lay providers in national policies and regulatory 
frameworks, such as human resource for health and HIV testing policies. 
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4.3 HIV testing service approaches 
WHO recommends making HTS available through a wide range of approaches, both in 
facilities and in the community, as appropriate to local epidemiology and context. 
4.3.1 facility-based HIV testing services 
Facility-based HIV testing services refers to HTS provided in a health facility or laboratory 
setting. 
Voluntary counselling and testing
Developed before treatment became available, voluntary counselling and testing (VCT) 
was an early model for delivering HTS in dedicated, standalone facilities. It is now 
recognized that HIV testing in clinical sites may be more effective when it is offered as part 
of general medical care. Therefore, in many settings HTS has been integrated with other 
health services so that it can be either offered routinely to all those attending services or 
offered in particular clinical settings to those with indicator conditions. However, despite 
limitations due to higher costs and the need for the client to initiate the process of testing, 
standalone HTS may still be a way to reach people that complements other approaches in 
some high burden settings (123–125). 
Provider-initiated testing and counselling
Provider-initiated testing and counselling (PITC) denotes HTS that is routinely offered in a 
health facility. It includes providing pre-test information and obtaining consent, with the 
option for individuals to decline testing. PITC has proved highly acceptable and has 
increased the uptake of HIV testing in low- and middle-income countries. Its outcomes in 
terms of uptake of post-test services are similar to those of other testing approaches (22). 
Although it involves the routine offering of HTS, PITC should not develop into 
mandatory testing or testing people without first informing them that they can 
decline. PITC seeks to increase HTS coverage, to provide diagnosis earlier for those 
attending health facilities, to normalize HIV testing and to remove the need for personal 
motivation to seek HTS. It saves clients the possible embarrassment of asking for an HIV 
test, and it saves time for clients attending clinical services for other reasons (126). In low 
prevalence settings routine PITC will most likely not be cost-effective. However, HIV testing 
should still be made available for people who request testing or who exhibit clinical signs 
and symptoms indicative of HIV (126–129). 
Since WHO first recommended PITC in 2007, this approach has been implemented in many 
clinical settings, particularly those with a high HIV burden: 
•	 PITC offered routinely in ANC has proved highly acceptable in many countries (21). It 
has been responsible for the high level of knowledge of HIV status among women in 
many countries, particularly high-burden countries, allowing women to benefit from 
PMTCT and ART. However, rates of PITC coverage in ANC vary; the rate remains low in 
some settings. (See section 5.3 for recommendations on testing in ANC settings.)
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•	 PITC offered routinely in TB clinics, to all TB patients, both active and presumptive 
cases (130), has proved highly acceptable (131). In 2014, 185 countries reported data on 
HIV testing for TB patients to WHO; 83 countries reported coverage of more than 75% 
among TB patients (132). In some countries, however, HIV testing is not standard 
practice in TB clinics, and the level of coverage remains low (130, 132). 
wHo recommendations  
1. Routine HIV testing should be offered to all patients with presumptive and 
diagnosed TB.
2. Partners of known HIV-positive TB patients should be offered HTS with mutual 
disclosure (strong recommendation for all people with HIV in all generalized 
HIV epidemic settings);
3. TB-control programmes should mainstream provision of HTS in their operations 
and routine services. 
Source: WHO, 2012 (64).
•	 PITC is less often offered in clinical settings, even in high burden countries. This is 
a major missed opportunity. In general clinical settings PITC can have high rates of 
uptake and of new diagnoses (133–137). (See Annex 12 for guidance on strategically 
selecting PITC approaches for a specific setting.) Opportunities include:
– PITC offered in clinical settings likely to be associated with higher rates of HIV 
infection, including STI clinics and services for key populations, including harm 
reduction services for people who inject drugs (126).
– PITC offered to people presenting in inpatient and outpatient hospital 
settings with symptoms and clinical conditions indicative or related to HIV 
infection, particularly in low-level or concentrated epidemic settings; this 
approach has proved effective in Europe (126–129).
– PITC offered in paediatric clinics. This approach has been effective in finding 
cases among previously undiagnosed children (138). PITC offered to adolescents 
has also proved to be efficient in high prevalence areas (54) (see Chapter 5, 
section 5.2 on adolescents). But PITC services for children and for adolescents are 
not common. In 2012 Global AIDS Response Progress Reporting (WHO/UNICEF/
UNAIDS) reported that only 55% of 84 countries said that they had a national 
policy requiring the routine offer of HTS for children (24). In many countries policy 
barriers, such as age of consent laws, hinder children and adolescents from 
obtaining HTS (54, 55). Even where favourable policies do exist, health-care 
providers are often uncomfortable testing children for HIV. A recent study in 
Zimbabwe reported that, although health workers in a primary care setting were 
asked to offer HIV testing to all children of unknown status, one-third of children 
were not offered HIV testing. Providers reported that they did not offer HIV 
testing because they perceived children to be at low risk of HIV and that they had 
greater discomfort counselling male caregivers than female caregivers (139).
48 Consolidated guidelines on HIV testing services
 In some low prevalence settings, PITC in paediatric general clinics and inpatient 
settings will not be cost-effective. However, offering HIV testing to all children 
whose parents have HIV or to all children with conditions indicative of HIV and in 
malnutrition clinics may identify many infections. 
•	 PITC offered in VMMC services in the 14 priority VMMC countries,1 as part of the 
package of services. There is generally high uptake of PITC among VMMC clients 
(140, 141). According to reports from Kenya, in 2011 86% of VMMC clients accepted PITC 
(2% of those tested were HIV-infected and referred to care and treatment services) 
(139, 140). This marks an increase in HIV testing among VMMC clients in Kenya, from 
60% in 2008 (140). Stock-outs of HIV test kits and long waits for HIV testing can pose 
challenges for sites providing HTS in the context of VMMC services, particularly in 
countries with high uptake such as the United Republic of Tanzania and Zimbabwe (141). 
Testing for TB through HIV services 
Tuberculosis is the leading cause of death among people infected with HIV (132). However, 
only an estimated 48% of TB patients with HIV receive an HIV test. HIV testing in TB 
settings needs scaling up (132). WHO recommends intensified TB case finding among 
people with HIV to facilitate early TB detection and treatment (142). HTS offer an 
opportunity to screen for TB and detect it early (see section 3.2.4). Systematic TB 
screening should be integrated into HTS and offered wherever HIV testing is 
carried out and to all populations receiving HIV testing, irrespective of their test 
results. Intensified TB case finding in clinical and outreach settings will facilitate early 
detection of HIV-associated TB and linkage to treatment. Particularly in settings with a 
high burden of both TB and HIV, TB case finding in HTS might also contribute appreciably 
to the detection and treatment of TB in general (143, 144) and so reduce morbidity and 
mortality associated with TB. 
Pre-test information for all clients willing to undergo HIV testing should include 
information on systematic assessment of TB. Screening findings should be returned 
promptly so that the results can be shared with the client along with post-test HIV 
information. All people with TB symptoms should be promptly referred for a TB diagnostic 
workup that includes investigations such as sputum smear microscopy, chest X-ray, 
histopathology and molecular testing, depending on country context and national 
guidelines (130). If a person is found to have TB, he or she should start TB treatment 
promptly.
Testing for both HIV and other STIs
HIV and STI coinfection is common (145). Services providing care for STIs are one of the key 
entry points for HIV prevention and referral services. WHO recommends routinely 
offering HIV testing to clients diagnosed with other STIs (146). Several studies have 
shown that HIV testing in STI clinics is feasible and uptake of testing is high (120, 147). 
Treatable STIs, such as gonorrhoea and syphilis, indicate recent condomless sex and, thus, 
identify people at a heightened risk of HIV acquisition. People receiving STI treatment may 
also have primary HIV infection and, therefore, a high HIV viral load. Thus, diagnosing 
individuals with coinfection is important both as a prevention strategy and to improve the 
quality of care for people with HIV. 
1 Botswana, Ethiopia, Kenya, Lesotho, Malawi, Mozambique, Namibia, Rwanda, South Africa, Swaziland, United Republic of Tanzania, 
Uganda, Zambia and Zimbabwe.
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Both syphilis testing and HIV testing should be routinely offered to women attending ANC 
(146, 148). Given their common mode of sexual transmission, HIV and syphilis coinfection is 
common. Syphilis infection is a recognized cofactor for HIV transmission and acquisition, 
and maternal syphilis infection has been associated with increased risk of mother-to-child 
transmission of HIV (149). In general, syphilis screening and treatment for pregnant women 
is one of the most cost-effective antenatal interventions, even in settings with a low 
prevalence of syphilis (148, 150). 
Chapter 6 offers additional guidance on selecting effective approaches to HTS. 
wHo recommendations  
•	 In generalized epidemics settings routine HIV testing should be offered to all 
clients (adults, adolescents and children) in all clinical settings.
•	 In low-level or concentrated epidemic settings, HIV testing should be 
offered to clients (adults, adolescents and children) in clinical settings who 
present with symptoms or medical conditions that could indicate HIV infection, 
including presumed and confirmed TB cases.
•	 Regardless of epidemic type routine HIV testing should be considered for 
malnutrition clinics, STI, viral hepatitis and TB services, and ANC settings and for 
health services for key populations. 
Source: WHO, 2004 (146); WHO, 2007 (126); WHO 2013 (130).
4.3.2 Community-based HIV testing services
Community-based HTS include a number of approaches – door-to-door/home-based 
testing and mobile outreach campaigns and testing in workplaces, parks, bars, places of 
worship and educational establishments. It is an important approach for increasing early 
diagnosis, reaching first-time testers and people who seldom use clinical services, 
including men and adolescents in high prevalence settings and people from key 
populations in all settings (3, 13).
Community-based HTS are now widespread, with 93 of 124 countries reporting in 2014 
that their national policies support community-based HTS.1 However, some studies find 
that linkage to prevention, treatment and care services following community-based HTS is 
suboptimal (152). Linkage to prevention and treatment services is critical and should be 
emphasized in all community-based HTS.
Mobile/outreach HTS include outreach to community sites through mobile vans or tents, 
in community sites such as churches, mosques or other faith settings, in places of enter-
tainment such as bars and clubs, at cruising sites and sauna or in schools or workplaces. 
Such services may be offered continuously, on a regular schedule or as a one-time or 
occasional promoted event. Also, outreach can be linked to public events, such as sports 
1 Global AIDS Response Progress Reporting (WHO, UNAIDS, UNICEF), 1 July 2015.
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events, music performances, theatre, agricultural fairs and holiday festivals. Outreach 
services may be designed to serve key populations, such as “moonlight HTS”, in which 
services are offered in the evening. HTS outreach may also be designed to serve rural 
populations, including pregnant women in remote areas, who may have limited access to 
facility-based HTS. Men in high prevalence settings can be reached through testing in 
market places and at transport hubs. Mobile approaches complement facility-based 
approaches, which often do not reach key populations because of stigma or cannot serve 
those in remote areas that lack health facilities.
Home-based HTS follow two main models: (1) testing that is offered door-to-door and 
provided to all consenting individuals, couples or families in a geographic area and (2) 
testing that is offered to households with a person known to have HIV (index clients) or an 
active or suspected TB patient, with consent obtained from the index client before the 
home visit. Door-to-door testing during the daytime may reach only women who are not 
working and younger children. Services during the evening or on weekends may increase 
uptake among others, including men. 
National HTS campaigns are nationwide efforts to increase access to and uptake of HTS. 
Campaigns have been implemented in many different ways, some focusing on testing in 
facilities, others using a community-based approach, and some combining the two. 
Widespread knowledge of where to get tested makes large-scale campaigns less useful at 
this point. Objectives of and outcomes from national campaigns have varied with regards 
to coverage of different population groups, linkage and cost-effectiveness. A national HTS 
campaign can affect the entire population, both those at risk and those not at risk for HIV 
infection, by normalizing HIV testing. National campaigns can increase the number of 
people tested (153), but they can be expensive, a substantial number of people with HIV 
remain undiagnosed despite such campaigns, and linkage to care and treatment from 
campaigns has been problematic (152). Campaigns should not be considered in low 
prevalence settings unless special efforts are made to reach key populations and to 
support effective referral and linkage. 
HTS and multi-disease campaigns offer HIV testing in addition to other health services. 
Depending on the context, these often include providing insecticide-treated bed nets, 
water filters, or screening for STIs, hepatitis, cardiovascular risk factors such as diabetes or 
hypertension and even depression (154, 155). However, these campaigns, too, can be costly 
and need to be evaluated. Linkage and the long-term impact of the other interventions 
provided have not been adequately assessed. 
Workplace HTS seeks to provide formally employed men and women with access to 
testing. These people may have limited access to outside clinical services and may lose 
wages if they must leave work to seek health care. Workplace testing has been implement-
ed with high levels of uptake and linkage to HIV and TB services, particularly in high burden 
settings (156–158).1 Confidentiality, coercion and weak linkages to services are concerns with 
this approach. In the Middle East and North Africa, over 60% of HIV testing is carried out in 
relation to the workplace and work visa procedures and is generally mandatory (159). This 
often results in adverse outcomes for those testing HIV-positive. Workplace testing should be 
confidential. It should not be promoted where it is likely to be abused.
1 Examples of workplace programmes include the International Labour Organization’s VCT @ Work Programme (http://ilo.org/aids/
WCMS_215899/lang--en/index.htm) and the Anglo American HIV Testing Programme (http://southafrica.angloamerican.com/media/press-
releases/2012/03-12-2012.aspx).
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Case example: Pharmaccess, Rwanda 
In 2001, to offer better services to employees, Heineken Breweries partnered with 
PharmAccess International Foundation (http://www.pharmaccess.org/) to launch 
a workplace HIV programme, called “the Heineken Access to HAART Programme”, 
at its facilities in Gisenyi and Kigali, Rwanda. The programme offers all employees 
and their dependents, including children, medical care services that include HIV 
testing services (HTS) and access to ART. Once started on ART, the worker retains 
the right to care until the end of life, even if he or she is laid off from work at the 
company.
As of 31 May 2015, the programme has performed 2951 HIV tests for a total of 
2808 eligible individuals. As a result, between 2001 and 2015, 139 HIV-positive 
individuals have been diagnosed. Of the individuals diagnosed with HIV, 13% 
(18/139) have died; 6% (8/139) were lost to follow-up; another 13% (18/139) 
were referred to other HIV programmes. Overall, the programme retained 68% 
(95/139) of individuals with HIV in the programme; 90% (86/95) are on ART and 
84% of these (72/86) have an undetectable viral load. Heineken has adopted the 
90–90–90 UN targets and is committed to not discriminating against individuals 
living with HIV.
Source: Annex 3.
HTS in educational establishments can address sexually active youth in the context of 
sexual health education and behaviour change interventions. In South Africa, for example, a 
national campaign provides HTS to students ages 12 and older (160). Other examples include 
providing HTS for children under age five in locations such as play centres (161–164). 
School-based HTS is often controversial, however, and currently there are few programmes 
in schools and few studies of the approach. The rationale for offering testing in schools is 
that it can be challenging for a young person to seek HTS at a health facility during school 
hours and in a school uniform, whereas school-based testing brings services to the 
students. Students are very difficult to reach otherwise, as they do not use health services 
or community services that are used mainly by older adults. As part of a well-resourced 
intervention that also provides post-test counselling on risk reduction, HTS in educational 
establishments may be a valuable tool to turn the rising tide of infection rates among 
adolescent women and young men who have sex with men. More research is needed to 
better understand issues of confidentiality, linkages to care and adolescents’ experiences 
with and expectations of school-based testing. 
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Case example: organization for Public Health Interventions and 
development (oPHId), Zimbabwe  
Early diagnosis of children living with HIV is necessary for timely access to HIV 
care and treatment services, which optimizes outcomes. In 2008 OPHID (http://
www.ophid.co.zw) developed a play centre project, as an addition to ongoing 
PMTCT programmes, to provide care and education to vulnerable children in 
three rural districts of Zimbabwe. By 2011, 176 community volunteers staffed 
16 play centres serving 697 children three to five years old. As part of the 
programme, 59% of children enrolled in the play centre had received HIV testing 
services. HIV testing was offered and performed with the consent of the caregiver 
or guardian. All children diagnosed HIV-positive were successfully linked to ART; 
the use of standardized registers prevented loss to follow-up. When caretakers of 
children in care did not pick up their children’s medications, community mobilizers 
visited them to offer help and support. 
Source: Annex 3.
4.3.3 Test for triage: a strategy to support expanding community-based HTS 
A simple approach to expanding community-based HTS is needed, particularly to reach 
higher risk populations who may not otherwise test for HIV and link to prevention, 
treatment and care. 
Test for triage is an approach to support community-based HTS provided by lay providers. 
In this approach trained and supported lay providers conduct a single HIV RDT, referred to 
in Fig. 4.2 as A0. Note that A0 does not replace A1 in the national testing algorithm. If this 
single RDT is reactive (A0 +), the individual is promptly linked to a facility for further HIV 
testing, where the validated national testing algorithm is performed, beginning with A1 
(see Chapter 7). If the reactive test result (A0 +) is confirmed and an individual is thus 
diagnosed HIV-positive, that person is then linked to clinical assessment and, if eligible, 
treatment. Individuals with a non-reactive test result (A0 –) are diagnosed HIV-negative, 
referred for and linked to appropriate HIV prevention services, and advised to retest if they 
have had recent or have on-going HIV risk (see section 3.4)(12). 
Many community-based services, particularly those offered by NGOs and other community-
based organizations, already use this “test for triage” approach. Although it may be ideal 
to provide a definitive diagnosis in a community setting, correctly conducting two or three 
RDTs for each individual with a reactive result on the initial test may be challenging. 
Particularly for lay providers, test for triage can reduce the complexity of testing 
procedures in outreach or home settings. Thus, test for triage may be particularly suited for 
countries without policies and infrastructure that enable lay providers or community-based 
organizations to perform HIV testing and issue test reports. Additionally, the “test for 
triage” approach can enhance access to other health services, using simple tools such as 
screening for cough of more than two weeks’ duration and referral for TB diagnosis. Other 
health interventions and referrals could be included, such as blood pressure checks and 
referrals to reproductive health or harm-reduction services. The success of this approach 
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will require partnership between the trained lay providers who perform the test for triage 
and other health workers who conduct the additional testing required to make a diagnosis 
and to provide clinical assessment for ART initiation. Such a programme must have a 
system to support clients and minimize loss to care between initial testing in the 
community (the test for triage) and diagnosis in a facility. 
Key advantages of the “test for triage” approach are that it:
•	 simplifies the scope of work for lay providers and task sharing arrangements;
•	 can reduce logistics, supply chain and training constraints, as a single RDT is used;
•	 improves access for those at highest risk and not currently testing for HIV;
•	 takes a first step toward introducing full community-based HTS, where a definitive 
diagnosis using the complete testing algorithm can be made;
•	 facilitates quick scale-up of HTS where HIV prevalence is high.
Potential challenges of the “test for triage” approach are that: 
•	 in low prevalence settings, the rate of false reactive test results is higher than in high 
prevalence settings, which, without proper messaging, could lead to mistrust of 
services;
•	 it may be challenging to maintain an uninterrupted supply of test kits to community sites;
•	 lay providers may not correctly communicate the meaning of a reactive “test for triage” 
result, and clients may then mistake a reactive test result for an HIV-positive diagnosis;
•	 linkage to additional testing to confirm the HIV diagnosis may be poor;
•	 it may be difficult to track and monitor clients who have a reactive “test for triage” and, 
if confirmed HIV-positive, are then linked to HIV treatment and care.
fig. 4.2. The “test for triage” strategy
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54 Consolidated guidelines on HIV testing services
Case example: Test for triage for community-based HTS
Although “test for triage” may be a new term, conducting one test in a 
community setting and then, for those with reactive results, conduct additional 
testing to confirm HIV status in a health facility or laboratory is routine practice 
in many countries. 
•	 In Brazil collaboration between the Ministry of Health and NGOs reaches key 
populations (men who have sex with men, sex workers, people who inject drugs 
and transgender people) in venues convenient for these groups, including bars, 
clubs, saunas and city streets. One RDT using oral fluid is performed; all those 
with reactive results are referred for additional testing to confirm their HIV 
status. Between May 2014 and March 2015, 28 400 tests were performed in such 
community outreach settings. 
•	 In Chengdu, China, a programme focused on men who have sex with men has 
provided testing for triage in outreach settings since 2007. By the end of 2014 it 
had served 18 683 men. Government-supported health facilities conducted 
additional testing to confirm HIV-positive status. In 2007 about 40% of men 
with a reactive test result went for testing to learn their HIV status. With careful 
follow-up, that rate improved to over 90% in 2014. 
Rates of confirmed HIV-positive results after test for triage
Not all people who have a reactive test result will link to additional testing and 
learn their HIV status, and not all who do link are confirmed and diagnosed 
HIV-positive. Programmes in various countries report somewhat different rates of 
reactive HIV test results and HIV-positive diagnosis resulting from additional 
testing following test for triage. 
•	 An NGO in Portugal has provided testing since 2011 in a community centre for 
men who have sex with men. Tests were reactive for 296 men (4% of those 
tested). Of these men, 82% underwent additional testing for confirmation of 
their HIV status at the National Health Service. Data on the first clinical 
assessment are available for 127 of those who underwent additional testing; 
almost all that were confirmed HIV-positive (98%) enrolled in ART immediately.
•	 A community-based programme in Greece reports providing free HIV testing to 
13 438 people, of whom 303 had reactive RDT results. All of these people were 
linked to additional testing and received a diagnosis. Those diagnosed HIV-
positive were referred for care and treatment.
•	 In Bolivia a mobile unit working during evening hours has offered HIV testing for 
two years to key populations including men who have sex with men, transgender 
people, sex workers and the homeless. Of 3371 people tested for HIV, 117 had 
reactive results and were referred for additional testing to confirm their HIV 
status. However, 51 (44%) did not undergo additional testing and did not 
confirm their HIV status.
Sources: Annex 3.
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wHo recommendations  
•	 In generalized epidemics settings a strategic combination of community-
based HIV testing and counselling is recommended, with linkage to prevention, 
treatment and care services, in addition to provider-initiated testing and 
counselling (strong recommendation, low quality of evidence).
•	 In all epidemic settings community-based HIV testing and counselling is 
recommended for key populations, with linkage to prevention, treatment and 
care services, in addition to provider-initiated testing and counselling (strong 
recommendation, low quality of evidence).
Source: WHO, 2013 (13); WHO, 2014 (10).
4.3.4 HIV self-testing 
By giving people the opportunity 
to test discreetly and conveniently, 
HIVST may increase uptake of HIV 
testing among people not reached 
by other HIV testing services.
HIV self-testing (HIVST) is a process in which an 
individual who wants to know his or her HIV status 
collects a specimen, performs a test and interprets 
the result by him or herself, often in private. HIVST 
does not provide a definitive diagnosis. Instead, 
it is an initial test (A0), as in the “test for triage” 
approach (see previous section). HIVST does not 
replace the need for the first HIV test in the validated national testing algorithm. A reactive 
self-test result always requires additional testing according to the validated national 
diagnostic testing algorithm. Therefore, a person distributing test kits for HIVST should 
advise anyone who has a nonreactive self-test result to retest if he or she has had recent or 
has ongoing HIV risk. Also, if a person has any uncertainty about correctly conducting the 
test procedure and reading the test result, he or she should go for facility-based or 
community-based HTS instead (14). 
By giving people the opportunity to test discreetly and conveniently, HIVST may increase 
uptake of HIV testing among people not reached by other HIV testing services (69), many 
of whom are first-time testers (165). As early as 2005 it was reported that health workers 
in sub-Saharan Africa were self-testing for HIV, particularly where they were concerned 
about confidentiality (166–169). In general, studies report that HIVST is highly acceptable 
among a variety of populations (170–172). 
User values and preferences for accessing HIVST vary. Potential users from key population 
groups, particularly men who have sex with men in high-income settings, want access to 
test kits for HIVST over the counter or through the Internet (172) (see Annex 4). In 
particular, in the USA men who have sex with men reported that they preferred online 
vouchers as a way to access test kits for HIVST, which could be mailed to them (173). 
Among the general population in Malawi, people preferred to obtain test kits for HIVST 
from a neighbourhood volunteer (165, 174). In Kenya people preferred access to test kits for 
HIVST in health facilities (175).
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Studies generally report that HIV self-test results can be accurate (170, 176) when 
appropriately regulated test kits are used and instructions for use are followed (170). HIV 
self-test results have been less accurate, however, when inappropriate test kits were used 
or instructions were unclear (177–179) or when the individuals self-testing have been 
recently infected with HIV or are living with HIV and already on ART (180). Mathematical 
modelling suggests that HIVST is cost-effective in identifying people with HIV in certain 
settings (181). With support, linkage to care can be good. For example, a cluster 
randomized trial of a community-based HIVST programme in Blantyre, Malawi, reported 
that, among adults who self-tested for HIV, the offer of optional home initiation of care 
resulted in a three-fold increase in the proportion of adults initiating ART compared with 
standard facility-based HIV care (69). To date there are no reports of serious adverse 
events or harm as a result of HIVST (165, 182). Still, where HIVST is used, this should be 
monitored, as experience is limited. Some countries, for example, Kenya, have already 
introduced questions on use of HIVST into national population-based surveys (183). 
A question regarding HIVST has been added to the Demographic and Health Surveys. 
There are several ways in which test kits for HIVST could be delivered or distributed (see 
Fig. 4.3). Programmes may offer more or less support along a continuum, combining 
different levels of access and distribution sites. 
fig. 4.3. Continuum of HIVST approaches 
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Globally, policy development regarding HIVST is at varying stages. The United States Food 
and Drug Administration approved over-the-counter sale and use of an HIV-1/2 RDT using 
oral fluid in the USA in 2012 (184–186), and approved two HIV-1/2 RDTs based on finger-stick 
whole blood in 2015 (185, 186). Several countries (Australia, China, France, Kenya and the 
United Kingdom) have introduced national HIV testing policies that include HIV self-
testing. Several other countries (Malawi, Zambia and Zimbabwe) are considering such 
policies. WHO has not issued recommendations on HIVST due to gaps in the current 
evidence but has developed a technical update describing the potential benefits and 
challenges of this approach (14). WHO is working with collaborators to generate the 
evidence needed to issue recommendations and additional guidance on this topic.
1 GZTZ is adopting a new name, Lingnan Partners Community Support Center.
Case example: Guangzhou Tongzhi, Guangdong Province, China
Guangzhou Tongzhi (GZTZ)1, with support from the Guangzhou Centre for 
Disease Control and Prevention, operates HIV testing services in five cities in 
southern China. GZTZ also runs the website GZTZ.org. It is China’s first and 
best-known website for men who have sex with men and transgender people and 
the most widely used to provide health education and to conduct surveys among 
men who have sex with men and transgender populations. Beginning in 2014, 
GZTZ has provided online support for HIV self-testing by sending HIV self-test kits 
to clients and providing online support and information, pre-test information and 
post-test counselling, referrals for further HIV testing and diagnosis and 
information on where and how to seek additional support services. 
In five months GZTZ sold 199 HIV self-test kits to users in Guangdong province 
for US$ 23, including a US$ 16 deposit refundable following submission of 
feedback after self-testing. Of the 199 purchasers, 174 submitted feedback online. 
Of these, four reported having a reactive test result and six individuals, who 
might not have done so otherwise, sought follow-up care at a GZTZ facility. 
Sources: Annex 3.
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       Key PoINTS 
This chapter considers HIV testing services for specific populations.
•	 Infants. Diagnosing HIV-exposed infants as early as possible through virological testing 
is critical to starting ART as soon as possible and thus preventing early morbidity and 
mortality. 
•	Adolescents. In high prevalence settings programmes should prioritize testing children 
and adolescents to diagnose and link to treatment and care those who were not reached 
through infant testing programmes.
•	Pregnant women. In many countries offering HIV testing in ANC as part of PMTCT has 
led to substantial decreases in new paediatric HIV infections and increased ART coverage 
for women. Testing of partners and retesting of pregnant women in late pregnancy or 
during breastfeeding has been less widely implemented and should be prioritized in high 
incidence settings.
•	Men. In most high prevalence countries, men have less access to HIV testing, and they 
are tested, diagnosed and started on ART later than women. Programmes need to find 
ways to increase men’s access to HTS and overcome this gender gap.
•	Key populations. In almost all countries and settings, HTS for key populations are 
inadequate, and their access to HIV prevention, treatment and care services remains 
limited. Countries should prioritize, fund and support acceptable services for key 
populations and recognize and address health system, social and legal barriers that 
currently prevent equitable access to HTS by key populations. 
60 Consolidated guidelines on HIV testing services
5 PRIoRITy PoPulaTIoNS
5.1 Infants and children
Mortality is very high in the first year of life among infants infected with HIV who go 
untreated. In this period early HIV testing, prompt return of results and rapid initiation of 
treatment are vital. HIV testing for infants should be implemented with the aim of 
identifying as many HIV-infected infants as possible as early as possible. See the 
glossary and Chapter 7 (particularly section 7.1.4) for details on terminology and testing 
strategies, including for infants.
For infants and children under 18 months, HIV infection can be diagnosed only by 
virological testing; maternal HIV antibodies remain in the infant’s bloodstream until 18 
months of age, making test results from serological assays ambiguous. Virological 
testing using nucleic acid testing (NAT) technologies can be conducted using dried blood 
spot (DBS) specimens, which are collected at local sites and sent to centralized 
laboratories for testing. While early testing is increasing, there are ongoing challenges of 
access, such as prompt return of test results and initiation of early ART among infants 
who test HIV-positive. 
Several approaches can increase infant testing. Scaling up early infant diagnosis (EID) 
through task sharing with lay providers is one promising approach (78). Development, 
now underway, of virological assays for use at the point of care is expected to greatly 
improve access to early diagnosis and treatment. HIV testing at the time of birth may 
improve linkage to treatment and reduce loss to follow-up; however, it is likely be an 
effective public health strategy only in settings with a high proportion of deliveries 
taking place in facilities. In any case, this approach would miss infant infections that 
take place during breastfeeding. 
For children 18 months of age and older (who were not breastfed or who have 
stopped breastfeeding at least six weeks earlier), standard HIV serological assays such 
as RDTs and EIAs can reliably determine HIV status. A negative serological test result for 
an infant does not completely exclude HIV exposure and infection, particularly when 
certain RDTs are used to test infants between four and 18 months of age, due to 
imperfect sensitivity during seroconversion for infection acquired postpartum through 
breastfeeding. During this time virological tests may be used to determine HIV infection.
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wHo recommendations1
•	 It is recommended that all HIV-exposed infants have HIV virological testing at 
four to six weeks of age or at the earliest opportunity thereafter (strong 
recommendation, high quality of evidence).
•	 It is recommended that well HIV-exposed infants undergo HIV serological 
testing at around nine months of age (or at the time of the last immunization 
visit). Infants who have reactive serological assays at nine months should have a 
virological test to identify HIV-infected infants who need ART (strong 
recommendation, low quality of evidence).
•	 It is recommended that children 18 months of age or older with suspected 
HIV infection or HIV exposure have HIV serological testing performed according 
to the validated national testing algorithm used in adults (strong recommendation, 
high quality of evidence).
•	 It is recommended that infants with signs or symptoms suggestive of HIV 
infection undergo HIV serological testing and, if reactive, should be referred for 
virological testing (strong recommendation, low quality of evidence).
•	 Children of school age (6–12 years old) should be told their HIV-positive status 
and their parent’s or caregiver’s status; younger children should be told their 
status incrementally to accommodate their cognitive skills and emotional 
maturity, in preparation for full disclosure (strong recommendation, low quality 
of evidence).
Source: WHO, 2010 (187); WHO, 2010 (2); WHO, 2013 (13).
5.1.1 approaches for delivering HIV testing to infants and children
All infants whose mothers have received PMTCT services should be followed up and 
routinely offered EID, and those diagnosed with HIV should be started on ART. However, 
some infants are lost to follow-up, and some mothers with HIV may not have received 
PMTCT services. Prioritizing additional paediatric case finding is important. This can be 
achieved through the routine offer of PITC in health facilities, particularly in high 
prevalence settings, and also through testing the family members of index clients (see 
box next page). 
Integration of HIV testing into child health programmes
In high prevalence settings HIV testing should be routinely available to all mothers 
and children through a variety of services – child health services, immunization clinics, 
under-5 clinics, malnutrition services, well-child services and services for hospitalized 
and all sick children, TB clinics, and services for orphans and vulnerable children. In 
Malawi, for instance, integrating testing for HIV-exposed infants at six weeks of age into 
routine postnatal, under-5 and immunization clinics has improved case finding and has 
proved acceptable and feasible (78). 
1 WHO is reviewing the evidence and plans to update recommendations on infant diagnosis in late 2015.
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In low prevalence settings immunization and under-5 clinics should test HIV-exposed 
infants who were not tested for HIV as part of PMTCT services. HIV testing for children 
and other family members of anyone known to be living with HIV should be prioritized. 
Such testing requires systems to track mother–infant pairs – for example, by using child 
health and immunization records to identify HIV-exposed infants.
Testing the family members of index clients 
In all settings all children with an HIV-positive parent should be tested for HIV as 
a priority. Gaps in HTS and in documenting the HIV status of children of HIV-positive 
parents constitute significant missed opportunities. These gaps can be closed by 
following up the families of cases identified in facility-based HTS and through improved 
case finding via ART clinics. In particular, HTS for orphans and vulnerable children in 
high prevalence settings, where one or both parents may have died from HIV, requires 
additional support (188).
Potential HIV testing approaches to improve HIV case finding among 
infants, children and adolescents
In all settings
•	 Offer early infant diagnosis for HIV-exposed infants.
•	 Offer testing to all children and adolescents presenting with indicator conditions 
or signs and symptoms that suggest HIV, including oral candidiasis, failure to 
thrive, chronic cough and skin conditions.
•	 Offer HIV testing to all children and adolescents attending TB clinics and 
malnutrition services.
In high prevalence settings also
•	 Offer HIV testing or retesting to mothers or infants in immunization clinics or 
under-5 clinics. If mothers are not available for testing or refuse testing, infant 
testing is an acceptable alternative. A negative serological test result for an 
infant does not completely exclude HIV exposure and infection, particularly when 
certain RDTs are used to test infants between four and 18 months of age, due to 
imperfect sensitivity during seroconversion for infection acquired postpartum 
through breastfeeding. During this time virological tests may be used to 
determine HIV infection. 
•	 Offer testing to all children with parents or siblings receiving any HIV service (for 
example, PMTCT, ART) through home-based or facility-based HTS.
•	 Offer HIV testing to all children and adolescents attending paediatric inpatient 
health services. 
•	 Offer HIV testing to all children and adolescents receiving orphan and vulnerable 
children (OVC) services.
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5.2 adolescents 
In high prevalence settings there are two groups of adolescents (that is, people 10–19 
years of age) who need access to HIV testing: (1) perinatally HIV-infected adolescents 
who were not diagnosed in infancy and (2) adolescents who acquire HIV through early 
sex or injecting drug use, particularly adolescents from key populations. 
Perinatally infected adolescents urgently need to be diagnosed so that they can be 
linked to HIV care and start ART. In sub-Saharan Africa there are a significant number of 
undiagnosed adolescents who were infected perinatally or through transmission in 
health-care settings (for example, through transfusions or unsafe injections).
Particularly in high prevalence settings, adolescence may be a period of high risk of HIV 
infection. In such settings adolescent girls are generally at higher risk than males in their 
age group. In all regions adolescents from key population groups are at especially high 
risk for HIV infection (10). 
Engaging adolescents in HIV testing, as well as in prevention, treatment and care, 
requires specific strategies. All HTS for adolescents, either in health services or in the 
community, should be based on adolescent-friendly principles to ensure that psychological 
as well as physical needs are addressed (54). Adolescents may need support particularly 
with issues of disclosure – when and to whom to disclose HIV-positive status (54) (see 
Chapter 3). 
Involving adolescents in the design, delivery and evaluation of HIV services is necessary to 
ensure that these programmes address their needs (54). Services need to be convenient 
and available, through flexible opening hours and/or walk-in or same-day appointments. 
Separate hours and special events exclusively for adolescents may help overcome 
adolescents’ concerns that older relatives, neighbours or family friends will see them 
attending HIV services, including HTS. 
HTS for adolescents should be based on a human rights and public health approach (54). 
As with all HTS, HTS for adolescents should offer protection from stigma and discrimina-
tion related to HIV-positive status and risk behaviours and should also be confidential, 
respectful, inclusive and non-judgemental. It should provide strong referrals and 
linkages to HIV prevention, treatment, care and support services. When appropriate, and 
only with the adolescent’s specific permission, health-care personnel should engage the 
support of adults – family members, teachers, community members – as adolescents 
learn to manage living with HIV. 
Services for adolescents need to be tailored to different epidemiological contexts and 
different adolescent populations. For example, in high burden, priority countries, 
adolescent boys can be linked to VMMC and adolescent girls to reproductive health 
services. Special considerations are needed for adolescents from key populations and 
vulnerable adolescents, including those living on the streets, orphans, adolescents in 
child-headed households, girls engaged in sex with older men or in multiple or concurrent 
sexual partnerships and adolescents who are sexually exploited (10). In some settings 
specific campaigns and use of social media or web-based approaches, involving 
adolescents in identifying communication channels and appropriate language, may help 
reach adolescents, including those from key populations. In low-level or concentrated 
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epidemic settings, however, adolescent-focused HTS for the general population usually 
are not prioritized due to the very low prevalence of HIV in adolescents.
Policies related to age of consent to testing can pose barriers to adolescents’ access 
to HTS and other health services, particularly for adolescents from key populations (55). 
Age of consent for HTS varies from country to country. WHO recommends that children 
and adolescents themselves be involved in the testing decision as much as possible (55). 
Governments should revisit age of consent policies in light of adolescents’ 
rights to make choices about their own health and well-being (with consideration 
for different levels of maturity and understanding). Authorities also should consider the 
role of surrogate decision-makers in HTS for adolescents without parents or for those 
unwilling to involve parents. In any case providers of HTS should be aware of laws and 
policies governing the age of consent and develop appropriate procedures based on this 
legal framework to ensure that children and adolescents have access to HTS. 
wHo recommendations
•	 In all settings HIV testing services, with linkages to prevention, treatment and 
care, are recommended for adolescents from key populations (strong 
recommendation, very low quality of evidence).
•	 In generalized epidemic settings HIV testing services, with linkage to 
prevention, treatment and care, are recommended for all adolescents (strong 
recommendation, very low quality of evidence).
•	 In low-level and concentrated epidemic settings, we suggest that HIV 
testing services, with linkage to prevention, treatment and care, be accessible to 
all adolescents (conditional recommendation, very low quality of evidence).
•	 In all settings we suggest that adolescents be counselled about the 
potential benefits and risks of disclosure of their HIV status and empowered and 
supported to determine if, when, how and to whom to disclose (conditional 
recommendation, very low quality of evidence).
Source: WHO, 2013 (55).
wHo good practice recommendation 
Governments should revisit age of consent policies in light of the need to uphold 
adolescents’ rights to make choices about their own health and well-being (with 
consideration for different levels of maturity and understanding).
Source: WHO, 2013 (55).
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5.3 Pregnant women
HTS as early as possible during pregnancy enables pregnant women with HIV to obtain 
and benefit most from prevention, treatment and care and to reduce the risk of HIV 
transmission to their infants. WHO recommends offering HTS to pregnant women 
through a PITC approach (126). Globally, this approach has been widely adopted and 
has proved acceptable to pregnant women. It is an essential component of all PMTCT 
programmes (21, 189). 
Many countries prioritize PITC in ANC as a key component of their effort to eliminate 
mother-to-child transmission of HIV (eMTCT). HIV testing is also being effectively 
combined with screening for syphilis and hepatitis B, hepatitis B vaccination for infants 
and other testing. 
PITC in ANC settings has considerable public health benefits. Still, measures must be 
taken to prevent unintentionally or intentionally coercive testing (21). These measures 
include regular mentoring and supervision of staff, retraining where necessary and 
monitoring of PITC procedures to ensure their acceptability to pregnant women. 
HTS for pregnant women is an entry point into couples or partner HTS. In high 
prevalence settings WHO recommends couples and partner HIV testing for all 
pregnant women and their partners (16) (see section 5.4). Particularly for women from 
migrant or key populations, HIV testing may also be a point of entry to a broad range of 
pregnancy care services (190). In low prevalence settings WHO recommends couples 
and partner HIV testing for pregnant women from key populations and for the 
partners of women diagnosed with HIV (16). 
The package of care for pregnant women with HIV should include systematic screening for 
TB symptoms and referral and treatment as necessary. The presence of undetected TB 
among HIV-positive pregnant women doubles the rate of vertical HIV transmission (191). 
Pregnant women testing HIV-positive must be linked to ART for PMTCT and HIV services 
for their own health. WHO recommends Option B+, which involves initiation of ART 
as soon as possible, regardless of CD4 count, and continuation of treatment for 
life for the mother’s infection (192). 
Retesting in pregnancy
Although ART prevents vertical transmission of HIV most effectively when given early in 
pregnancy, it has some efficacy (especially when combined with infant ARV prophylaxis) 
even when started late in pregnancy, at the time of delivery or during the breastfeeding 
period. Therefore, in high prevalence settings HTS should be recommended to all women 
of unknown HIV status late in pregnancy, in labour or, if that is not feasible, as soon as 
possible after delivery. In all settings pregnant woman who are diagnosed HIV-
positive should be retested to verify their HIV status prior to enrolling in care 
and/or treatment. 
In settings of high HIV incidence, follow-up through the breastfeeding period is 
important to determine the HIV status of the infant and to identify possible seroconversion 
of the mother. Also, retesting of pregnant and postpartum women who have tested 
HIV-negative is important. For example, a recent study in communities in Malawi, Kenya 
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and South Africa found that an average of 4.1% of breastfeeding women had become 
infected during pregnancy or breastfeeding (193). In contrast, in low prevalence 
settings, retesting all pregnant women in ANC or in the breastfeeding period is 
not warranted, as the incidence of HIV infection will be extremely low. 
wHo recommendations 
In high prevalence settings 
•	 PITC is recommended for women as a routine component of the package of care 
in all antenatal, childbirth, postpartum and paediatric care settings.
•	 Retesting is recommended in the third trimester, or during labour or shortly 
after delivery, because of the high risk of acquiring HIV infection during 
pregnancy.
•	 In settings where breastfeeding is the norm, lactating mothers who are 
HIV-negative should be retested periodically throughout the period of breast-
feeding, as there is a risk of acquiring HIV at this time and a resulting high 
likelihood of transmission through breast milk. Early identification of such 
mothers enables immediate interventions to prevent transmission to the child.
In low prevalence settings
•	 PITC can be considered for all pregnant women. 
•	 HIV testing is recommended for all pregnant women from key populations or 
who have partners with HIV or from a key population group.
Source: WHO, 2012 (16); WHO, 2013 (13).
5.4 Couples and partners 
Testing the partners of people 
with HIV is an efficient and 
effective way of identifying 
additional people with HIV, who 
also can benefit from treatment.
Participating in couples and partner HTS has a 
number of benefits. These include adoption of 
prevention strategies by the couple (for example, 
condom use, immediate ART, PrEP), safer 
conception, improved uptake of and adherence to 
practices for PMTCT as well as to one’s own ART 
(thus reducing transmission risk as well as 
morbidity and mortality) (16). Partner testing is an efficient and effective way of 
identifying additional people with HIV, who also can benefit from treatment. Couples 
and partner HTS help more people know their HIV status, particularly men, who in 
generalized epidemic settings are substantially less likely to test than women. Couples 
and partner HTS for the partners of women attending ANC, in particular, is a focus in the 
21 priority eMTCT countries1 (194). 
1 Angola, Botswana, Burundi, Cameroon, Côte d’Ivoire, Democratic Republic of Congo, Ethiopia, Ghana, Kenya, Lesotho, Malawi, 
Mozambique, Namibia, Nigeria, Rwanda, South Africa, Swaziland, United Republic of Tanzania, Uganda, Zambia and Zimbabwe.
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Couples and partner HTS can be conducted in various settings, including ANC and 
community-based TB services, through home-based HTS, during premarital health visits 
and in couples’ HIVST (169, 195–197). People attending ART services can be encouraged 
to bring their partners to be tested. Couple and partner testing should also be a priority 
for people in key populations, including men who have sex with men. Programmes that 
particularly serve key populations should provide and encourage partner testing.
As with all HTS approaches, couples and partner HTS should be voluntary. Informed 
consent should be obtained from all individuals receiving HIV testing. Providers must be 
aware of the potential for intimate partner violence and should support people’s decisions 
not to test with their partners. 
Currently, the prevalence of serodiscordance is estimated at one-half to two-thirds of 
cohabitating couples or partners where one partner has HIV (198–201). Nonetheless, 
many people do not know their partner’s HIV status. With the exception of a few 
countries such as Rwanda and Zambia, in most countries the proportion of couples and 
partners who test together is less than 20% (24). According to the WHO HIV Country 
Intelligence database, as of April 2014 only half (28/58) of WHO HIV focus countries 
made it a policy to offer ART to the HIV-positive partner in a serodiscordant couple, 
irrespective of CD4 count, as WHO recommends. A recent desk review of national 
policies in 21 priority countries found that most did not have specific targets or 
indicators to monitor their progress in couples and partner HTS or to measure its uptake 
or coverage.1 In an associated online survey of field experts from these priority 
countries, less than half judged that most people would find couples and partner HTS 
acceptable, accessible or both.
In low-level and concentrated epidemics, couples and partner HTS should be made 
available for partners of people with HIV and people from key populations. 
wHo recommendations 
•	 Couples and partners should be offered HIV testing services with support for 
mutual disclosure (strong recommendation, low quality of evidence).
•	 Couples and partners in antenatal care settings should be offered HIV testing 
services with support for mutual disclosure (strong recommendation, low quality 
of evidence).
•	 In all epidemic settings couples and partner HIV testing services with support for 
mutual disclosure should be offered to all individuals whose partners have 
HIV. 
•	 Partner testing for HIV-negative people should be offered only in high 
prevalence settings (conditional recommendation, low quality of evidence). 
Source: WHO, 2012 (16).
1 Unpublished review, Darbes L et al., 2015.
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5.5 men
In high prevalence settings fewer men than women report ever testing for HIV (24). As a 
consequence men are more likely to start ART at later stages of HIV infection and thus 
experience higher morbidity and mortality after starting ART (202, 203). There are a 
number of barriers to men’s access to available HTS, including fear, stigma, the 
perception that health facilities are “female” spaces and both the direct costs and the 
opportunity costs of accessing services. 
Greater emphasis on reaching men 
with HIV testing services is required 
in many high prevalence settings.
Despite these barriers current approaches to 
delivering HTS can reach men. Successful 
approaches include PITC in ANC and other clinical 
settings and home-based and mobile HTS (106, 
204–206). As reported in section 4.3.2, on-site 
HTS at the workplace reaches men in formal employment (156–158). The availability of 
HTS services in VMMC clinics in the 14 VMMC priority countries has provided adolescent 
and adult males seeking circumcision with an opportunity to learn their HIV status. 
Those testing HIV-positive can be referred to prevention, treatment and care services. 
Although they will not have the benefit of HIV prevention from circumcision, they should 
not be denied circumcision if they want it nonetheless. Although these approaches do 
reach men, in many settings rates of men’s use of available HTS remain low. This low 
uptake compromises the impact of proven HIV prevention interventions, including VMMC 
and treatment for prevention. Greater emphasis on reaching men is required in many 
high prevalence settings. 
To increase men’s uptake of ANC-based PITC, a letter to male partners of ANC clients can 
invite them to test at ANC (207, 208) or in a community-based setting (209). A trial in 
Malawi found that provider-initiated notification increased uptake of HTS among partners 
of those attending STI services, including male partners (204). A high proportion of these 
partners tested HIV-positive for the first time. This notification was undertaken with 
consent from the HIV-positive client who had attended STI services (87). 
Men are less likely than women to use clinical health services. Therefore, community-
based approaches to reaching men, including home-based and mobile HTS, may be 
helpful. Mobile HTS can reach many men (206). In high prevalence settings in sub-
Saharan Africa, men were as likely as women to accept an offer of home-based HIV-
testing, provided services were delivered when men were at home, for example, in the 
evenings or during weekends (210). Home-based HTS has also been shown to reach 
couples and partners (106). 
Maximizing men’s uptake of HTS requires a strategic combination of facility- and 
community-based approaches. As discussed in section 4.3, selecting a strategic 
combination of service delivery approaches for men requires considering men's 
preferences, local context, epidemiology and available resources. In addition, services 
should be delivered at times and in locations suitable to men who are not being reached 
by existing services. Support for HIVST may also increase men’s uptake of HIV testing 
(165, 174).
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5.6 key populations
In many high prevalence settings, 
the HIV response has focused 
largely on the general population 
and not adequately appreciated 
the role of key populations in the 
dynamics of the epidemic.
Key populations – men who have sex with men, 
people in prisons and other closed settings, people 
who inject drugs, sex workers and transgender 
people – continue to have limited access to health 
services, including HTS. In many settings these 
groups experience particularly high HIV incidence 
(10). In many high prevalence settings, however, the 
HIV response has focused largely on the general 
population and not adequately appreciated the role of key populations in the dynamics 
of the epidemic. Even in countries with concentrated epidemics, efforts to reach people 
from each key population group often remain inadequate. 
For key populations, especially those whose behaviour is criminalized, HTS services are 
sometimes misused in punitive or coercive ways (26). As a result, people from key 
populations avoid health services that they need. Stigma, discrimination, lack of confi-
dentiality, coercion and fear of repercussions, as well as lack of appropriate health 
services, resources and supplies, prevent people from testing and, if HIV-positive, linking 
to care (211, 212). Like all HTS, programmes for key populations need to emphasize 
WHO’s “5 Cs” – particularly consent, confidentiality and connection to comprehensive 
prevention, treatment and care (see section 1.7). 
Community-based HTS is a critical approach for reaching people from key populations 
who are unlikely to go to a facility for HIV testing, particularly those who are 
asymptomatic. To improve access to and uptake of HIV testing, community-based HTS 
should be made available in locations and settings acceptable and convenient to people 
from key populations (213). Also, HIVST may prove to be another important way to 
increase access to HIV testing among key populations and, hence, to prevention, 
treatment and care services (14, 172). PITC among key populations is recommended, so 
long as it is not compulsory or coercive and it is linked to treatment and care (10). In 
addition to HTS, testing and screening for STIs, TB and viral hepatitis should be offered 
to key populations (10). Intensified TB case finding, along with HTS, also is particularly 
beneficial among key populations. These populations are highly vulnerable to TB, 
particularly in countries with high burdens of both TB and HIV (214).
In prisons and other closed settings, offering voluntary HIV testing as part of a package 
of care is a critical approach (see box next page). HIV testing using RDTs could improve 
uptake of HTS and increase the speed with which clients receive test results and learn 
their HIV status. Particular attention should go to providing accurate information, 
obtaining informed consent and maintaining confidentiality. Also, there are often major 
challenges to continuity of care within closed settings and between prisons and the 
community (215) ; these need to be addressed.
Retesting at least annually is recommended for all people from key populations. More 
frequent voluntary retesting may be beneficial, depending on risk behaviours (see 
sections 3.3 and 7.4). 
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wHo recommendations 
•	 HIV testing services should be routinely offered to all key populations in the 
community, closed settings such as prisons, and clinical settings. 
•	 Community-based HIV testing services for key populations, with linkage to 
prevention, treatment and care services, is recommended in addition to provider-
initiated testing and counselling (strong recommendation, low quality of 
evidence). 
•	 Couples and partners should be offered HIV testing services with support for 
mutual disclosure. This applies also to couples and partners from key populations. 
Special considerations for people in prisons and other closed settings 
•	 It is important to guard against negative consequences of testing in prisons – for 
example, segregation of prisoners – and to respect confidentiality. It is also 
important that people who test positive have access and are linked to HIV care 
and treatment services.
•	 HTS should be voluntary in all settings. 
•	 The use of “on-site” HIV testing using RDTs can increase the likelihood that 
prisoners will receive their results. 
•	 Testing in conjunction with other risk-reduction services can increase the 
benefits of HIV testing. Such services include provision of condoms with 
lubricants; STI, TB and viral hepatitis screening; and provision of sterile injection 
equipment and opioid substitution therapy. 
Source: WHO, 2014 (10).
5.7 other vulnerable populations
Depending on context, there are a number of other groups, in addition to key populations, 
that are particularly vulnerable to HIV infection. These include, in high prevalence settings, 
migrant workers, refugees and other displaced populations, and other country-specific 
populations that may be at increased risk, for example, fisherfolk and long-distance truck 
drivers, all of whom can be hard to reach and, typically, seldom use HIV services. 
Migrant workers, refugees and people who are displaced have difficulty accessing 
health-care services because of stigma, language differences, lack of required 
documentation, lack of transportation and long distances to services, discrimination and 
legal barriers. Some jurisdictions mandate HIV testing of immigrants; this requirement is 
not justified and can exacerbate the challenges of providing voluntary health services, 
including voluntary HIV testing. Displacement of key populations and others through 
human trafficking may further complicate the provision of HTS (216).
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To address the needs of vulnerable populations, countries need to evaluate their epidemic 
and its social context and identify the groups, in addition to key populations, that are at 
highest risk and in need of services. Based on these assessments, programmes can adapt 
HTS approaches and deploy them so as to increase access to testing and uptake. Special 
policies and practices to protect vulnerable populations from mandatory or compulsory 
testing may be needed. 
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       Key PoINTS 
•	Selection and programming of HIV testing services must focus on identifying and 
testing people who are unaware of their HIV infection and diagnosing people earlier in 
the course of their infection. HIV-negative people at high ongoing risk should be linked to 
effective prevention services. 
•	Linkage to and enrolment in care and treatment following an HIV-positive test 
is essential to reduce HIV transmission and prevent HIV-related morbidity and 
mortality. 
•	A mix of facility-based and community-based HTS approaches is needed to reach 
different populations. 
•	All available epidemiologic data from surveillance, surveys, programmes and research 
should be used to determine geographic, population, facility and service 
prioritization.
•	The selection of HTS approaches should be based on patterns of HIV prevalence, 
current HTS coverage, uptake, available resources and programme cost-
effectiveness at national and subnational levels, as well as the preferences of the 
populations to be served.
•	Programmes should monitor HTS data and in general favour the HIV testing approaches 
that result in the highest proportion of HIV-positive diagnoses in priority 
populations.  
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6 STRaTEGIC PlaNNING foR HIV TESTING 
SERVICES 
6.1 Introduction 
When HIV testing was first introduced and few people had been diagnosed, HIV testing in 
almost any setting in a generalized epidemic would find a high proportion of HIV-positive 
cases. Thus, there seemed little need to focus services on specific populations with unmet 
need for HIV testing. Countries with low HIV prevalence and concentrated epidemics also 
often had much unmet need for HIV testing, and few data were available to inform 
decisions about where to strategically introduce testing services. HTS in many countries 
was often initially implemented in clinical settings, either widely through ANC services or 
as diagnostic testing offered to people with symptoms suggestive of HIV infection. 
Over the past 30 years, much has changed in terms of HTS coverage and the availability 
of treatment and in terms of the data and tools available for informed and strategic 
decision-making. Between 2010 and 2014 nearly 600 million adults (ages 15+) received 
HIV testing services in 122 low- and middle-income countries reporting in this period.1 
The percentage of people with HIV who know their HIV status has increased 
substantially. UNAIDS estimates that 45% of people with HIV have been diagnosed (20). 
The focus of HTS must now shift to identifying and testing the remaining 55% who 
are unaware of their HIV infection and to diagnosing people earlier in their 
infection. Benefits of identifying people earlier in their infection and linking them to 
ART sooner include reduced morbidity, mortality and HIV transmission. 
In addition, the role of retesting is much clearer today. Offering retesting to HIV-
negative people at low ongoing risk is now considered unnecessary and a waste of 
human and financial resources. However, this practice persists in some settings. 
Retesting to rule out acute infection is recommended for people with recent known 
exposures, and routine retesting is recommended for people at high ongoing risk of 
exposure (12). See sections 5.3 and 7.4 for more information on retesting.
Considering variations in prevalence when planning HTS
Currently, guidance on how to implement HTS is often based on the broad definitions of a 
generalized or a concentrated epidemic in a country, based on the prevalence threshold of 
>1% in the “general population” to define a generalized epidemic and of <1% in the 
“general population” and >5% in at least one defined subpopulation to define a concentrat-
ed epidemic. These categories are not always helpful in determining how and where to best 
deliver HTS among populations and locations. In most countries HIV prevalence varies greatly 
across the country and even within districts, metropolitan areas and service delivery settings 
and among sociodemographic groups. Also, within the generalized epidemics there are 
1 Global AIDS Response Progress Reporting (WHO, UNAIDS, UNICEF), 6 July 2015.
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subpopulations that have significantly higher 
HIV prevalence and incidence than the general 
population. The choice among HTS approaches 
will be different in a generalized epidemic with 
prevalence between 1% and 2% from that in 
an epidemic with prevalence greater than 10%. 
South Africa is an example. HIV prevalence differs greatly among the provinces, with rates 
from above 13% in KwaZulu-Natal, Mpumalanga, Free State and the North West to 5% in 
Western Cape (217). Within provinces there are substantial differences among metropolitan 
areas. Residents of informal urban areas have much higher HIV prevalence than those 
living in formal urban areas. Among people ages 15–49 years, HIV incidence is 1.7 times 
higher in females than in males. The incidence among young females, ages 15–24, is over 
four times higher than in males in this age group (2.5% versus 0.6%) (217). 
Kenya serves as another example. According to the 2014 Kenya HIV estimates, 65% of 
HIV infections are found in nine of Kenya’s 47 counties (218). According to the 2012 AIDS 
Indicator Survey, by region, infection rates in Nyanza in western Kenya were more than 
twice as high as in any other region and differed by sex (Fig 6.1) (183). Key populations, 
which tend to be concentrated in certain areas, amount to less than 2% of the 
population but account for one-third of new infections (183).
fig. 6.1. HIV prevalence among women and men ages 15–64 years by region, 
kenya aIdS Indicator Survey, 2012
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Source: NASCOP, 2014 (183).
The tools for identifying these variations and using data for programming are improving. 
Rather than relying on one estimate for HIV prevalence for a country as in the past, now 
programmes often have subnational data from surveillance, surveys and programmes, 
The broad categories of “generalized” 
and “concentrated” epidemic are not 
always helpful in determining how best 
to distribute HTS among populations and 
locations. A closer look is needed.
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with HIV prevalence data disaggregated by sex, age, risk behaviour and location. 
Geographic mapping can be used to plot estimated HIV prevalence, estimated HIV 
incidence, population density, estimated population size and location of key populations, 
as well as the coverage and the proportion of HIV-positive cases identified by existing 
testing services (see Fig. 6.2 for an example from the Dominican Republic). Population-
based surveys now include questions about HIV testing access, thus providing 
information about populations and locations with high unmet need for testing (183). 
Cost estimates and budgets can now be informed by actual expenditure analysis, not 
only at the national level but even at the site or facility level. Countries should use all 
available data, as well as tools for analysis and mapping, to help inform strategic 
decision-making. This includes decisions about how to maintain wide coverage of 
essential testing services, such as for pregnant women and clients with TB and STIs, as 
well as how to increase focused coverage for populations at high risk and for groups 
previously underserved. 
fig. 6.2. Population size estimates (PSE) and HIV prevalence estimates among 
female sex workers, by province, in the dominican Republic 
Source: UNAIDS, WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria, unpublished report from 
Dominican Republic data, 2015.
National programmes can benefit from collaborations with research partners, 
universities, local and international implementing partners, national statistics offices, 
procurement specialists and civil society organizations to gather a full array of high-
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quality data and apply a wide range of tools to understand and analyse these data to 
inform HTS strategies (see Chapter 10).
A crucial feature of any HTS approach is its linkage to care and treatment services 
for those identified as HIV-positive and to prevention services for those at ongoing risk 
of HIV acquisition. The effectiveness of linkage varies considerably among different HTS 
approaches. In general, linkage to care may be easier when HTS is facility-based; still, 
not all facilities have successful client follow-up and enrolment. Although linkage may 
often be lower in community-based settings than in facilities, high levels of linkage can 
be achieved with support and intensive interventions. Thus, proactive linkage 
approaches are a critical component of comprehensive HTS. See section 3.6, which 
outlines various approaches that may be useful for facilitating linkage to care and 
treatment following HIV testing.
The success of linkage should be measured by enrolment in care and not by intermediary 
process indicators such as the number of referral cards issued. Without strategies that 
ensure linkage and enrolment in care, the effect of HTS in reducing HIV transmission, 
morbidity and mortality cannot be fully realized (see section 3.6). Tracking systems 
should be established to monitor and evaluate the success of linkage to care approaches 
and identify areas for improvement. The costs associated with different linkage 
strategies for a given HTS approach also should be considered when assessing which are 
most successful and should be scaled up (see Annex 5).
Financial and human resources 
should be allocated to ensure that 
HTS is available to, and used by, the 
largest possible number of people 
with HIV who remain undiagnosed.
This chapter discusses key strategic decisions 
regarding the implementation of HTS along with 
tools to help inform decisions. As a first step to 
reaching the first 90 of the global fast track 
90–90–90 targets (that is, 90% of people with 
HIV diagnosed) (20) , an in-depth analysis of 
country-specific HIV epidemiology, HTS 
coverage and cost is needed. This analysis can help to identify the optimal 
combination of approaches to HIV testing. Financial and human resources should be 
allocated to ensure that HTS is available to, and used by, the largest possible number of 
people with HIV who remain undiagnosed.
6.1.1 Routinely offered HTS versus focused HTS
When HTS is routinely offered, every child, adolescent and adult in a given 
geographical location or setting is offered HIV testing. This routine testing approach can 
be delivered in health facilities or in the community. 
Routinely offered HTS in a facility setting is often referred to as PITC (126). 
•	 PITC is highly acceptable to both clients and providers. It is feasible, assists in the 
diagnosis of people with HIV who do not report or perceive their own HIV risk (219) and 
increases HIV case finding among infants, children and adolescents as well as adults.
•	 Routine offer of HTS normalizes HIV testing and reduces barriers such as stigma and 
discrimination, which prevent some people from seeking services.
•	 In high prevalence settings PITC will result in a high proportion of HIV-positive cases 
identified and be cost-effective, as it enables the testing of many people at a low unit 
78 Consolidated guidelines on HIV testing services
cost (220). However, it tends to reach people at later stages of disease; people 
diagnosed through PITC have significantly lower CD4 counts than those diagnosed 
through community-based approaches (3, 221).
•	 HIV prevalence may vary among client populations in different clinical services or 
facilities. Therefore, the proportion of people diagnosed HIV-positive should be closely 
monitored to assess whether the HIV testing strategy needs to be more focused. For 
example, programmes could prioritize PITC in certain clinical services or in facilities with 
higher positivity rates.
•	 PITC alone will not be adequate to reach global coverage targets, as it is available only 
to those who attend health facilities. Many people with HIV, especially men, key 
populations and adolescents during the first few years of their infection, may be 
asymptomatic and, therefore, unlikely to seek facility-based services unless it is for 
other reasons. However, the percentage of people who test HIV-positive in facility-based 
HTS will likely decrease as HTS and ART coverage increase. For example, in ANC settings 
with low HIV incidence and where a high proportion of women with HIV have been 
previously diagnosed, few new cases will be identified. 
Routinely offered community-based HTS. In some settings approaches such as 
home-based (door-to-door) HTS are used to try to reach all people in a geographical 
area. 
•	 This approach can be acceptable and feasible (3).
•	 If well-designed, it can help to reach groups such as men and adolescents who may 
utilize health services infrequently. Additional strategies to reach couples (222) and men, 
such as weekend and evening home visits, may further increase access (204). 
•	 The proportion of HIV-positive cases identified is usually lower, but the mean CD4 count 
at the time of diagnosis is generally higher, than with facility-based testing (3).
•	 This approach is unlikely to be cost-effective outside high prevalence settings. 
•	 Linkage to HIV care and treatment services may be difficult unless efforts to support 
linkage are prioritized (223). 
Given current levels of undiagnosed HIV infection in many settings, and the need to use 
limited funds most efficiently to reach the largest number of undiagnosed people, 
focused community approaches to HIV testing are needed, in addition to testing in 
health facilities to reach men, adolescents and key populations. Home-based testing will 
likely be needed to achieve 90% coverage levels in high prevalence settings. However, it 
will likely be unfeasible in most settings, and some form and level of targeting based on 
epidemiology and coverage should be prioritized to increase cost-effectiveness. 
Focused HTS aims to reach specific groups of people who remain undiagnosed or to 
prioritize implementation in specific geographical areas or clinical settings according to 
epidemiology and current levels of HIV testing coverage. A strategy for focused HTS 
should take into account the cost and the cost-effectiveness of delivering different HTS 
approaches in relation to locale, HTS venue, populations reached and successful linkage 
to care. For example, even if unit costs of outreach testing for key populations are higher 
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than for testing in ANC, the cost per new HIV diagnosis may be significantly lower, as 
the proportion of HIV-positive cases identified is likely to be much higher. 
HTS can be focused on a particular: 
•	 population, such as a key population or partners and family members of people with 
HIV (index testing). Other groups may include men and adolescents in high prevalence 
settings and other underserved vulnerable groups (for example, migrant workers), 
according to context.
•	 geography, such as districts or counties with high HIV prevalence or, more specifically, 
transport hubs, border crossings or specific urban locales where key populations work 
or reside. Other examples include workplace, home-based or school-based programmes 
in specific settings with low current HIV testing coverage and high HIV prevalence or 
incidence. 
•	 health facility type, such as facilities with a high proportion of HIV-positive cases 
identified. 
•	 service, such as offering routine testing in clinical services where HIV prevalence is 
likely to be high, including TB, STI, and hepatitis services and harm-reduction clinics. 
•	 indicator conditions, such as offering HTS to people with specific clinical conditions 
associated with HIV, such as cervical or anal cancer, herpes zoster or unexplained fever 
(129). 
The challenges to focused approaches to HIV testing are that, by definition, they reach 
only certain subpopulations, and they may be more expensive due to the effort required 
to reach these groups. In a clinical setting they may be more complicated to deliver and 
may miss people who do not disclose risk behaviours to health-care providers. They may 
also increase stigma and discrimination if they are seen to target certain people. For 
services focused for key populations, countries need strong political commitment to 
providing acceptable services and avoiding harm to these clients, whose behaviour may 
be criminalized. Qualitative research and community consultation will be critical to 
designing and developing approaches to deliver HTS that can reach specific populations. 
Focused HTS may miss the emergence or re-emergence of high infection rates in clinics 
or geographical areas where testing is not or no longer offered. In countries with limited 
resources, decisions to focus testing on specific sites, certain clinical services and people 
with indicator conditions will have to be made with careful ongoing monitoring to assess 
the effectiveness of the approaches. Variations and trends in incidence throughout the 
country will also need monitoring to ascertain whether focused approaches continue to 
be focused on the right places and populations.
Countries need political commitment not only for providing services to key populations 
but also to develop systems for collecting and analysing epidemiological and 
programmatic data concerning them while protecting client confidentiality. 
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6.2 Strategic decision-making for selecting approaches to HIV 
testing
As discussed in Chapter 4, HTS can be delivered in different ways and to different people. 
HTS can be offered in a variety of settings in both health facilities and the community. To 
facilitate the diagnosis of as many people with HIV as early as possible, countries need to 
select a strategic mix of approaches to deliver HTS based on epidemiologic data, available 
resources and the populations that most need HTS. Also, the selection of HTS approaches 
should support timely and complete linkage to prevention, treatment, care and support 
services for those testing HIV-positive.
To develop and implement the optimal combination of approaches to HIV testing, countries 
will need to review national and subnational epidemiology, current HIV testing coverage 
(for example, the number and proportion of those ever-tested and tested in the last 
12 months by population, age and sex), the costs and cost-effectiveness of different 
approaches and the human and financial resources available. A mix of HTS approaches that 
maximize linkage will likely be most cost-effective and have the greatest impact if they are 
focused on geographic locations and populations with high HIV prevalence (224). 
6.2.1 Steps for selecting strategic approaches to HIV testing services in a 
national programme
1. Set HTS coverage targets.
•	 Review the most recent data, including data on HIV prevalence and incidence (if 
available), the estimated number of people with HIV in the population and the 
proportion undiagnosed, to understand where disproportionate undiagnosed HIV 
burden exists geographically and by age, sex and population group.
•	 Coordinate with treatment scale-up. The primary reason for diagnosing people with 
HIV is so that they can benefit from ART. Therefore, it is important to directly link HIV 
testing and ART targets. Plans for major scale-up of ART services will not succeed 
without testing. Likewise, major scale-up of HTS, which will create demand for ART, will 
have limited benefit without concurrently expanding ART capacity. Identify sites, 
geographic areas and populations where targets for enrolment in HIV care or initiation 
on ART are not aligned with HIV testing coverage, the proportion of HIV-positive cases 
identified and linked to HIV care and treatment services, and adjust plans accordingly.
2. Review effectiveness and identify gaps. 
•	 Analyse HTS data to see what is being achieved by specific approaches in various sites 
and locations in terms of numbers and proportions of people tested, new cases 
diagnosed and enrolment in care. 
•	 Assess commodity and human resource needs, availability and policies to 
identify barriers to and opportunities for expanding or shifting the focus of programmes 
(for example, availability of rapid test kits or trained lay providers and policies regarding 
task sharing).
•	 Assess available HTS resources, including investments by the government and all 
funding partners.
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•	 Revisit and revise national targets and approaches to HIV testing so as to better 
reach those who are undiagnosed and to capitalize on comparative advantages and 
cost-effectiveness, taking into account linkage and enrolment in treatment.
3. adjust programmes. 
•	 Develop and follow a national consensus plan for expanding and refocusing HTS in 
line with the treatment plan.
•	 Evaluate implemented programmes through routine programme monitoring, 
programme-specific evaluations, surveillance and population-based surveys.
Adjust programme
Identify areas for focus/re-focus
•	 Population
•	Geography
•	 Sites and setting
•	Clinical services and conditions
Review effectiveness and 
identify gaps
•	 Proportion HIV-positive by 
different approaches
•	Cost per new case identified
•	 Linkage rate
•	By population group and locale
Set targets
Based on
•	ART targets
•	 Epidemiology
•	Current coverage
fig. 6.3. Steps to assess and improve selection and implementation of HIV testing 
service approaches
6.2.2 Identifying populations and locations with high HIV prevalence and 
incidence
Identifying populations at high risk for HIV infection and where they live and spend time 
is important for developing successful HTS. Although it is impossible to know the exact 
number of people with HIV infection or the number of new infections in a given area, 
these numbers can be estimated through the analysis of data from multiple sources. 
Typically, these sources include surveillance data from HIV testing among pregnant 
women, national household surveys, smaller studies among groups of interest such as 
key populations and modelling exercises such as those conducted through UNAIDS’ 
Spectrum AIDS Impact Model (AIM) (225). Although any one data source has limitations, 
when used together they can paint an informative picture of HIV epidemic trends.
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Data from national population-based surveys provide the most accurate information if 
response rates are high and there are no large biases or exclusions of specific population 
groups. National surveys often can determine prevalence only at the regional or 
provincial level. Thus, programmatic data at the district level or even the facility level 
should be explored for more detailed information on HIV testing coverage and the 
proportion of HIV-positive cases identified. 
National household surveys or ANC surveillance will seldom identify key populations and 
marginalized vulnerable groups. Specific approaches are needed to identify key 
populations and people that standard surveys do not reach or identify. There may be 
significant differences in knowledge of HIV status between the general population and 
marginalized populations, such as undocumented migrants, where the great majority of 
those with HIV may not be aware of their status. 
data relevant to HIV testing include:
•	 national and sub-national HIV prevalence (and/or incidence) and population size 
estimates among: 
– men and women, stratified by age group to identify which ages are at highest risk
– pregnant women attending antenatal clinics 
– key populations and other priority populations; 
•	 number and proportion of people who are aware of their HIV status. Depending 
on the data available, this may be the proportion of individuals who have ever been 
tested for HIV or of people who were tested in the last 12 months and received their 
results. These data should be disaggregated by sex, age, geographic region, service 
delivery setting and population type; 
•	 proportion of people tested HIV-positive who have been enrolled in HIV care and 
treatment services;
•	 CD4 count at diagnosis, stratified by gender and age to identify the proportion and 
distribution of late presenters in the population;
fig. 6.4. Critical HIV testing services data to inform strategic planning
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•	 HTS uptake, by HTS approach (from studies among key populations, for example);
•	 proportion of those tested who are HIV-positive, by population, HTS approach or 
facility; 
•	 cost and cost-effectiveness of various HTS approaches (see section 6.2.4).
6.2.3 understanding HIV testing service delivery and gaps
Following epidemiologic analysis, an assessment of current HTS coverage and mapping 
of HTS can determine how well services are covering populations in need. This exercise 
could include the following: 
•	 Mapping of current services, including availability, uptake (by sex, age and 
population), coverage rate, funding source and location for all current HTS, including: 
– clinical settings providing PITC in ANC, TB, STI, harm reduction, outpatient and 
inpatient services
– HTS for key populations
– standalone testing sites (VCT) 
– specific services, such as VMMC in VMMC priority countries
– community-based and mobile HTS
– HIV testing at educational institutions 
– workplace HTS
– private health-care providers (who offer HTS); 
•	 Identification of gaps in current HTS coverage in relation to HIV burden, by 
geographic location and population, focusing on areas of highest prevalence or 
incidence that are not being reached by available services;
•	 Assessment of barriers to HTS, including social, cultural and geographical factors, 
psychosocial, behavioural factors, stigma and discrimination, gender and legal factors 
(including age of consent requirements) and structural and health system factors that 
may impede access; 
•	 Assessment of the linkage between HTS and other programmes, in particular, 
enrolment in HIV treatment and care programmes following an HIV-positive diagnosis; 
•	 Review of policies on who can perform tests, including whether lay providers can 
collect specimens, perform RDTs and issue test status reports; whether point-of-care 
testing is permitted; and what education, training and certification are required for 
those conducting tests; 
•	 Assessment of site performance, including the quality of test performance.
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Case example: Strategic planning for HIV testing services: data use 
workshops in the Republic of South africa
In 2012 the National Department of Health (NDH) in the Republic of South Africa, 
with support from the US Centers for Disease Control and Prevention and the 
University of California at San Francisco, held a series of workshops to build 
capacity for the use of programme and surveillance data in strategic planning for 
HIV testing programmes. These workshops included sessions on compiling data 
from multiple sources to generate tables, charts and maps and on analyses of 
programme gaps and needs. This work led to action plans for improving 
programme alignment to populations and geographic areas with disproportionate 
HIV burden. 
Decision-makers were interested in understanding where best to scale up 
community HTS and where facility HTS coverage needed strengthening. 
Participants concluded that, while the number of people tested in the community 
had increased from 2011 to 2012, community testing strategies still contributed a 
small proportion of the overall numbers. They also found that testing coverage in 
provinces and districts was not well-matched with HIV prevalence. These findings 
helped to guide efforts to increase HTS coverage in the higher burden districts, 
including expansion of community-based testing in those areas. 
Sources: CDC and NDH, unpublished, 2015.
6.2.4 assessing costs and cost-effectiveness 
Cost-effectiveness analyses compare the costs and health impacts of different 
intervention options to identify interventions that provide good value for money. Such 
analyses are useful for optimizing the allocation of public health resources (226). 
Although important for decision-making, cost-effectiveness is only one consideration for 
countries designing a national HIV testing strategy. Acceptability, social and contextual 
factors and public health impact should be taken into consideration.
Comparing the costs associated with a given HTS approach can be challenging. Costs for 
similar services often differ significantly between countries and by HTS approach within 
a country. For example, a recent literature review from Botswana found that reported 
HTS costs for different approaches ranged from US$ 5 to US$ 75 per person tested (227). 
Differences in programme costs may be due to general cost differences between 
countries and to differences in what specific services are provided (for example, referral 
to a clinic for those testing HIV-positive versus enhanced linkage support), cadre of staff 
employed (for example, nurses versus community health workers), the ease of reaching 
different populations, the capacity of the health system and the level of HIV testing 
coverage. Also, the policies regarding who can perform HIV tests, as well as the specific 
testing strategy and algorithm employed, may affect costs. Direct cost comparisons of 
different HTS approaches are easier to interpret when they are from the same country 
and use the same costing inputs. 
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However, costs for similar HTS programmes can differ even within a country. For example, 
in Uganda the cost per case detected in home-based testing programmes ranged from 
US$ 71 (228) to US$ 322 (220). The cost per case detected in the latter programme was 
higher because it used a household index approach to testing, it tested a large number of 
children and adolescents, and it identified fewer HIV-positive cases. It is important not only 
to assess the cost per person tested but also the cost per HIV-positive case identified 
– and, ideally, per new case identified (Fig. 6.5). For example, the cost per person tested in 
a community-based programme may be higher than the cost per person tested among the 
general population in a facility-based setting. However, the cost per case identified may be 
lower in the community-based programme, or similar to those of other approaches, 
because of the high prevalence among key populations and their poor access to other 
testing venues. 
Fig. 6.5 summarizes the literature on HTS studies examining cost. As the figure 
illustrates, facility-based approaches in low-income countries generally have the lowest 
cost per case identified, regardless of the proportion found to be HIV-positive. Home-
based programmes, nearly all of which were in low-income countries, generally find a 
low proportion of HIV-positive cases and have a wide range of costs per case identified. 
(See Annex 5 for details.)
Source: Annex 5.
fig. 6.5. Cost per case detected and proportion HIV-positive among the general 
population and key populations in low- to upper middle-income income countries
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A common approach to estimating costs involves identifying and estimating costs 
incurred in the following broad categories: 
•	 personnel (for example, staff salaries and allowances);
•	 recurrent costs (for example, HIV test kits and commodities, printed materials, office 
supplies);
•	 capital expenses, often amortized over their useful life and discounted annually at 3% 
(for example, office space, vehicles, equipment);
•	 Other economic costs, such as clients’ time, donated goods and use of existing 
equipment may also be included, depending on the goals of the analysis. 
These costs can be added to compute the total expected cost of an intervention per year. 
Considering the extent of costs averted also is important; for example, successful PMTCT 
prevents paediatric infection and thus avoids subsequent treatment costs that would 
have been required for the lifetime of an infected infant.
It is also important to recognize and estimate the costs averted and health impacts 
associated with earlier HIV diagnosis. Since 2002 average CD4 counts at ART initiation 
have remained at around 200 cells/μL (39). This indicates that people continue to be 
diagnosed late and to start treatment, on average, about eight years after being infected 
(229, 230). To maximize the therapeutic and preventive benefits of ART, early diagnosis 
and effective linkage to HIV care and treatment are critical. Therefore, approaches to 
HIV testing that achieve earlier diagnosis but cost more than other options may be more 
cost-effective than approaches that cost less but diagnose people later in the course of 
their infections. Many countries also combine HIV testing with testing and treatment for 
syphilis in ANC settings. Countries should assess the costs and the benefits of this, 
particularly countries that are prioritizing dual elimination of HIV and syphilis.
Health outcomes that can be used in cost-effectiveness analysis of HTS include: 
•	 numbers of people tested 
•	 numbers of HIV cases identified 
•	 numbers of early diagnoses (CD4 >350 cells/μL)
•	 numbers of infections averted (when linked to prevention, PMTCT and ART)
•	 numbers of disability-adjusted life years or number of quality-adjusted life years gained 
(dependent not only on being diagnosed but also on CD4 count at diagnosis and 
whether linked to ART). 
One challenge with cost-effectiveness analysis is that cost-effectiveness estimates will 
be overly optimistic if they omit important costs such as transportation or rent. Also, the 
health benefits associated with HTS are not derived from the HIV test itself, but rather 
from the treatment and prevention interventions that occur subsequently, which should 
ideally be taken into consideration in the analysis. Thus, the effectiveness of linkage 
from HTS to treatment is crucial to cost-effectiveness. Another challenge is that cost-
effectiveness analyses may not be widely generalizable across settings. Furthermore, the 
cost of a programme, and hence its relative cost-effectiveness, depends greatly on the 
details of the programme itself. For example, a programme designed to reach sex 
workers by running late-night “moonlight” mobile camps at various locations can have 
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significantly different costs than a similar approach provided in the daytime or only in a 
fixed location, such as a brothel. Still, both HTS approaches may be necessary to reach 
this key population. Finally, different approaches may be cost-effective for different 
populations.
Therefore, assessing which HTS approaches make the most efficient use of resources 
requires a detailed understanding of the approaches themselves, including how and to 
whom they are delivered. The final selection of HTS approaches should be informed not 
only by cost-effectiveness but also by HIV prevalence, unmet need (the estimated 
number of people with HIV who remain undiagnosed), priority populations for the 
country and the anticipated proportion testing HIV-positive. 
1 Very high coverage was defined as ANC coverage of 95%, HIV testing among ANC attendees of 95% and ARV coverage among mothers 
who tested HIV positive of 95%.
2 Low coverage was defined as the current country level of ANC coverage, 20% HIV testing among ANC attendees and 95% ARV coverage 
among mothers who tested HIV-positive.
3 http://www.who.int/choice/cost-effectiveness/inputs/health_service/en/
Case example: Cost-effectiveness analysis for assessing different HTS 
strategies for PmTCT
Four illustrative country scenarios were developed based on data from Namibia, 
Kenya, Haiti and Viet Nam, with national HIV prevalence among females ages 
15–49 years of 17%, 7%, 3% and 0.1%, respectively. Subnational HIV prevalence 
estimates were used to divide each country into high, medium and low burden 
areas (see Annex 6 for specifics of country scenarios and methodological details). 
Different levels of coverage for pregnant women, including coverage of ANC, HTS 
and ARV services, were then assigned to each sub-area for the following four 
strategies: 
•	 highly focused HTS (very high coverage1 for high burden areas and low coverage2 
for medium and low burden areas)
•	 focused HTS (very high coverage1 for high and medium burden areas, low 
coverage2 for low burden areas)
•	 current coverage (current coverage levels from national surveys)
•	 universal HTS (very high coverage for all pregnant women).
Standardized unit costs were applied for all scenarios except health services costs, 
which varied by country and were obtained from the WHO CHOICE database 
(2010).3 Costs included HIV testing (HIV test kits and counselling services), PMTCT 
costs (HIV testing, maternal and infant ARVs and health services) and total costs 
(PMTCT costs and paediatric treatment costs for 20 years). 
Health outcomes, costs and cost-effectiveness from this analysis can be examined 
in different ways. The narrowest approach is to assess the number of HIV-positive 
cases identified under the different scenarios, the cost of HIV testing, and thus the 
cost per HIV case detected. In this case study the average HIV testing cost per 
HIV-positive mother identified across approaches in Namibia were US$ 17.00−18.40, 
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in Kenya US$ 15.07−23.80, in Haiti US$ 29.80−35.60, and in Viet Nam US$ 400−570. 
Considering this narrow definition of health benefits and costs associated with these 
programmes, of the four scenarios highly focused HTS was the most efficient way to 
detect new cases within a given country. However, highly focused HTS also results in 
the fewest number of HIV-positive mothers being identified, as less focused 
approaches provide coverage to more women.
The main limitation to considering only HIV testing costs and HIV-positive cases 
detected is that this approach does not account for paediatric infections averted 
and downstream health effects of infections, nor for the costs for providing PMTCT 
or for treating infected infants whose mothers did not receive PMTCT. These are 
important health outcomes and costs that decision-makers should consider. 
Based on a broader analysis that considers PMTCT costs (including HIV testing) 
and infections averted by the different programmes, the current-coverage HTS 
approach was the least efficient in each country scenario, indicating that 
resources are not currently being distributed as efficiently as they could be 
(Appendix table 6.2A). When considering infections averted and PMTCT costs, in 
all four country scenarios highly focused HTS was again the most efficient 
strategy, followed by focused HTS and then universal HTS, which averts the 
greatest number of infections. Although the differences in efficiency between 
approaches were modest, implementing a universal HTS approach averts twice 
the number of new infections that highly focused HTS averts, while also costing 
approximately twice as much. This budgetary reality may have bearing on 
decision-making for HTS implementation in the context of limited resources.
Finally, the above analyses are still somewhat incomplete in that they ignore the 
downstream costs required to provide ART to infected newborns. When the cost 
of 20 years’ worth of future treatment for paediatric infections was considered in 
addition to HIV testing and PMTCT costs, universal HTS for all pregnant women 
saved the most in terms of total costs in the three generalized epidemic country 
scenarios (that is, Haiti, Kenya and Namibia). This means that universal HTS both 
saves money and improves health outcomes compared with focused approaches. 
In Viet Nam, which has a concentrated HIV epidemic, all approaches were 
cost-saving compared with no PMTCT rogramme. The focused approaches saved 
slightly more than the universal approach. However, the number of HIV-positive 
mothers identified and paediatric infections averted was twice as high in the 
universal approach as in highly focused approaches. 
Therefore, if a decision-maker is concerned about all current and future costs and 
health outcomes associated with a PMTCT programme, the most efficient 
approach for the generalized epidemic scenarios would be universal HTS for all 
pregnant women. This approach identifies the most HIV-positive mothers, 
minimizes the number of infections among infants and actually saves money 
compared with other approaches. In the Viet Nam-based scenario of a 
concentrated epidemic, the highly focused, focused or universal approach could 
be considered cost-effective, and all three have lower costs than no intervention.
Another consideration in addition to cost-effectiveness is a country’s current 
coverage of both ANC and PMTCT services. In a situation where there is poor 
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6.3 developing a strategic, efficient and cost-effective HIV testing 
services plan 
Routine HIV testing in clinical settings and focused HIV testing approaches in and outside 
of facilities for particular populations remain a priority for high prevalence settings. 
Evidence suggests (see case example above and Annex 6) that routine HIV testing for 
pregnant women can be beneficial and cost-effective, even in low prevalence settings if 
the costs due to averted HIV infections among infants and improvement of mothers' lives 
are considered. However in many settings with low HIV prevalence and limited resources, 
implementing all of these approaches will be challenging and focused testing based on the 
positivity rate, and the resultant cost per HIV case detected can guide prioritization; if HTS 
coverage is low, countries could consider geographic prioritization. 
Table 6.1 suggests the combinations of HIV testing approaches that countries could 
consider based on epidemiological context. 
As HTS are scaled up, more people will become aware of their HIV status and be treated, 
and HIV prevalence and incidence will decrease. As a result, the proportion of people 
who test HIV-positive will begin to drop. Some clinical settings, such as TB, STI, harm 
reduction and key population clinics, likely will continue to find a higher proportion of 
HIV-positive people than general outpatient settings. In generalized epidemic settings, 
offering routine HIV testing to children in specialized facilities, such as malnutrition and 
under-5 clinics, may also yield higher rates of HIV-positive case detection. Routine 
monitoring data should guide ongoing adaptation of programme strategies to keep pace 
with shifts in context and disease burden over time. 
In some settings programmes should implement location-specific prioritization 
cautiously and review this prioritization regularly, as HIV prevalence may not always be a 
good indicator of trends in HIV incidence. If HTS is not provided in some facility- or 
community-based settings and data are not collected regularly through surveillance or 
ANC and/or PMTCT coverage, and programmes are planning their scale-up, a 
phased approach in which high prevalence areas are targeted first, followed by 
areas of lower prevalence, would likely be the most rational use of resources. 
However, in reality, achieving the highly focused testing and retention goals 
defined in this case study is likely to be difficult, and costs for reaching the final 
5–10% of pregnant women are likely to be higher than for reaching women who 
access programmes on their own.
Ultimately, programme managers need to make difficult decisions based on 
available resources for HTS. Conducting cost-effectiveness analyses such as in 
this case study will provide information on the most efficient approach to reach 
the maximum number of people who need testing, treatment and care with given 
resources. Other non-economic reasons, such as the programmatic logistics of 
either initiating or withdrawing HTS, should be thought through when evaluating 
whether incremental gains in efficiency are worthwhile.
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surveys, changes in the underlying epidemiology of different groups may be missed in 
these underserved areas. 
Ensuring that HIV testing programmes are reaching their intended populations and 
identifying previously undiagnosed HIV-positive people will require continued monitoring 
and evaluation. For long-term success, the impact of different HTS approaches on 
uptake, the proportion that test HIV-positive, cost and changes in the prevalence of HIV 
in different population groups must be evaluated and measured regularly, and 
programmes must be adjusted appropriately.
Table 6.1. Summary of routinely offered and focused HIV testing 
approaches that can be considered for generalized and concentrated 
epidemic settings
Generalized 
epidemic settings
Concentrated 
epidemic settings
Approaches to HIV testing Routinely 
offered
Focused Routinely 
offered
Focused
Health facility-based approaches
1. Primary care settings for adults, adolescents and 
paediatric clients (including integrated VCT) ✔ ✔
2. Antenatal clinics ✔ ✔ ✔
3. TB clinics ✔ ✔
4. STI clinics ✔ ✔
5. Drug dependence and harm reduction services ✔ ✔
6. Indicator condition-based testing ✔ ✔
7. Risk-based screening ✔ ✔
Partner/index testing (in all HTS)
1. Index testing of family members ✔ ✔
2. Partner testing (for all partners) ✔
3. Partner testing (for all partners of people with HIV) ✔ ✔
Community-based approaches
1. HIV and multi-disease campaigns ✔ ✔
2. Home-based/door-to-door testing ✔ ✔
3. Mobile/outreach for key populations ✔ ✔
4. Mobile/outreach for the general population (for 
example, men, young people) ✔
5. Workplace testing ✔
6. School/educational institution testing ✔
7. Services for orphans and vulnerable children ✔ ✔
8. HIV self-testing* ✔ ✔ ✔
Geographic prioritization
1. Regional (for high prevalence areas) – facility- 
and/or community-based ✔ ✔
2. Facility (by proportion of cases diagnosed  
HIV-positive) ✔ ✔
* As yet, WHO does not formally recommend HIVST, but pilot projects and programmes should be considered. 
See Annex 12 for details on HTS approaches and considerations by epidemic setting.
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       Key PoINTS 
•	Rapid diagnostic tests (RDTs) are a critical tool for scaling up HIV testing services. 
They can be performed by trained lay providers, health-care workers and laboratory 
professionals in various settings, irrespective of the infrastructure, as they do not require 
specialized equipment or specimen collection by venepuncture. 
•	 Immunoassays such as enzyme immunoassays (EIAs), chemiluminescence immunoassays 
(CLIAs) and electrochemiluminescence immunoassays (ECLs) are best suited to settings 
with high throughput of clients and where infrastructure (electricity, cold storage, 
climate-controlled rooms) and skilled staff are consistently available. These assays are 
typically used only with serum/plasma specimens, which require specimen collection by 
venepuncture.
•	The length of the window period is determined primarily by the type of serological 
assay used and by an individual’s immune response. 
•	The first-line assay (A1) for any testing algorithm should be the most sensitive 
assay available, with more specific assays used as second-line (A2) and third-line (A3), 
irrespective of the assay format.
•	Retesting to verify HIV diagnosis is recommended: 
– for all individuals with newly established HIV-inconclusive results and 
– for all individuals who have tested HIV-positive, before they enrol in care and start 
ART.
•	Retesting is also recommended for certain individuals with ongoing risk who test HIV-
negative.
•	Retesting is not recommended for individuals on ART. For individuals who have taken 
PEP, for infants exposed to PMTCT regimens via their mothers and for individuals taking 
PrEP, negative status should be interpreted with caution.
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7 dIaGNoSTICS foR HIV dIaGNoSIS 
See glossary on page xii and Annexes 7 and 8 for a detailed description of HIV in vitro 
diagnostic (IVD) formats discussed in this chapter.
7.1 overview of HIV diagnosis 
HIV testing may take place at any level of the health-care system, and a diagnosis can be 
established for a majority of individuals on the same day. Many people will access HIV 
testing in their community (level 0) or in primary care facilities (level 1). Fig. 7.1 depicts 
how HIV testing services are typically organized and shows the different assay formats 
that could be available at each of the levels (for both facility-based and community-
based testing). The degree of infrastructure required for the assay format, such as need 
for reliable electricity and climate-controlled testing rooms, as well as the staff skills and 
competencies required, will determine how complex an assay can be used in a given 
testing setting.
fig. 7.1. a tiered testing service, with assay format menu and staff qualifications
4
3
2
1
0
National
Senior laboratory specialists
Provincial / regional
Senior laboratory specialists /
technicians
District
Laboratory technicians
Primary care
Health-care workers, 
trained lay providers
Community/
outreach
Community workers, 
trained lay providers
Facility-
based 
testing
Non-
facility-
based 
testing
Lab-NAT / CLIA / ECL / EIA / 
WB
Lab-NAT / POC-NAT / 
CLIA / ECL / EIA / WB
POC-NAT / EIA /  
RDT
RDT
RDT
 
 
Source: WHO, 2012 (231).
Lab-NAT: laboratory-based nucleic acid testing; POC-NAT: nucleic acid testing at point-of-care; CLIA: chemiluminescence 
immunoassay; ECL: electrochemiluminescence immunoassay; EIA: enzyme immunoassay; WB: Western blot; RDT: rapid 
diagnostic test.
93Chapter 7: Diagnostics for HIV diagnosis
7.1.1 Basic principles for performing HIV testing
All HIV testing should be performed in accordance with the assay manufacturer’s 
instructions for use (the package insert). In addition, SOPs and job aids should be 
developed that help testing providers to minimize testing and reporting errors and, thus, 
to improve the quality of the testing results. See Chapter 8 for details on how to assure 
the quality of HIV testing. 
For people over 24 months of age, HIV is typically diagnosed through the detection of 
HIV antibodies (a serological marker) and/or HIV p24 antigen rather than direct 
detection of the components of the virus itself (virological markers). Serological assays 
used for HIV diagnosis detect HIV-1/2 antibodies, with fourth generation assays 
incorporating detection of both HIV-1/2 antibodies and HIV p24 antigen. When initial 
HIV testing cannot discern a diagnosis, supplemental assays may be used, such as assays 
that detect HIV p24 antigen only or assays that can detect specific types of HIV-1/2 
antibodies. These are discussed in detail in section 7.1.2. Fig. 7.2 illustrates the types of 
assays that can be used at different points in the natural history of HIV infection. 
fig. 7.2. detecting HIV-infection with various formats and generations of in vitro 
diagnostics over the natural history of infection
Source: Rosenberg et al., 2015 (1).
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Table 7.1. HIV serological assays
Generation Antigen source and attributes of the assays
First generation Crude viral lysate as antigen 
Relatively sensitive but lacked relative specificity. Detects 
immunoglobulin G antibodies (lgG) only.
Second generation Recombinant proteins and synthetic peptides as antigen
Improved specificity and sensitivity. Detects IgG only.
Third generation Recombinant proteins as antigen, with same antigen conjugated to 
enzyme (antigen sandwich)
Further refines sensitivity and specificity. Detects IgG and 
immunoglobulin M antibodies (IgM).
Fourth generation Recombinant proteins as antigen and monoclonal antibodies
Detects IgM and IgG antibodies and HIV p24 antigen; therefore, 
increased sensitivity in early infection, that is, during seroconversion. 
For a period of about 10 days following HIV infection, known as the eclipse period, no 
currently available serological or virological assay can detect any marker of HIV 
infection. The end of the eclipse period is marked by the appearance of HIV RNA or DNA 
detectable by nucleic acid testing (NAT) and then HIV p24 antigen, detectable by 
immunoassay (IA). The period prior to detection of HIV-1/2 antibodies is often referred 
to as “acute infection” (1, 23). The number of HIV virus particles rises rapidly during 
acute infection and may be associated with higher infectivity and rate of transmission. 
As the level of HIV-1/2 antibodies increases, these antibodies form immune complexes 
with free HIV antigen circulating in the bloodstream. Thus, free HIV antigen is captured 
(complexed) and, therefore, unable to bind to monoclonal antibody presented on the 
test device. As a result, the level of detectable HIV antigen decreases. The detection of 
HIV-1/2 antibodies by serological assay signals the end of seroconversion and, therefore, 
the window period for diagnosis. 
The duration of the window period depends on three main factors: (1) the genetics of 
the virus, (2) the genetics and immunocompetence of the host and (3) what exactly the 
assay detects (antigen, antibodies). In particular, the format of the assay determines its 
ability to detect early HIV antibodies (including IgM, IgA, IgG); this may also depend on 
the specimen type, such as oral fluid, venous or capillary whole blood and serum/
plasma. The shortest window period is generally observed with fourth generation 
serological assays, followed by third and then second generation assays, with first 
generation assays having the longest window period. Among RDTs, those using oral fluid 
specimens exhibit the very longest window period, irrespective of their generation, likely 
because the concentration of HIV-1/2 antibodies is lower in oral fluid than in other 
specimen types. However, they have been successfully used in many settings, particularly 
where high HIV incidence is not expected (180, 232, 233). 
95Chapter 7: Diagnostics for HIV diagnosis
7.1.2 Types of HIV assays
Serological assays are the most commonly used assays for the diagnosis of HIV. The type 
and format of the assay selected will depend on a variety of factors, most importantly ease 
of use and the characteristics of the testing site such as storage facilities, infrastructure 
and level of staff skills. 
The test results of any visually read assay (such as RDTs or simple assays) should ideally 
be reread by an independent second reader within the time frame recommended in the 
instructions for use. Timely rereading is critical; the second reader must not read the test 
result after the maximum incubation time specified by the manufacturer. The second 
reader need be trained only in reading the test results and does not necessarily need to 
be trained to perform the assay itself. Table 7.2 describes different formats of HIV assays 
and their characteristics. 
Diagnostic sensitivity is defined as the percentage of HIV-infected individuals who are 
identified as HIV-positive by the assay. Analytical sensitivity describes the smallest 
amount of analyte (HIV-1/2 antibodies and/or HIV-1 p24 antigen) that an assay can 
accurately measure. Seroconversion sensitivity refers to the ability of any assay to 
detect HIV infection during or soon after seroconversion. It is important to note that the 
adaptive immune response may decline after HIV acquisition, which results in lower 
levels of specific gp41 HIV antibodies. Thus, false-negative test results may be more 
common with RDTs that contain gp41 as their antigen source, and particularly for oral 
fluid specimens, as the level of HIV-1/2 antibodies in oral fluid is orders of magnitude 
less than in other specimen types (180, 234, 235). Other variables to consider when 
choosing an assay include the HIV variants in a particular geographical region, for 
example, HIV-1 group O or HIV-2. HIV-1 group O is prevalent in western Africa, but the 
strain has been reported worldwide. Some, but not all, current assays claim detection of 
group O HIV infections (9, 97, 236).
Diagnostic specificity is defined as the percentage of HIV-uninfected individuals who 
are identified by the assay as HIV-negative. Analytical specificity is the ability of an 
assay to identify a particular analyte (HIV-1/2 antibodies and/or HIV p24 antigen), rather 
than others, in a specimen and thus rule out false reactivity. False reactivity refers to a 
reaction on a given assay that is not confirmed by additional testing and, therefore, is 
ruled as false (not true). An understanding of false reactivity, including cross-reactivity 
within the specific testing population, is critical to constructing accurate testing 
algorithms (237, 238). Heightened false cross-reactivity is likely to be related to alteration 
of the immune response, that is, polyclonal B-lymphocyte activation caused by exposure 
to an infection other than HIV (237). These heightened rates of cross-reactivity are 
observed particularly for assays containing one antigen; they may vary in different 
populations and over time. Additional exogenous factors and endogenous substances 
have some effect on the performance of certain generations of assays (239–241). 
Therefore, it is important to understand the limitations of the assays; these are typically 
described in the manufacturer’s instructions for use. Table 7.3 lists causes of false-
negative and false-positive test results. 
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It is recommended that any reactive HIV test result be confirmed with a second assay (in 
settings where prevalence is ≥5%) or with both a second and third assay (in settings 
where prevalence is <5%). HIV serological assays typically have exceptionally high 
sensitivity and specificity compared with those of assays for other infectious diseases. 
That being the case, there is generally a trade-off that favours sensitivity over specificity 
for the first-line HIV assay so as not to miss true positive specimens. Additional testing is 
required to resolve cases of false reactivity (that is, to rule out false positives) and to 
verify reactivity (that is, to rule in true positives).
Annex 7 describes each test format in detail.
Table 7.3. Common causes of false results in HIV serological assays 
Potential causes of false non-reactive (negative) test results, irrespective of assay format
Biological error
Ongoing seroconversion 
Divergent HIV strain
Inhibitory factors in specimen
Human error
No specimen or insufficient specimen added 
Too much buffer added
Test kits stored outside of recommended storage conditions (either too hot or too cold) during 
transport or storage, leading to denaturation of reagents or test devices
Use of expired reagents or test devices
Manufacturing error
Manufacturing defects due to lapse in quality management system
Potential causes of false-reactive (positive) test results, irrespective of assay format
Biological error
Non-specific IgG binding
Cross-reactive antigens
Contaminating proteins in specimen
Human error
Test kits stored outside of recommended storage conditions (either too hot or too cold) during 
transport or storage, leading to denaturation of reagents or test devices
Over-interpretation of weakly reactive test lines on visually read assays
Manufacturing error
Manufacturing defects due to lapse in quality management system
98 Consolidated guidelines on HIV testing services
7.1.3 use of fourth generation serological assays
Fourth generation serological assays (RDTs, EIAs, CLIAs, ECLs) that detect both HIV p24 
antigen and HIV-1/2 antibodies have the potential to identify infected individuals earlier 
in the course of disease. In other words, these assays greatly shorten the diagnostic 
window period (Fig. 7.2). Thus, fourth generation serological assays are a suitable 
choice for a first-line assay when seroconversion sensitivity is preferred, such as in blood 
screening. 
Certain fourth generation serological assays can produce a result that indicates whether 
the assay is reactive to HIV p24 antigen or to HIV-1/2 antibodies, rather than combined 
detection of these markers. Thus, it is theoretically possible to identify individuals with 
acute infection (HIV p24 antigen present but non-reactive for HIV-1/2 antibodies). 
However, recently published data show that the HIV p24 antigen detection component of 
some fourth generation RDTs lacks analytical and diagnostic sensitivity (242–245). A 
further caveat is that the presence of HIV p24 antigen should not always be interpreted 
as acute infection. This is because levels of free and circulating HIV p24 antigen can be 
detected again late in the course of HIV infection, when the immune (antibody) response 
wanes and a lack of HIV-1/2 antibodies (and, therefore, rising titres of HIV p24 antigen) 
are observed. 
Due to the high sensitivity of both third and fourth generation serological assays, 
a certain low level of false reactivity is to be expected. Therefore, any testing 
algorithm using a third or fourth generation serological assay as the first-line 
assay should include more specific second-line and third-line assays to verify the 
HIV diagnosis and rule out false reactivity.
7.1.4 HIV RdTs for use in infants and children
Many settings use HIV-1/2 RDTs to assess HIV exposure in infants and children younger 
than 18 months and to diagnose HIV infection in children older than 18 months. The 
performance of these assays is acceptable for infants younger than four months. 
Concerns have been raised, however, concerning the reliability of certain serological 
assays between four and 18 months, most notably for second generation RDTs that do 
not include detection of IgM (220, 246, 247). For this reason HIV testing of the mother is 
preferable, whenever possible, to rule out HIV exposure of the infant and to diagnose 
the mother. Where possible, use of virological testing to rule in HIV infection should be 
considered if HIV infection is suspected. Serological testing of the child, according to the 
validated national testing algorithm, should be repeated after 18 months of age to 
assess final status, with the caveat that exposure to ART may lead to false-negative 
results with certain serological assays.
7.1.5 Specimen types used for HIV testing
Specimen integrity is critical to the accuracy of HIV testing. Each manufacturer specifies 
in the instructions for use the recommended specimen collection procedures, the storage 
99Chapter 7: Diagnostics for HIV diagnosis
requirements and specimen stability after collection. These instructions always take 
precedence, but for a broad summary, see Table 7.4. When the instructions for use 
issued with the assay do not include a certain specimen type within the intended use, it 
means that the assay manufacturer has not validated that specimen type for use with 
that assay.
Table 7.4. Specimen types and processing requirements
Specimen type Time to processing/storage/time to testing
Venous whole blood 
Whole blood freshly collected 
by venepuncture
Use the specimen immediately.
Serum 
Freshly collected whole blood 
is allowed to coagulate, and 
the serum fraction is collected 
away from the clotted red 
blood cells.
Collect whole blood, mix by hand 4–5 times immediately, 
and let stand for the clot to form. 
Process within 30 minutes of collection.
Store at 2–8 °C, and test within 5 days or as specified by the 
instructions for the assay to be used.
Plasma 
Freshly collected whole blood 
is added to the recommended 
anticoagulant, such as 
EDTA, heparin or citrate. 
After centrifugation, the 
plasma is separated. Use only 
anticoagulants validated by 
the assay manufacturer.
Collect whole blood, mix by hand 8–10 times immediately, 
and centrifuge for up to 10 minutes. 
Process within 6 hours of collection.
Store at 2–8 °C, test within 5 days or as specified by the 
instructions for the assay to be used.
Capillary whole blood 
Capillary (finger-stick) whole 
blood is collected using 
a lancet and a specimen 
transfer device.
Use the specimen immediately, with the specimen transfer 
device recommended by the instructions for use. 
Note that the specimen transfer device may or may not 
include an anticoagulant. An anticoagulant contributes to 
accuracy. 
The hanging drop method, whereby blood is dropped directly 
from the fingertip onto the test device, is not recommended, 
as it does not ensure that the specimen volume is accurately 
added.
Oral fluid 
Oral mucosal transudate 
(not saliva) is collected from 
the gums using a collection 
device.
Use the specimen immediately, with the specimen transfer 
device recommended by the instructions for use. 
Dried blood spot (DBS)  
Venous or capillary whole 
blood is applied to a filter 
paper by hanging drop or 
microcapillary. Whole blood 
is later eluted from the filter 
paper and used for the test 
procedure. 
Store at 4 °C for up to 3 months, at –20 °C for longer. 
The use of specific assays with DBS should be validated by 
the manufacturer. When the manufacturer has not validated 
their assay for DBS, the use of DBS is considered “off-label”, 
or unauthorized for returning medical results. 
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7.1.6 HIV-2 diagnosis
Some assays can discriminate between HIV-1 and HIV-2 antibodies, but differentiation 
between dual infection and monoinfection remains challenging for HIV testing 
programmes. Dual infection with HIV-1 and HIV-2 in one individual is quite rare, but 
misclassification of HIV type can affect the efficacy of ART and so affect the health of 
the individual (248, 249). Dual reactivity observed in any given discriminatory HIV-1/
HIV-2 assay is more likely to be caused by cross-reactivity than true dual infection. 
Recent data suggest that the amount of cross-reactivity between HIV-1 and HIV-2 may 
be significant. Evaluations conducted by the WHO Prequalification of In Vitro Diagnostics 
Programme observed rates of cross-reactivity between 3% and 57%, which would 
potentially incorrectly over-diagnose HIV-2 by a large degree (250).
In settings where HIV-2 is present, to determine the virus type or diagnose coinfection, 
appropriate supplemental testing should be performed, including serological assays 
specific to HIV-1 and to HIV-2 and virological technologies.
7.1.7 multiplex, multi-analyte, multi-module testing
Multiplex testing refers to testing using one specimen in the same test device for 
detection of HIV and other infections, for example, Treponema pallidum (syphilis), 
hepatitis C and hepatitis B. Offering combined or discriminatory detection of two or 
more analytes in one device has several advantages over separate tests. These include: 
•	 less overall specimen volume needed and thus fewer finger-sticks
•	 cost-savings through lower cost per analyte tested 
•	 improved client flow, with both results available at the same time 
•	 overall service delivery efficiencies, with less time required per analyte per visit. 
Multiplex RDTs are in development for anti-HIV/HBsAg (hepatitis B), anti-HIV/anti-HCV, 
anti-HIV/anti-HCV/HBsAg and HIV/anti-Treponema pallidum (syphilis). Further data on 
their diagnostic accuracy and impact on outcomes important to clients are required.
Multi-analyte testing refers to a similar principle, whereby the same platform with 
different sets of serological reagents can be used to test one or more specimens for a wide 
variety of analytes – for example, anti-HIV/anti-HCV/HBsAg. Current multi-analyte 
platforms, in the form of simple immunoanalysers, and random access chemiluminescence 
and electrochemiluminescence immunoanalysers are best suited to facilities with medium 
to high throughput, that is, greater than 100 specimens per day. Typically, they are most 
suitable for district, provincial and national laboratories (levels 2, 3, 4), as the current 
platforms may require certain precision steps, utilize serum/plasma specimens and require 
constant electricity supply and regular maintenance. 
Multi-module testing refers to testing a specimen with one testing system comprised 
of multiple modules (platforms) for each category of analyte. For example, serological 
testing can be performed with the same system (different platform) used for clinical 
chemistry and haematology. As with multi-analyte testing, current multi-module systems 
are usually best suited to medium to high throughput facilities located in district, 
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provincial and national laboratories (levels 2, 3, 4). The requirements of multi-module 
testing are similar to the requirements of multi-analyte platforms.
7.1.8 HIV self-testing 
To date, three commercial HIV RDTs specifically labelled and packaged for self-testing 
are available; several others are in development. In general, these RDTs use oral fluid or 
capillary whole blood specimens. Development of assays for HIVST that meet regulatory 
standards is critical to both reducing the cost of and improving the quality of assays 
available for HIV self-testing. For more information see http://www.hivst.org. See 
section 7.3 for additional comments.
7.2 HIV testing strategies for diagnosis (after 24 months of age)
WHO recommends standardized testing strategies to maximize the accuracy of HIV 
diagnosis while minimizing cost and increasing simplicity (251). A testing strategy for 
diagnosis describes a testing sequence for the specific testing objective of diagnosis (as 
opposed to screening only) taking into consideration the presumed HIV prevalence in the 
population (19). In both high and low prevalence settings, three different assays may be 
required to establish the diagnosis of HIV infection. 
The testing strategies for diagnosis described in this section have been developed 
assuming that all HIV serological assays used will have sensitivity of at least 99% 
(lower bound of the 95% confidence interval) and specificity of at least 98% 
(lower bound of the 95% confidence interval) and will aim to result in an overall 
positive predictive value for the testing strategy of 99% or higher (44, 251). 
These testing strategies apply equally to facility-based testing (for example, in laboratories, 
standalone HIV testing sites, clinical facilities and other testing services) and non-facility-
based testing (for example, community-based testing conducted outside of conventional 
health facilities). Also, these testing strategies are applicable to all serological assay formats 
and combinations of assay formats. All personnel who perform testing, including specimen 
collection, the testing procedure and reporting of HIV status, should adhere to these 
testing strategies. This includes both laboratory personnel and other health workers who 
are trained for these tasks, including through task sharing. Annex 7 presents the 
mathematical model used as a rationale for development of these strategies. 
7.2.1 Serological testing strategy for HIV diagnosis in high prevalence settings 
The testing strategy depicted in Fig. 7.3 applies in high prevalence settings, that is, a 
national or subnational prevalence of ≥5% in the population to be tested. These settings 
may include generalized HIV epidemics and epidemics concentrated in key populations. 
The figure describes the sequence of assays and the number of tests to be performed. 
Assay 1 (A1), Assay 2 (A2) and Assay 3 (A3) should be three different serological assays 
that do not share the same false reactivity. This testing strategy is intended for use with 
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serological assays. It would require adaptation if NAT technologies were used as A2 or A3.
All specimens are first tested with one assay (A1), and specimens that are non-reactive 
(A1−) are considered HIV-negative and reported as such. A1 should be the most sensitive 
assay available, taking into account diagnostic sensitivity, seroconversion sensitivity and 
analytical sensitivity. 
Any specimens that are reactive on the first assay (A1+) should be reflexed (tested 
again) using a separate and distinct second assay (A2) comprising a different antigen 
preparation to avoid false cross-reactivity with A1. For specimens that are reactive both 
fig. 7.3. Testing strategy for HIV diagnosis in high prevalence settings
Perform
A2
Perform
A1
A1+ A1–Report HIV-negative
A1+ A2–
A1+ A2+
Report HIV-positive
A1+ A2–
Perform
A3
A1+ A2– A3+
Report HIV-inconclusive 
(retest in 14 days)
A1+ A2– A3–
Report HIV-negative,  
if A1 is 2nd or 3rd generation assay
Report HIV-inconclusive,  
if A1 is 4th generation assay 
(retest in 14 days)
A1– A2–
Report HIV-negative
Repeat
A1 and A2
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on the first-line assay and the second-line assay (A1+; A2+), HIV status should be 
reported as HIV-positive. All individuals that are diagnosed HIV-positive should be 
retested prior to starting ART to verify their HIV-positive status (see section 3.4). 
Specimens that are reactive on the first-line assay but non-reactive on the second-line 
assay (A1+; A2−) should be repeated using the same specimen with the same two 
assays. When the test uses finger-stick whole blood, a new specimen will have to be 
taken and the same two assays repeated.
Following repeated testing, if the results remain discrepant (A1+; A2−), the specimen 
should be reflexed (further tested) using a separate and distinct third-line assay (A3). 
•	 If the third assay is reactive (A1+; A2−; A3+), an HIV-inconclusive status is reported, 
and the client should be asked to return in 14 days for retesting. 
•	 If the third-line assay is non-reactive (A1+; A2−; A3−), the HIV status is reported as 
HIV-negative. If the first-line assay (A1) is a fourth generation assay, however, 
the test result A1+; A2−; A3− should be reported as HIV-inconclusive, and the 
client should be asked to return for retesting in 14 days.  
For individuals with A1+, then A2−, then A3+, using the reactive test result 
from the third assay as a tiebreaker to rule in HIV infection and issue an 
HIV-positive diagnosis is not recommended; it over-selects for false-positive 
results and, therefore, leads to greater potential for misdiagnosis of HIV infection 
(252–258).
In some settings where HIV testing is offered, it may not be feasible to conduct all three 
assays on the same day in the same facility, for a variety of reasons. Where the third-line 
assay is unavailable, any individual with an initially reactive result on A1 (A1+) or 
discrepant results on A1 and A2 (A1+; A2−) should be referred to a higher-level facility, 
with a record of their test results, for additional testing. Annex 7 presents the rationale 
for this testing strategy. 
7.2.2 Serological testing strategy for HIV diagnosis in low prevalence settings
The testing strategy shown in Fig. 7.4 should be used for HIV testing in low prevalence 
settings, that is, with an HIV prevalence of <5% in the population to be tested. This 
includes settings with low-level HIV epidemics and testing of the general population in 
areas with concentrated HIV epidemics.
The figure describes the sequence of assays and number of tests to be performed. Assay 1 
(A1), Assay 2 (A2) and Assay 3 (A3) should be three different serological assays that do not 
share the same false reactivity. This testing strategy is intended for use with serological 
assays and would require adaptation if NAT technologies were used as A2 or A3.
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All specimens are first tested with one assay (A1), and specimens that are non-reactive 
(A1−) are considered HIV-negative and reported as such. A1 should be the most sensitive 
assay available, taking into account diagnostic sensitivity, seroconversion sensitivity and 
analytical sensitivity. 
Any specimens that are reactive on the first-line assay (A1+) should be retested using a 
separate and distinct second assay (A2) comprising a different antigen preparation to 
avoid false cross-reactivity with A1. 
Specimens that are reactive on the first-line assay but nonreactive on the second-line 
assay (A1+; A2−) should be repeated using the same specimen with the same two 
fig. 7.4. Testing strategy for HIV diagnosis in low prevalence settings
Perform
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Perform
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A1+ A1–Report HIV-negative
A1+ A2–A1+ A2+
A1+ A2+
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Report HIV-
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A1– A2–
Report HIV-negative
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assays. When the assay uses finger-stick whole blood, a new specimen will have to be 
taken to be tested with the same two assays.
A specimen that remains reactive following repeat testing with the first assay but is 
non-reactive on the second assay (A1+; A2−) is considered HIV-negative and reported as 
an HIV-negative status. The negative predictive value of the test result of A2− is very 
high. If the first-line assay (A1) is a fourth generation assay, however, the test 
result A1+; A2− should be reported as an HIV-inconclusive status, and the client 
should be asked to return for retesting in 14 days.
In a low prevalence population, the positive predictive value based on two test results is 
too low to provide an HIV diagnosis. Therefore, for specimens that are reactive on the 
first and the second assays (A1+; A2+), a third separate and distinct assay (A3) should 
be used to confirm the results and issue an HIV-positive diagnosis. 
•	 If the third test result is also reactive (A1+; A2+; A3+), the status is reported as 
HIV-positive. Retesting to verify the HIV diagnosis should be performed prior to 
enrolment in care or ART (see section 3.4). 
•	 If the result of the third assay is non-reactive (A1+; A2+; A3−), then the test result is 
discrepant and inconclusive HIV status should be reported. The client should be asked to 
return in 14 days for additional HIV testing. 
In low prevalence populations, for individuals with A1+, then A2− test results, an 
HIV-negative status should be reported. There is no need for specimens to be 
reflexed (tested again) on a third assay; the negative predictive value of A2 is 
high (≥99%), meaning the probably that the negative result observed on A2 is 
truly negative is ≥99%.
In some settings where HIV testing is offered, it may not be feasible to conduct all three 
assays on the same day in the same facility. Any individual with an initially reactive result 
on A1 (A1+) or dual reactive results on A1 and A2 (A1+; A2+) should be referred to a 
higher-level facility, with a record of their test results, for additional testing. Annex 7 
presents the rationale for this testing strategy.
7.3 HIV testing algorithms
An HIV testing algorithm describes the specific assays used in a given HIV testing 
strategy (19). Combinations of RDTs or combinations of RDTs and EIAs can provide 
results as reliable as, or even more reliable than, testing using the conventional EIA/
Western blot combination and at much lower cost when they are correctly chosen (251, 
259).
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7.3.1 Selecting assays for validation of testing algorithms
order of assays to be used within a testing algorithm 
A given testing strategy is populated with the assays available and is then called a 
testing algorithm. First-line assays should have the ability to identify any potential 
HIV-positive specimen and, thus, should have superior diagnostic sensitivity. These 
assays (sometimes referred to as screening assays) are likely to detect all true positive 
specimens as well as some specimens that are false-positive. Second-line and third-line 
assays are used to confirm the initial reactivity observed in the first-line assay, and so 
they should have superior diagnostic specificity, to rule out false reactivity.
It is essential to minimize the potential for shared false reactivity through 
careful selection of the combination of HIV assays used by validating testing 
algorithms. The choice of first-line (A1), second-line (A2) and third-line (A3) assays all 
must be validated. Where possible, assays based on different antigen preparations 
should be used in combination. Assays from different manufacturers are more likely to 
be made of different antigen preparations. Increasingly, however, WHO has noted that 
manufacturers sell finished or semi-finished products to other manufacturers under 
re-branding or re-labelling arrangements, making it difficult for the user to determine 
the antigen preparation used. In the absence of information about the antigen source, a 
validation study to determine the optimal testing algorithm should be conducted. If the 
validation panel is chosen carefully, this study provides data on the degree of cross-
reactivity. 
Performance characteristics
The following performance characteristics should be considered when selecting assays to 
validate as testing algorithms (see also Table 7.5):
•	 highest sensitivity (clinical, analytical, seroconversion) for first-line assay, irrespective of 
format
•	 highest specificity for second- and third-line assays, irrespective of format
•	 lowest invalid rate, irrespective of format
•	 lowest inter-reader variability, if a visually read assay, for example, an RDT or simple 
assay.
In resource-limited settings HIV testing services may use combinations of RDTs or 
combinations of RDTs/EIAs/supplemental assays rather than EIA/Western blot 
combinations1 (251, 259, 260).
Annex 7 presents an example of validation of an HIV testing algorithm. 
1 In some countries immunofluorescence assays (IFAs) and Western blot are still used as supplemental assays. However, these assays 
are generally less sensitive, as they are first generation assays, and they can be expensive. They are being replaced by more specific 
supplemental rapid diagnostic tests that use recombinant proteins and/or peptides.
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operational characteristics
In addition to performance characteristics, various operational characteristics should be 
considered in the selection of assays. Performance evaluations, including the evaluation 
that is part of the assessment conducted by the WHO Prequalification of In Vitro 
Diagnostics Programme, take into account these characteristics in order to assess the 
suitability of assays for use in both facility-based and non-facility-based testing. 
Due to differences in regional or country requirements for specific operational character-
istics, testing algorithms should always be validated in the context in which they will be 
used before large-scale implementation. Table 7.5 lists these considerations. 
Table 7.5. Specific considerations for selection of HIV diagnostics 
Performance characteristics Minimum requirements or options
Clinical sensitivity
First-line assays ≥99% for RDTs, 100% for EIAs
Second-line/third-line assays ≥99% for RDTs, 100% for EIAs
Clinical specificity
First-line assays ≥98% for RDTs and EIAs 
Second-line/third-line assays ≥99% for RDTs and EIAs
Seroconversion sensitivity (window period)
First-line assays Best possible, that is, shortest window period 
Inter-reader variability (if a visually read assay)
Rate of variability when the same 
test result is read by more than 
one reader
≤5%, usually a result of faint test results (test lines for 
RDTs/test spots for simple assays)
Invalid rate 
Rate of invalid test devices, if RDT 
or simple assay; rate of invalid test 
runs, if EIA
≤5% (Higher invalid rates lead to more wastage.)
Operational characteristics 
Specimen type
Are any specimen types excluded 
from use on the assay? (Strictly 
observe the instructions for use of 
each assay.)
Venous whole blood Capillary whole blood 
Serum Oral fluid 
Plasma (including specific anticoagulants)
Detection type
For second and third generation 
assays, does the assay detect each 
analyte separately?
Combined detection of HIV-1/2 antibodies 
Discriminatory (separate) detection of HIV-1 and HIV-2 
antibodies. Additional HIV-2 supplemental testing should 
be available.
For fourth generation assays, does 
the assay detect each analyte 
separately?
Combined detection of HIV p24 antigen and HIV-1/2 
antibodies 
Discriminatory (separate) detection of HIV p24 antigen 
and HIV-1/2 antibodies. Utility depends on availability 
of additional p24 antigen supplemental testing. If not 
available, retest in 14 days.
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Operational characteristics 
Subtype detection
Relevant subtypes for testing 
population?
Groups M, N, O 
Does the assay exclude any 
subtypes?
Time to result for 1 specimen (minimum reading time)
Is shorter or longer incubation 
time desirable? 
Immunofiltration RDT Less than 5 minutes for 
batch of 5 specimens
Immunochromatographic 
RDT
Minimum of 15 minutes, 
maximum of 30 minutes 
for batch of 10 specimens
Agglutination 2 hours for batch of 15 
specimens
EIA 2 hours for batch of 90 
specimens
Endpoint stability – maximum reading time
How long is the test result stable? 
Is a longer or shorter reading time 
desirable?
May range from “read immediately” to “stable for up to 
x minutes”
Ease of use
Consider combination of the 
following aspects
Specimen collection requirements, for example, 
finger-stick whole blood or venous whole blood by 
venepuncture
Number of steps in the test 
procedure 
Number of steps that 
require precision
Ease of reading the test 
band, line, spot, that is, 
few faint bands 
Ease of interpretation 
of testing results, that 
is, more bands = more 
complicated 
Extent of infrastructure required at testing sites
Are there any infrastructure 
requirements that would prohibit 
use of certain assays?
Refrigeration for storage of 
test kits
Refrigeration of 
reconstituted reagents and 
controls 
Electricity/generator Temperature-controlled 
work space
Storage/stability
Transport requirements for test kits 
(temperature, humidity)
Any excursion ranges accepted during transit? Any 
specialized shipping requirements?
In-use stability for specific 
reagents (temperature, humidity)
Any specific requirements once reagents are opened or 
once the specimen is added to test device/cartridge?
Equipment/consumables required but not provided in the test kit
Reasonable exclusions from the 
test kit. 
Can these be obtained from 
the manufacturer/distributor or 
obtained separately?
Lancets, alcohol swabs, 
cotton wool for finger-stick 
whole blood 
Blood collection equipment 
for venous whole blood 
Other general laboratory consumables: gloves, precision 
pipettes, etc.
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Operational characteristics 
Specimen throughput and individual testing service delivery models
Throughput per operator/provider RDTs if ≤10 specimens per hour per operator with 
limited laboratory infrastructure
EIAs if ≥40 specimens per day per operator with 
standard laboratory infrastructure
Technical skill of staff conducting testing
Number of precision steps required For example, counting of multiple drops, timing of steps 
required, use of precision pipette, interpretation of 
results
Is phlebotomy required?
Quality control
Inclusion of procedural quality 
control
Control line appears when human specimen is added 
(that is, qualitative IgG control, likely not to indicate 
adequate volume of specimen) AND/OR 
Control line appears when reagents only are added (that 
is, does not indicate addition of human specimen)
Colour control upon addition of specimen and/or certain 
reagents with some EIAs
Availability of internal test kit 
controls and external quality 
control specimens
Compatibility with quality control materials; some are 
available but separately from test kit.
7.3.2 Rationale for validation of testing algorithms
The combination of assays used in a testing algorithm(s) should be validated at the 
national or regional level. It is suggested to select one testing algorithm, with a back-up 
assay for the first-line assay and a back-up assay that can serve as the second-line or 
third-line assay. The number of algorithms used in a country should be limited, with 
back-up assay options in the case of lot failures or stock-outs and to respond quickly to 
recalls or corrective actions recommended by the manufacturer.
National or regional validation is important to ensure that the chosen testing algorithms:
•	 are relevant in the testing population, for example, subtype distribution and interfering 
factors that might lead to cross-reactivity (see Table 7.3);
•	 do not involve assays that share high levels of the same false reactivity in the testing 
population, for example, especially avoid A1 and A2/A3 assays that falsely identify the 
same specimen as positive; 
•	 are feasible to implement.
Regular review of the testing algorithm, every three to five years, will ensure that assays 
continue to perform adequately, that improved assays are introduced and that there is 
competition among manufacturers. It is critical that testing algorithm validation studies 
are well-conducted. The programmatic suitability of testing algorithms should be 
considered in any review of existing testing algorithms. Also worth consideration are 
rates of HIV-inconclusive status, rates of discrepant test results (A1+; A2−) and invalid 
rates, as well as needs for retraining and for revision of SOPs and job aids.
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7.3.3 Suggested methodology for validation of testing algorithms 
At the national or regional level, programmes should establish a working group 
consisting of diagnostic and programmatic experts to develop the validation study 
protocol, devise a list of candidate assays, conduct the study and analyse the results. For 
harmonization and standardization, programmes should inform implementing partners 
about the validation exercise and ask them to follow the resulting testing algorithms. 
algorithms. Thus, the process consists of three phases: 
•	 Phase 1: Identify candidate assays 
•	 Phase 2: Conduct validation study according to the prescribed methodology
•	 Phase 3: Monitor implementation of the testing algorithm(s).
The aim of this study is not to reconfirm the diagnostic accuracy of the assays, for 
example, diagnostic sensitivity and diagnostic specificity, but rather to ensure that the 
most appropriate testing algorithm(s) is being used in the country or region. Annex 7 
presents an example of validation of a testing algorithm. 
7.4 Retesting to verify HIV status
Retesting refers to using the same testing algorithm on a second specimen from the 
same individual. Supplemental testing refers to further testing of the same specimens 
with additional assay(s) to obtain more information. 
For information on messages for retesting, see Chapter 3.
7.4.1 Retesting of individuals who test HIV-negative 
The vast majority of individuals do not require retesting to verify an HIV-negative status, 
particularly in the absence of any ongoing risk. However, it is important to accurately 
identify individuals who test HIV-negative and may require retesting in certain 
circumstances. 
HIV-negative individuals with ongoing risk
Certain individuals who test HIV-negative warrant retesting:
•	 people from key populations
•	 people with a known HIV-positive partner
•	 people with known recent HIV exposure
•	 pregnant and breastfeeding women in high incidence/prevalence settings
•	 individuals seen for a diagnosis or treatment of STIs
•	 TB patients with a possible recent HIV exposure or who are at higher risk for HIV 
exposure
•	 outpatients with clinical conditions indicative of HIV infection
•	 individuals taking PEP or PrEP.
Annex 7 describes the intervals for retesting, in addition to other key information.
111Chapter 7: Diagnostics for HIV diagnosis
HIV-negative people taking PrEP 
Optimal intervals for retesting individuals on PrEP have yet to be determined. HIV testing 
is required to identify individuals who are uninfected before starting PrEP, to minimize 
development of resistance. In addition, periodic retesting is needed for those on PrEP to 
identify new infections. Specific WHO guidance on the frequency of testing for those on 
PrEP is in preparation.
7.4.2 Retesting clients with HIV-inconclusive status 
WHO recommends that clients with HIV-inconclusive status be retested in 14 days in 
order to:
•	 rule in seroconversion, if HIV reactivity evolves to concordant between A1 and A2, that 
is A1+; A2+; 
•	 rule out seroconversion, if HIV reactivity remains unchanged, with likely non-specific 
false-positive reaction for A1 and A3 (the negative predictive value for A2 will be very 
high);
•	 rule out specimen mix-up, particularly if a unique client identifier and consecutive 
specimen identifiers are not assigned; or
•	 rule out random error, either user/operator error or test device error.
Specimens from individuals with clinical signs meeting the WHO criteria for stage 
III or IV may have discrepant test results and an HIV-inconclusive test result due 
to a decrease of HIV antibodies with advanced disease progression and/or 
impaired or reduced immune response. 
If the HIV status is the same upon retesting, then the individual should be considered 
HIV-negative. If HIV status is not the same upon retesting, the individual or the specimen 
may be referred for additional testing at a higher-level facility. 
7.4.3 Retesting to verify HIV-positive diagnoses before initiating care or aRT 
Since 2013 WHO has recommended initiation of ART for all people with CD4 counts of 
<500 cells/mL (13). Further, WHO recommends ART initiation based solely on HIV 
serological diagnosis, without additional immunological (CD4 count) or virological (NAT) 
testing, for certain populations, including all pregnant women, serodiscordant couples, 
people with TB or viral hepatitis (HBV or HCV) coinfection and children less than 5 years 
of age (but over 24 months of age) (9). Thus, it is critical that policy-makers, programme 
managers and providers be aware of and reduce the risk of misdiagnosis of HIV status. 
To ensure that individuals are not needlessly placed on life-long ART (with potential 
side-effects, waste of resources, psychological impact of misdiagnosis), WHO 
recommends that all individuals be retested to verify their HIV status prior to 
enrolling in care and/or starting ART.
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Misdiagnosis, irrespective of its scale, is of critical importance. Any incorrect 
diagnosis, whether a false-positive or a false-negative, has deleterious personal 
and public health consequences, often with severe repercussions.
As noted, retesting refers to the testing of a new specimen for each newly diagnosed 
individual, conducted by a different provider using the same testing algorithm, prior to 
initiation of ART. Retesting should be conducted at a different site, ideally the site where 
the decision about ART initiation will be made. Retesting according to this procedure 
aims to rule out possible technical or clerical errors, including specimen mix-up through 
mislabelling and transcription errors, as well as random error either by the provider or of 
the test device. Retesting will not exclude misdiagnosis related to poor choice of a 
testing algorithm. However, with adequate validation of the testing algorithm, this risk 
should be minimal. 
Certain testing services, such as PMTCT services operating with Option B+, are 
programmatically organized to conduct HIV testing, provide a diagnosis and offer 
immediate initiation of ART irrespective of CD4 count. In these programmes it may not 
always be feasible to retest at a different site, although it should usually be feasible for a 
different provider to conduct retesting on a new specimen. 
If the HIV status is the same upon retesting, the individual’s HIV-positive status should 
be considered verified. If the status is not the same upon retesting, the individual or 
their specimen should be referred for additional testing at a higher-level facility. 
wHo recommendation 
Retest all clients diagnosed HIV-positive with a second specimen and a second 
operator using the same testing strategy and algorithm before enrolling the client 
in care and/or initiating ART, irrespective of whether or not ART initiation 
depends on CD4 count. 
Source: WHO, 2014 (57).
7.4.4 Retesting people on aRT 
The effect of ART in suppressing viral replication may extend to suppression of the 
immune response and, thus, of antibody production. Therefore, non-reactive test results, 
particularly on assays using oral fluid, must be interpreted cautiously. Individuals 
undergoing HIV testing must be made aware of the risk of incorrect diagnosis if they do 
not disclose that they are on ART. All individuals receiving HIV testing should be asked if 
they have been tested previously and told they are HIV-infected and/or if they are now 
on ART or have ever received ART. 
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wHo recommendations 
Retesting is warranted for the following populations: 
Individuals testing HIV-negative who: 
•	 have ongoing risk for HIV infection; 
•	 can identify a specific incident of HIV exposure in the preceding four weeks; OR
•	 are pregnant, in high HIV prevalence settings; for those who test HIV-negative in 
the first trimester, retesting should be offered in the third trimester, during 
labour or shortly after delivery.
Individuals whose HIV status is inconclusive, irrespective of risk.
Individuals diagnosed HIV-positive should be retested to verify their HIV 
diagnosis prior to initiation of care and/or treatment. 
Retesting is not recommended for individuals on ART.
Source: WHO, 2010 (12, 57) ; WHO, 2014 (12, 57).
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       Key PoINTS 
•	Quality assurance implemented through quality management systems is essential for 
any testing service, ranging from HIV testing conducted in laboratories and health 
facilities to community-based settings, including rapid diagnostic tests (RDTs) performed 
by lay providers. 
•	 It is the ethical responsibility of all people conducting HIV testing (including lay 
providers) and all programmes or facilities offering HTS to conduct testing according 
to quality management system principles to ensure the highest level of quality and 
accuracy.
•	All programmes should use the document entitled Improving the quality of HIV-related 
point-of-care testing: ensuring reliability and accuracy of test results (121) for guidance 
on how to plan, implement and improve the quality of HIV testing.
•	 In vitro diagnostics (IVDs) should meet regulatory standards according to national 
guidelines. In addition, WHO conducts an independent prequalification assessment of 
IVDs, with particular emphasis on HIV RDTs and IVDs intended for use at or near to the 
point of care in resource-limited settings.
•	 In certain situations providers may refer individuals to another site for additional testing 
to verify their HIV status. Consistent, clear, confidential and accurate record-
keeping and communication are critical at both the initial testing site and the referral 
centre. 
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8 QualITy aSSuRaNCE of HIV TESTING  
definitions
Quality management system: a system to direct and control an organization 
with regard to quality. 
Quality assurance (QA): a part of quality management focused on providing 
confidence that quality requirements will be fulfilled.
External quality assessment (including proficiency testing) (EQA): inter-
laboratory comparison to determine if the HIV testing service can provide the 
correct test status.
Quality control/process control (QC): a material or mechanism which, when 
used with or as part of a test system (assay), monitors the analytical 
performance of that test system (assay). It may monitor the entire test system 
(assay) or only one aspect of it.
Quality improvement (QI): a part of quality management focused on increasing 
the ability to fulfil quality requirements.
Source: WHO, 2010 (11).1
8.1 assuring the quality of HIV testing results 
Ensuring correct HIV test results is a priority and a crucial component of WHO’s 5 Cs for 
HTS (44). Recent reports suggest that the quality of HIV testing may be suboptimal in 
many settings. Misdiagnosis of HIV status – both false-positive and false-negative 
results – has been reported (40, 42, 43, 238, 258, 261). It is a priority for ministries of 
health and national AIDS control programmes to implement robust quality management 
systems that deliver high-quality and accurate reporting of HIV status (262). 
Any programme considering the expansion of HTS, including facility-based testing 
(laboratories, clinical facilities), community-based testing and testing conducted at point 
of care should have the following elements in place:
1. a national HIV testing policy that is regularly updated and linked to the national 
laboratory policy and strategic plan;
1 See also, ISO 9000:2005. Quality management systems – Fundamentals and vocabulary. Geneva: International Organization for 
Standardization; 2005 (https://www.iso.org/obp/ui/#iso:std:iso:9000:ed-3:v1:en, accessed 30 June 2015).
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2. access to quality-assured in vitro diagnostics with adequate pre-market and 
post-market regulatory controls;
3. validated national testing algorithm(s) with back-up options in accordance with 
the appropriate WHO-recommended testing strategy (44) ;
4. quality management systems for all HIV testing, irrespective of where testing 
takes place;
5. adequate training and supportive supervision of HIV testing providers, with 
requirement for certification;
6. accreditation (or registration/certification) of testing sites, where applicable;
7. accurate forecasting and, therefore, quantification, with procurement systems in 
place to avoid stock-outs of test kits and critical consumables (44, 97).
Countries implementing HIV testing should ensure that a comprehensive training 
package has been developed and training conducted that focuses on ensuring the 
competency of HIV testing providers. All providers should have adequate hands-on 
training on the requisite SOPs in order to perform individual assays and follow national 
testing algorithms. In addition to training on specific test procedures and testing 
algorithms, training should also include (1) how to keep testing records as standardized 
logbooks or testing registers, (2) an understanding of the importance of QC, (3) an 
understanding of the importance of EQA schemes (proficiency testing programmes) and 
of the role of providers who perform HIV testing in these schemes and (4) how to 
respond to site supervisory visits and any recommended corrective actions.
At the country level the national reference laboratory, with mandate from the ministry of 
health, should plan and implement a variety of quality assurance activities to monitor 
and improve the quality of testing. These activities may be decentralized at the 
provincial or district level depending on the scope of the activities. These activities 
include promoting the use of standardized logbooks or registers, implementing EQA 
schemes, extraction and analysis of EQA data and implementation of corrective actions. 
These key activities should be systematically planned and implemented to maximize their 
impact on the accuracy of HIV testing (Fig. 8.1). 
A quality management system requires a continuous cycle of quality assurance 
regardless of where HIV testing is carried out or the type of assays used. It is critical that 
quality assurance is not seen as a one-off activity or an activity that is undertaken by 
one person only. Instead, quality assurance should be seen as an integral part of the 
continuing roles and responsibilities of each and every staff member. Through this 
framework countries can plan, implement, evaluate, improve and sustain quality 
assurance activities. Such frameworks and provisions apply not only to test accuracy but 
also to ensuring the quality of pre-test information and post-test counselling. 
Planning focuses on planning for QA through engaging leadership, establishing a 
national QA coordination team, defining roles and responsibilities, reviewing and 
developing policies that include QA and financing and staffing for QA. 
Implementing focuses on implementing QA through training of HIV testing providers 
and their certification, site accreditation (may also be called site registration or 
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certification), supportive supervision, adequate quality/process control, documentation 
and record-keeping and ensuring a robust supply chain. 
Monitoring focuses on evaluating quality through post-market surveillance and EQA, 
using data for decision-making, making improvements, undertaking advocacy and 
communication, and increasing country ownership. 
For information on how to implement a quality system, particularly for HIV testing at the 
point of care, see WHO/CDC guidance on this topic, Improving the quality of HIV-related 
point-of-care testing: ensuring reliability and accuracy of test results (97) and Guidelines 
for assuring the accuracy and reliability of HIV rapid testing: applying a quality system 
approach (263) (http://www.who.int/diagnostics_laboratory/publications/
HIVRapidsGuide.pdf).
The responsibility for ensuring the quality of testing should be seen as a continuum 
throughout each tier of the health system. Users of HTS should also demand quality in 
the testing services provided to them, in both community-based and facility-based HTS. 
Table 8.1 details roles and responsibilities of HTS staff. 
QualITy 
aSSuRaNCE CyClE:
ensuring accurate 
results
TAKE 
CORRECTIVE 
ACTION
MONITOR
IMPLEMENT
DEFINEIMPROVE
PLAN
fig. 8.1. Quality assurance cycle: a continuous quality assurance and 
improvement process
Source: WHO, 2015 (97).
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Table 8.1. Roles and responsibilities for all staff to ensure the quality of HIV 
testing services
Level Where Counselling Testing Records Supplies
0 Community Outside of 
facilities 
(home-based, 
mobile, 
outreach)
Monitor own 
performance
Conduct 
client exit 
interviews
Adhere to 
SOPs
Conduct QC 
Participate in 
EQA schemes
Keep 
accurate 
testing 
records
Ensure 
sufficient 
test kits and 
supplies
1 Primary Facility-based 
(stand-alone, 
clinical, 
laboratories)
2 District Clinical 
facilities, 
district 
laboratories
Monitor own 
performance 
Conduct 
client exit 
interviews
Provide 
supportive 
supervision of 
counselling in 
levels 0, 1, 2
Suggest 
corrective 
actions
Adhere to 
SOPs
Conduct QC
Participate in 
EQA schemes
Provide 
supportive 
supervision 
of testing 
processes in 
levels 0, 1, 2
Suggest 
corrective 
actions
Aggregate 
data (EQA 
schemes, 
NCs) on a 
monthly 
basis
Order test 
kits/supplies 
from national 
level
Distribute QC 
specimens & 
EQA scheme 
panels
3 Provincial Clinical 
facilities, 
provincial 
laboratories
Level Where General roles/responsibilities
4 National National 
reference 
laboratory
Validate national testing algorithms
Perform lot verification testing for post-market surveillance
Produce QC specimens and EQA scheme panels 
Evaluate data (EQA schemes, NCs) from all districts/provinces 
on a monthly basis, suggest corrective actions
Develop site SOPs and job aids
Conduct training using standardized hands-on curriculum
Ministry of 
health 
Ensure testing sites’ readiness for accreditation (laboratories, 
clinical facilities) or site registration (stand-alone sites, 
community programmes)
Establish national HIV testing policy that includes QA
Establish national QA coordination team
Allocate resources for QA
Procure, store and distribute test kits/supplies 
Regulatory 
bodies
Set national regulatory standards for IVDs
Set standards for accreditation/certification of testing sites
Respond to field safety notices arising from post-market 
surveillance
 
Sources: Taegtmeyer et al., 2003 (264); WHO, 2010 (11); WHO, 2015 (97). 
SOP: standard operating procedure; EQA scheme: external quality assessment scheme; NC: non-
conformance; IVDs: in vitro diagnostics. 
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8.2 Regulations for in vitro diagnostics 
Before an HIV assay is marketed and after it is on the market, its quality must be 
assured. In vitro diagnostics (5) (hereafter referred to as diagnostics) are classified by 
regulatory authorities according to the risk they may pose to public health and individual 
health, taking into account the potential outcomes and impact if the result is incorrect. 
Diagnostics for HIV usually attract the highest level of scrutiny in their pre-market 
assessment review, given the high impact of an incorrect result on individual and public 
health in terms of HIV transmission. 
The WHO Prequalification of In Vitro Diagnostics Programme promotes and facilitates 
access to safe, appropriate and affordable diagnostics of good quality (265). The current 
state of regulation for diagnostics in many countries is less than optimal, both for 
pre-market assessment and post-market surveillance. Therefore, WHO independently 
reviews the quality, safety and performance of diagnostics that are available in markets 
in resource-limited settings. 
8.2.1 Pre-market assessment of diagnostics
WHO conducts the prequalification assessment of diagnostics using a standardized 
procedure to determine if the product meets WHO prequalification requirements. The 
assessment consists of three key components: 
•	 review of safety, quality and performance of the assay as presented in a product 
dossier prepared by the manufacturer
•	 desk review of the quality management systems applied during production, followed by 
a site inspection
•	 independent laboratory evaluation of performance and operational characteristics. 
The publication Overview of the prequalification of in vitro diagnostics assessment (265) 
provides further information. Annex 8 provides additional details about how the WHO 
prequalification assessment is conducted.
8.2.2 Post-market surveillance of diagnostics
Once a product is placed on the market, its quality, safety and performance must be 
monitored to ensure that diagnostics continue to meet standards. WHO has established 
a system for post-market surveillance of diagnostics that supplements the obligations of 
manufacturers, who must also conduct their own post-market evaluation activities. 
In this context post-market surveillance consists of:
•	 proactive post-market surveillance (to identify any problem before use) through 
in-country lot verification testing, both before and after distribution of test kits to 
testing sites; and
•	 reactive post-market surveillance (when a problem has been identified during use of 
the diagnostic) through reporting and evaluation of complaints, including reports of 
adverse events, and any required actions to correct the problem and prevent recurrence.
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WHO’s Guidance for post-market surveillance of in vitro diagnostics provides further 
information (http://www.who.int/diagnostics_laboratory/postmarket/150210_pms_
ivds_guidance.pdf?ua=1). 
Annex 8 provides a detailed description of activities that contribute to post-market 
surveillance.
8.3 Quality management systems, irrespective of the testing setting 
A quality management system can be implemented to varying degrees, but the basic 
principles still apply to any service providing HIV testing results. Any site conducting HIV 
testing should implement a quality management system that incorporates the elements 
summarized in Fig. 8.2 and detailed in the following pages. 
The WHO Laboratory quality management system: handbook (266) (http://www.who.int/
ihr/publications/lqms/en/) provides further guidance on quality management systems. 
Organization Personnel Equipment
Purchasing & inventory Process control Information management
Documents & records Organizational management Assessment
Process improvement Customer service Facilities & safety
!
fig. 8.2. The 12 components of a quality management system 
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  organization 
Irrespective of their location, both facility-based testing services (laboratories and 
clinical facilities) and community-based testing services should have a commitment to 
assure quality. All testing services should have a quality policy that specifies the 
following aspects of the quality of HTS:
•	 ensuring that competent staff (including lay providers) are employed (see "Personnel" 
below)
•	 ensuring purchase of quality-assured test kits, equipment and consumables (see 
"Equipment" and "Purchasing and inventory") 
•	 ensuring QC of testing processes (see "Quality control")
•	 creating and managing documents (see "Information management")
•	 keeping records confidential (see "Information management")
•	 recording and following up on complaints (see "Occurrence management") 
•	 evaluating and following up on results of EQA schemes/proficiency testing and on-site 
supervision (see "Assessment"). 
A generic quality policy may be developed nationally for all types of testing sites that are 
similar on the basis of, for example, assay formats used, infrastructure available and 
type of testing providers. These policies may require adaptation, based on input from 
management and other staff and volunteers, to ensure that they are appropriate to the 
specific site. 
How to implement 
•	 Ensure that policies, processes and procedures are relevant for the specific type of 
testing service.
•	 Ensure that there is professional commitment to the quality of the HTS, with regular 
management review of the quality policy.
•	 Assign one staff member in each HTS site as the quality representative, who 
champions the quality of all aspects of the HTS. 
  Personnel 
All testing services must employ the number of trained, certified and supported 
personnel to conduct each of the elements of HIV testing that is adequate for the 
expected number of tests conducted and the number of people being served. To assess 
and manage human resource planning, tools such as the WHO Workload Indicator for 
Staffing Need (WISN) (http://www.who.int/hrh/resources/wisn_user_manual/en/) can 
be useful to calculate the number of health workers and lay providers needed to provide 
adequate HTS. 
All personnel, including those taking specimens, conducting testing, providing reports of 
HIV status and data clerks and other auxiliary staff, must be trained adequately. All staff 
123Chapter 8: Quality assurance of HIV testing
members should have appropriate qualifications, such as certifications according to 
national guidelines, and demonstrated proficiency in performing the tasks within their 
scope of work. 
Both pre-service and in-service training, including periodic refresher trainings, 
should be part of the training requirements for all testing services. This is particularly 
important for sites with very low specimen throughput or where HIV testing is performed 
occasionally. In addition, regular supportive supervision and ongoing mentoring of 
all staff are essential. Ensuring the psychological and physical well-being of HIV testing 
providers is critical. In particular, good vision is required for visually read assays. 
How to implement
•	 Develop a site organogram that describes the roles and responsibilities of all staff 
members in the testing service, including those who may collect specimens, who may 
perform testing, who may report HIV status and who may double-check test results and 
HIV status reports.
•	 Maintain training checklists for all staff members.
•	 Encourage a yearly bidirectional performance appraisal to discuss any issues that 
may affect a provider’s ability to perform his or her assigned tasks.
Furthermore, at a national level, it is critical to have: 
•	 national human resources planning and management systems, including human 
resource information systems;
•	 strong pre-service education institutions;
•	 standardized and coordinated in-service training (with hands-on practicum and 
competency-based assessment);
•	 an inclusive national policy that supports task sharing, with scope for lay providers to 
conduct testing and issue test reports;
•	 recruitment and retention strategies, especially for rural and underserved areas;
•	 advancement of health worker regulation and policy, including capacity-building of 
regulatory bodies and professional associations.
  Equipment
Regardless of where testing takes place and whether it is performed using HIV RDTs or 
laboratory-based diagnostics, it is critical to have appropriate equipment available and 
fully functional. 
For testing services using primarily RDTs, it is important to have timers and access to 
refrigerators if ambient temperatures will exceed the manufacturer’s recommended 
storage temperatures.
For HTS that rely on laboratory-based techniques, calibration and maintenance of 
equipment is paramount for providing accurate testing results.
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How to implement
•	 Maintain an inventory of all equipment.
•	 Ensure that all equipment in the inventory is subject to preventive and corrective 
maintenance on an appropriate cycle, depending on throughput. 
•	 Ensure that equipment that is not working is prominently labelled as such and, 
therefore, not used in any process to provide testing results.
•	 Ensure that SOPs exist for all equipment, with instructions, for example, on how to turn 
on and off, how to clean and any calibration that the user must make.
  Purchasing and inventory 
Purchasing refers to activities that must be undertaken at the programmatic level to 
ensure that adequate supplies of test kits and other items required for the testing 
process are available on-site.
Stock-outs of HIV test kits or any essential consumables, such as lancets, alcohol swabs 
or specimen transfer devices, are one of the biggest sources of poor quality and client 
dissatisfaction with HTS. Lack of the first-line assay (A1) may lead to use of a less 
sensitive assay instead (A2 or A3 instead of A1). The lack of single-use specimen transfer 
devices will lead to an incorrect specimen volume added, which will increase the risk of 
an inaccurate test result. 
It is necessary to ensure that an adequate system is in place at the testing service site to 
track procurement of test kits, reagents and consumables (venous or capillary 
blood collection supplies) when they are ordered and when received. Each HIV testing 
service should then track consumption of all test kits and consumables so that they can 
inform the central medical stores (or other purchasing body) when they need to 
replenish stock. As stocks are received, it is critical to take special note of expiry dates 
and to order ahead, allowing adequate time for the next delivery.
Further information is available in WHO manual for procurement of diagnostics and 
related laboratory items and equipment (http://www.who.int/diagnostics_laboratory/
procurement/en/). A second edition is planned for 2015.
How to implement
•	 Maintain a list of inventory requirements, for example, assays, consumables or 
additional supplies such as gloves, lancets, alcohol swabs and disposal containers. 
•	 Ensure adequate physical space to store test kits (including refrigeration if room 
temperature is above manufacturer’s recommended storage conditions) and record 
storage temperatures.
•	 Do not split larger test kits into smaller quantities.
It is critical at the national level to have regulatory processes and procedures that 
support the procurement of quality-assured diagnostics, equipment and other items 
required for providing HTS.
For additional information see Annex 8.
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  Quality control
Quality control, also known as process control, refers to processes and activities to 
ensure that testing procedures are performed correctly, that environmental 
conditions are suitable and that the assay works as expected. QC intends to detect, 
evaluate and correct errors due to assay failure, environmental conditions or operator 
performance before test results are reported as the HIV status. Hence, QC is a multi-step 
process with certain checkpoints throughout the testing process.
•	 Before testing (pre-analytical):
– Check that the temperature of the testing area is within the manufacturer’s 
recommendations and record the temperatures. 
– Check that stocks of test kits and required consumables are on hand. 
•	 While testing (analytical): 
– Ensure that any QC specimens have been run (for example, test kit controls and/or 
external QC specimens) and that the results are within QC acceptance criteria. 
– Ensure that a second reader will reread (double-check) all visually read assays.
•	 After testing (post-analytical): 
– Double-check the report of the test status to the client.
Ideally, a second reader should make a blinded rereading of any visually read 
assay. This is standard practice for visually read assays, both for HIV and for other 
conditions. The second reader needs to be trained only on how to read the assay, 
not necessarily on the test procedure itself. If the two readers interpret the test 
results the same way, then an HIV status is reported as is. If the two readers do 
not agree, HIV testing should be repeated using a new specimen and a new test 
device. Interreader disagreement for RDTs ranges from 0 to 1.6% (9, 250).
Internal QC refers to processes within the assay that check whether the test procedure 
is working; the appearance of a control line for HIV RDTs is an example of internal QC. 
Only a few RDTs contain a control line that indicates that the specimen has been 
added. Instead, most RDTs contain a control line that indicates only the flow of 
liquid, rather than that the specimen has been added or that the correct volume 
of specimen has been added.
Test kit controls (known as positive and negative controls) may be supplied by the 
manufacturer. They are standard for most assay formats, with the exception of RDTs. 
Few HIV RDTs have accompanying test kit controls, making QC problematic. 
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As an addition to or even a substitute for the test kit controls, external quality control 
specimens may be produced. These are prepared and validated by the QC specimen 
provider (usually the national reference laboratory or a commercial entity) for the assay 
separately from the manufacturer. The dried tube specimen methodology is useful in this 
regard. See Annex 8 for information about the preparation of QC specimens for RDTs. 
Any test kit controls should be run according to the manufacturer’s instructions, and 
external QC specimens should be run:
•	 once weekly, preferably at the beginning of the week 
•	 for any new operator (including trained staff members who have not conducted testing 
for some time)
•	 for each new lot of test kits
•	 for each new shipment of test kits
•	 when any environmental conditions (for example, temperature and humidity) fall 
outside the range recommended by the manufacturer.
How to implement
•	 Establish criteria for specimen acceptance or rejection and specimen storage, 
retention, disposal and referral of the specimen to another site for testing.
•	 Establish criteria for QC of qualitative and quantitative assays with established 
limits of acceptability.
  Information management 
Information management consists of the paper-based and electronic systems for 
storing records and documents, including emails or text messages that provide testing 
results or reminders to clients. It is closely linked to documentation and record-keeping.
To assure the quality and integrity of the test status given to a client, HTS must minimize 
the risk of transcription errors. Assigning client identification numbers and specimen 
identification numbers to each subsequent specimen received from the same individual 
will reduce the possibility of transcription errors. It will also protect the confidentiality of 
people undergoing HIV testing. Linking a series of HIV test results also is critical when 
retesting is used to verify a client’s HIV-positive diagnosis or to resolve a client’s 
HIV-inconclusive status.
It is critical that all information be kept confidential, with access restricted to 
qualified staff.
Automated electronic RDT readers that can accommodate one or many brands of RDTs 
are increasingly becoming available. Many of these RDT readers can connect to 3G or 4G 
wireless networks. Such connectivity also can be useful for quality assurance, for 
procurement and for data management.
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How to implement
•	 Each client who enters the service should be assigned a unique client identifier so 
that the results of each subsequent specimen tested from the same person can be 
tracked. An identifier number comprised of three letters and three numbers could be 
used for the client identifying number, for example, AAA 000, AAA 001, etc.
•	 Each specimen should be assigned a unique specimen identifying number. An 8-digit 
consecutively assigned number is sufficient for the specimen identifying number, for 
example, 0000 0001, 0000 0002, etc. 
  documents and records 
Documentation is critical to ensure that a correct HIV status goes back to the correct 
individual undergoing testing. Documents are policy, process and procedural 
documentation for all aspects of the testing service and its quality management system. 
It is critical that documents are approved prior to use, revised when necessary and 
removed from circulation when they become obsolete.
Job aids are useful tools for HTS. These are short, concise documents that describe each 
test procedure, how to interpret test results according to the validated testing algorithm 
and how to refer for retesting. Annex 8 presents an example of a generic job aid for an 
HIV RDT.
Records are generated as a result of performing testing activities. It is critical that these 
are filed correctly and stored for up to five years. Records are particularly important for 
retesting referrals to rule in or rule out HIV infection and community-based testing 
services where the results may be confirmed at another testing facility.
The types of records required for a quality system are:
•	 specimen request forms
•	 testing/laboratory logbook
– The logbook should record details to identify the person undergoing testing (client 
identifier, name [optional], date of birth [optional]), the assays used (with lot 
numbers and expiry dates), the test results (preferably, band intensity when using 
RDTs), both readers’ results (when using RDTs), date of test run, name of operator 
and QC results. 
•	 overall status as given to the individual
•	 referral slips for retesting or other post-test services
•	 staff training records and other personnel records
•	 internal and external audit reports
•	 non-conformance and complaint records, with action taken
•	 equipment maintenance records and inventory charts. 
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How to implement
•	 Ensure that SOPs exist for all procedures, including specimen collection and processing 
requirements, testing algorithms and all test procedures, with QC and final reporting (in 
accordance with a validated testing algorithm). 
•	 Keep equipment maintenance records and temperature records for refrigerators, freezers 
and the testing room. 
•	 Keep laboratory notebooks, testing registers and forms used to record testing results.
For an example of a standardized testing register, or logbook, see Improving the quality 
of HIV-related point-of-care testing: ensuring reliability and accuracy of test results (97)
or Guidelines for assuring the accuracy and reliability of HIV rapid testing: applying a 
quality system approach (263) (http://www.who.int/diagnostics_laboratory/publications/
HIVRapidsGuide.pdf).
  occurrence management
Occurrence management refers to processes for detecting and documenting non-
conformances and then implementing any necessary corrections. A non-conformance 
is something that went wrong; a problem has occurred and needs to be addressed. A 
non-conformance might be a lack of documented processes or procedures or when 
documented processes or procedures are not followed. For occurrence management to 
have a meaningful effect, it must be investigated and the problem corrected. 
The following sources of data may be used to check if there are problems or potential 
mistakes made:
•	 internal audit reports
•	 supervisory visit reports
•	 QC data, including higher than expected rates of invalid results (for example, when 
using RDTs, if no control line appears or a high background on the test strip obscures 
the reading window)
•	 results of EQA schemes (proficiency testing)
•	 a higher than expected rate of discrepant test results.
How to implement
•	 Establish a system to immediately capture quality issues or problems, and then 
identify the root cause and implement corrective action. 
•	 To identify non-conformance, routinely monitor indicators, such as turnaround times 
for each assay, turnaround time for an overall testing report, rate of discrepant results, 
rate of invalid results, rate of specimen rejection, rate of test kit stock-outs, rate of 
supplies stock-outs and frequency of expiration of test kits. 
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  assessment  
Testing services should undertake both internal and external assessment to assure the 
quality of testing. Internal assessment usually takes the form of an internal audit, by 
either a site supervisor or a district health management team, that observes testing 
practices at least annually but preferably every three to six months. For certain tasks an 
internal audit may be performed by another staff member who does not usually perform 
the task but has enough familiarity with the process to conduct an audit. 
External quality assessment assures that assays are performed accurately, results are 
reproducible, and errors are detected and corrected to avoid misclassification or 
incorrect diagnosis. EQA usually takes the form of participation in EQAs (also called 
proficiency testing), which include following up any unacceptable EQA results with 
corrective actions. 
The objectives of participating in EQA schemes are to:
•	 evaluate testing competence
•	 assess performance of specific testing providers
•	 evaluate the reliability of HIV testing procedures
•	 establish the accuracy of reports of HIV status
•	 provide information for self-evaluation.
Annex 8 presents additional details on how to implement EQA schemes. 
Rechecking specimens using dried blood spots (DBS) as an EQA mechanism is no 
longer recommended, given the recommendation to retest all HIV-positive 
individuals prior to starting ART.
Another form of external assessment is accreditation of testing sites (may be referred 
to as registration or certification) by an external certification body. 
How to implement
•	 All testing sites (facility- and community-based) should participate in EQA schemes.
•	 All testing sites (facility- and community-based) should receive support through on-site 
supervision. 
•	 All testing sites (facility- and community-based) should be registered, certified or 
accredited, according to national guidelines.
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  Process improvement 
Testing services need to identify areas requiring improvement, plan and undertake 
improvements and evaluate their effect. This is sometimes referred to as quality 
improvement (QI). Depending on the improvement suggested, programmes can 
improve processes at the site level or at the district or national level. Local factors, which 
may not be predicted at the national level, may define site-level improvements such as 
changes to opening hours or changes to the flow of clients through the testing site. 
Programmes may use data from internal audits, participation in EQA schemes and 
on-site supportive supervision to improve testing processes. 
A corrective action is an action taken to address a problem, removing its root cause or 
reducing or eliminating its recurrence. A preventive action is an action taken to avoid a 
possible problem or reduce the likelihood that it will happen. Data from EQA activities 
and process control can guide corrective and preventive actions in the framework of 
continued process improvement. 
Process management links closely with activities associated with occurrence 
management.
How to implement
•	 Site supervisors should proactively identify opportunities for improvement of 
services and then relay these to a higher level of management for implementation of 
better working practices. 
  Client service 
Programmes need to ensure client (customer) satisfaction with the testing service. This 
includes both so-called internal clients, such as doctors, nurses, counsellors and other 
health-care workers, and external clients, such as individuals undergoing testing, 
professional associations and regulatory agencies. Ensuring client satisfaction means 
meeting their expectations of quality, for example, delivering accurate results in a 
timely manner. 
How to implement
•	 Seek feedback from clients through, for example, periodic exit interviews. Feedback 
may focus on such aspects as convenience of opening hours, friendliness of the testing 
environment and satisfaction with post-test counselling. 
•	 Establish a client suggestion box for anonymous reporting, including complaints. 
!   facilities and safety 
It is critical that testing facilities are well-designed and maintained. The testing site, 
including where counselling takes place, where specimens are taken and where the test 
is performed, should be clean and comfortable, with adequate lighting (for reading 
visually read assays) and free of any potential hazards. 
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It is imperative to follow the assay manufacturer’s recommendation for the ambient 
temperature of areas where testing is performed. Where possible, testing should take 
place in climate-controlled areas. There must be proper waste disposal for biological 
(infectious and non-infectious), chemical and paper waste and sharps. 
Facilities should be organized to protect the confidentiality of clients, including 
a separate waiting room for those requiring additional testing, as how long a 
person stays in the same waiting room or how often a person leaves and returns 
may imply the result of their first assay (A1). 
It is critical to guard against harm to any client, HIV testing provider or other person at 
the testing site. This means that a safe working environment must be maintained by 
and for all staff, with necessary procedures in place. These procedures include universal 
precautions (assuming that all specimens are potentially infectious), prevention of 
and/or response to needle-stick injuries or other occupational exposures, chemical and 
biological safety, spill containment, waste disposal and use of personal protective 
equipment.
For HIV testing that takes place outside of a facility, programmes must ensure 
that the providers can conduct the testing without hazard to themselves or to the 
clients. Providers must observe universal precautions and appropriate waste 
disposal procedures. In addition, providers must make all efforts to protect 
clients’ confidentiality and privacy.
How to implement
•	 All staff should be trained on biological and chemical safety measures. 
•	 One staff member at each testing site should act as a safety champion. 
8.4 Quality improvement for HIV testing 
Quality assurance is not a once-and-done occurrence. Testing providers and managers 
must continually monitor and evaluate their programme and improve the quality of 
services. To maintain a coherent, functioning quality management system that addresses 
national, subnational, facility and community concerns, all stakeholders must be 
involved at every level to monitor quality and make improvements. Middle- and low-
income countries have applied a range of QI methods in health care over the past two 
decades. Deciding which method to use for HTS will depend on the country context, the 
commitment of policy-makers and programme managers and the complexity of the 
problems that need to be addressed. 
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       Key PoINTS 
•	 In light of the individual and public health benefits of widely available ART, WHO and 
UNAIDS recommend that countries work toward enabling all participants in biological 
surveillance to receive their HIV status.
•	Key populations and vulnerable groups should be prioritized in HIV surveillance 
activities. In generalized epidemics additional periodic national population-based surveys 
are recommended. 
•	HIV surveillance activities that issue results back to participants should use the same 
testing strategies (tailored to HIV prevalence) and testing algorithms as used for 
HIV diagnosis (see Chapter 7).
•	HIV surveillance systems should use programmatic data whenever possible, 
particularly data from PMTCT programmes and HIV diagnosis.
•	HIV surveillance activities are encouraged to collaborate with biological surveillance 
activities for other, overlapping epidemics such as TB, STIs and viral hepatitis. This 
collaboration expands monitoring and enhances the efficiency of the HIV response. 
•	Providers of HTS are encouraged to participate in HIV case reporting, which should 
be part of a country’s national HIV surveillance system. Case reporting data are used to 
assess the number of people in need of treatment and care and to inform the planning 
and allocation of resources.
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9 HIV TESTING IN THE CoNTExT of 
SuRVEIllaNCE   
9.1 overview 
The surveillance of HIV is essential for monitoring epidemic trends and evaluating the 
effectiveness of a country’s response. HIV sentinel surveillance and population-based 
and community surveys that include HIV testing are important components of HIV 
surveillance. They are used to estimate the prevalence and geographical distribution of 
infection, identify and characterize key populations at risk for HIV infection and track 
trends over time. Countries need these data to inform effective policies, strategic plans 
and programmes and to set evidence-based programme targets. 
HIV testing is a component of HIV surveillance. The type of testing strategy and 
algorithm applied affects biological surveillance results. This chapter updates previously 
published WHO/UNAIDS guidelines for HIV testing in the context of surveillance, last 
revised in 2009 (http://www.who.int/hiv/pub/surveillance/hiv_testing_technologies_
surveillance.pdf) (267). Advances in HIV testing, treatment and care have prompted this 
update. In particular, the wide availability of treatment, increasing evidence of the 
patient-level and public health benefits of treatment and an unmet demand for HIV 
testing have propelled a move away from surveillance using unlinked anonymous testing 
(UAT), in which remnant specimens that cannot be linked back to the study participant 
are tested for HIV. In the current context the use of UAT raises ethical concerns (268–
270). In addition, opportunities to use leftover specimens from testing for other analytes 
(infections) for HIV biological surveillance are diminishing, as RDTs are more commonly 
being used, which leave no remnant specimen. 
As HIV programmes evolve, countries increasingly want to use programme data to 
complement or to replace data generated from sentinel sites. ANC clinics with PMTCT 
services, in particular, may seek to use programme data in place of conducting annual 
sentinel surveys. As biological surveillance is not the primary purpose of testing in 
programmes, any use of these data requires a thorough assessment of the potential 
impact that a transition from HIV sentinel surveillance to the use of programmatic data 
may have on national estimates, given the potential bias introduced by a different 
sampling frame.
The aim of this chapter is to help countries with different epidemic contexts (generalized or 
concentrated) and populations to adopt an appropriate approach to HIV testing in the 
context of biological surveillance (99, 271–274). The chapter provides technical information 
for providing HTS and for HIV surveillance systems in the following areas: (1) populations 
selected for biological surveillance; (2) approaches for HIV testing in the context of 
surveillance; (3) the use of programme data for biological surveillance; and (4) HIV case 
reporting. 
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With an extensive consultative and review process by international experts and WHO 
regional offices, the UNAIDS/WHO Working Group on Global HIV/AIDS/STI Surveillance 
developed, reviewed and revised the guidance included in this chapter. 
9.2 Populations selected for biological surveillance
The populations selected for HIV biological surveillance depend on the state of the 
epidemic. For low-level and concentrated epidemics, HIV infection is mainly confined to 
key populations, as well as context-specific subgroups. Key populations include men who 
have sex with men, people in prisons or other closed settings, people who inject drugs, 
sex workers and transgender people. Other groups at high risk for HIV, depending on 
country context, may include: long-distance truck drivers, military personnel, and in 
sub-Saharan Africa young women. Children and adolescents from key populations and 
vulnerable groups are at increased risk for HIV, and their inclusion in surveillance is 
important. Countries must take into account, however, domestic laws governing child 
protection in addition to ethical considerations for conducting research among children. 
UNICEF provides further guidance on these issues (275). Surveillance activities among 
key groups must not place new burdens on these populations and must undergo 
appropriate ethical review (273, 276). Specific guidance has been developed to ensure 
that surveillance adequately covers these populations, as these populations are often 
underserved and their access to HTS is often insufficient (277). 
In generalized epidemics, where HIV transmission is established among the general 
population, national population-based biological surveys are used to obtain estimates of 
HIV prevalence (272). Additionally, sentinel surveillance may be conducted among 
attendees (pregnant women) in ANC services (271). It is recommended that programmes 
shift from using ANC surveillance data to PMTCT data. For further information, see 
section 9.5 and Guidelines for assessing the utility of data from prevention of mother-to-
child transmission (http://who.int/hiv/pub/surveillance/2013package/module3/en/).
In some regions HIV presents a significant challenge to the control of TB and, likewise, 
TB is a major burden among people with HIV. HIV testing for biological surveillance 
should include people with diagnosed or presumed TB and, where feasible and 
appropriate, HIV biological surveillance should incorporate TB screening as routine 
practice among those found to be HIV-positive (278). 
HIV testing for surveillance should also include people at risk of other STIs, including 
HCV and HBV infections. The management of infections diagnosed as part of HIV 
surveillance should follow WHO guidelines (279–282). 
Given the overlap of the HIV and TB epidemics, and the shared risk factors for HIV, STIs, 
HCV and HBV infections, countries should seize any opportunity to integrate biological 
surveillance activities. This integration can both expand epidemic monitoring and 
response and enhance efficiency. For all these closely linked diseases, WHO recommends 
that HIV biological surveillance activities adopt a collaborative approach to maximize the 
return on investment and meet programme objectives (279, 283). 
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wHo recommendations
•	 HIV surveillance should prioritize key populations as well as other vulnerable 
groups.
•	 Biological surveillance should be conducted among people with presumed or 
diagnosed TB or at high risk for other STIs, including HBV and HCV infections. 
•	 WHO recommends a collaborative approach to surveillance of HIV and closely 
linked infections to expand epidemic monitoring and response and enhance 
efficiency. Any of these infections that are diagnosed as part of HIV surveillance 
activities should be managed according to WHO guidelines.
•	 It is recommended that programmes move from using ANC surveillance data to 
PMTCT programmatic data. However, WHO still recommends regular, national 
population-based surveys and sentinel surveillance among ANC clinics in 
countries with generalized epidemics. 
•	 WHO recommends that surveillance systems use the same testing strategy 
(tailored to HIV prevalence; see Chapter 7) and the validated national testing 
algorithm recommended for HIV diagnosis. This is particularly critical when test 
results and an HIV status are reported back to an individual. 
Sources: UNAIDS/WHO, 2003 (271); UNAIDS/WHO, 2005 (272); UNAIDS/WHO, 2011 (273); WHO, 2013 (274); 
UNICEF, 2013 (275), WHO, 2013 (275); UNAIDS/WHO, 2015 (277); WHO, 2012 (278); UNAIDS/WHO, 1999 
(279); WHO, 2003 (280); WHO, 2003 (281); WHO, 2015 (282); UNAIDS/WHO, 2004 (283); WHO, 2014 (284).
Case examples: Test result discrepancies between surveillance and 
programmatic data in antenatal care services 
Across nine countries with generalized HIV epidemics, substantial discrepancies 
in HIV test result were reported between on-site PMTCT diagnostic testing and 
central-level testing done for ANC sentinel surveillance. The reasons for these 
discrepancies are unknown. Discrepant results may be caused by suboptimal 
stock management, operation or interpretation of field-based HIV rapid tests or 
suboptimal operation or interpretation of laboratory-based EIA tests. Suboptimal 
testing strategies and algorithms for surveillance and diagnosis may be one factor 
contributing to the difference in test results. To prevent such discrepancies, it is 
important not only to monitor and improve the quality of diagnostic and 
surveillance testing, but also to encourage programmes and countries to use a 
testing strategy and a validated national testing algorithm that are suitable for 
both HIV diagnosis and biological surveillance. 
Source: CDC, unpublished, 2014.
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9.3 Returning HIV test results to participants in biological 
surveillance
In the past HIV surveys that collected biomarkers typically did not return test results to 
study participants. The 2009 WHO guidance on ethical principles in HIV surveillance 
stated that participants in surveillance must be given the opportunity to learn their 
status (276). At a September 2014 WHO/UNAIDS global meeting to update the Guidelines 
for using HIV testing technologies in surveillance, the group further discussed ethical 
considerations concerning returning HIV status to participants in surveys. 
The group reached consensus on the importance of surveillance systems' assuring that 
all participants receive their HIV status and that this should be prioritized in any 
biological surveillance activity. At the same time, all efforts must be made to prevent 
any adverse consequences of informing participants of their status, especially in surveys 
that collect biomarkers among marginalized or criminalized populations. Any 
consideration of potential additional costs should factor in returns in life-years saved due 
to earlier diagnosis and treatment.
Details on the meeting discussion and conclusions can be found in Routine feedback of 
test results to participants in HIV clinic-based surveillance and surveillance surveys: 
WHO and UNAIDS meeting on HIV testing in surveillance (268).
wHo recommendation
HIV surveillance systems should work toward assuring that all participants in 
biological surveillance receive their HIV status to further facilitate appropriate 
linkage to care. However, all efforts must be made to prevent any adverse 
consequences of informing participants of their HIV status, especially in surveys 
among marginalized and criminalized populations. 
Sources: WHO/UNAIDS (276); Baggaley et al., 2015 (268). 
9.4 approaches for HIV testing in the context of surveillance
Linked testing is the HIV testing approach used in surveillance that enables 
participants to receive their HIV status. Linked testing can be confidential (using 
personally identifiable information) or anonymous (using only a code or number as a 
unique identifier). This approach contrasts with unlinked anonymous surveillance, 
which is no longer recommended. With linked HIV testing, the participants should 
receive pre-test information and post-test counselling as well as their test results and 
their HIV status (see Chapter 3). Chapter 7 provides details on HIV testing strategies and 
algorithms for linked testing. 
In linked confidential testing, the participants agree to be tested for HIV with the 
assurance that their HIV status will remain confidential and will be available only to the 
participant and, on a need-to-know basis, to health-care staff. As with all HIV testing, 
the staff member must obtain the participant’s consent before collecting the specimen 
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and conducting HIV testing (see box). The consent process must inform the person how 
the data are to be used, including security details of any registry where the data are 
maintained. The staff member collects the demographic details of the participant (for 
example, age, sex, marital status, geographical area of residence, parity, education and 
medical history) at the time the specimen is obtained and records this information on a 
surveillance form (either paper or electronic). The surveillance form should be indexed 
with an identifying code or other details (for example, the participant’s name or the 
clinic’s client/patient identification number) that can be used to match the form to the 
specimen. On completion of HIV testing, the demographic details collected on the 
surveillance form are linked to the result. 
Consenting to HIV testing for biological surveillance
Informed consent is an essential part of HIV testing, including testing for surveillance. 
Consent should always be obtained individually and in private. To give informed 
consent, the participant must have an adequate understanding of the HIV testing 
process. Health workers should ensure that no one is coerced into testing, and 
participants must understand that they have the right to opt out at any point. 
Under no circumstance should HIV testing be mandatory. See Chapter 3 for details 
on obtaining consent for HIV testing.
In linked anonymous testing only the participant with knowledge of his or her unique 
study code can link himself or herself to the test result when provided with a list of 
results and study codes. The same methods are used for collecting and processing the 
specimen as for linked confidential testing, except that the specimen is labelled with an 
anonymous, unique study code. No personally identifiable information should be 
recorded. With this approach it is important not to collect too much information, which 
could identify the client through a combination of their characteristics. It is not possible 
to add participants in anonymous linked testing to a registry. 
The variables to be collected for biological surveillance should be listed clearly on 
standardized surveillance forms. These variables may include results of other tests 
related to the HIV diagnosis (for example, CD4 cell count and viral load), results of tests 
for recent HIV infection, any STI diagnoses or diagnoses of co-morbidities including TB 
and information on previous use or exposure to ARVs. Which variables to include will 
depend on the setting, collaboration with other programmes and the intended outputs 
of biological surveillance.
The choice of confidential or anonymous linked testing will depend on the setting and the 
population to be surveyed. Linked anonymous testing may be preferred by surveillance 
system staff for hard-to-reach or marginalized populations, as participants may not want 
personally identifiable information to be linked to information on their risk behaviours, 
which may be stigmatized (for example, same-sex sexual partners). Confidential testing 
has the advantage of enabling health workers to refer positive participants to care 
promptly. However, confidential testing could introduce participation bias if the request for 
personally identifiable information deters people from participating.
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wHo recommendations
Linked HIV testing approach for biological surveillance 
•	 A linked HIV testing approach for biological surveillance, either confidential 
(using personally identifiable information) or anonymous (using unique study 
codes) should be used. This allows test results to be readily accessible to the 
survey participant, either during the study period or at a later date.
Source: UNAIDS/WHO, 2014 (285).
•	 Increasingly, countries are attempting to measure HIV incidence – the rate of 
new infections – through surveys that collect biomarkers, using assays that can 
distinguish recently acquired infections from established ones. Currently, these 
HIV incidence assays are intended only for population-level incidence estimates 
and not for individual disease staging, as they are not sufficiently accurate. 
Consequently, returning these test results to participants is not recommended. 
Sources: UNAIDS/WHO, 2011 (286); UNAIDS/WHO, 2015 (287); UNAIDS/WHO, 2015 (288).
9.5 using PmTCT programme data to replace aNC sentinel 
surveillance data
With the expansion of HIV testing, PMTCT services, and HIV prevention, treatment and 
care services, there are increasing opportunities to use data from HIV programmes along 
with or in place of HIV sentinel biological surveillance. In particular, as PMTCT programmes 
expand and evolve, the data that they routinely collect are increasingly robust and may be 
able to provide the same information as that collected through ANC surveys. PMTCT sites 
that endeavour to use routine programme data for surveillance should be high-performing, 
meeting the following criteria:
•	 high coverage of services, that is, >80% of the pregnant women in the population to be 
surveyed use these services;
•	 high data quality; for example, sites use routine data collection tools, collect all the 
variables needed for surveillance outputs and have high data completion rates (>90%);
•	 high uptake of HIV testing (>90%);
•	 high quality of HIV testing, supported by a quality management system (see Chapter 8).
HIV surveillance systems must assess the suitability of programme data for biological 
surveillance before using them. In PMTCT settings, for example, this assessment involves 
evaluating the likely impact of switching from ANC sentinel data to programme data on 
surveillance outputs; this can be assessed by comparing HIV prevalence estimates based 
on both PMTCT programme and ANC sentinel data. Any differences should be investigated 
to determine likely sources of error, which could be in record-keeping or in conducting 
assays, including interpretation of test results or using a different testing strategy and/or 
algorithm. Any differences in the populations included in the survey and programme data 
should also be examined.
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Further guidance on methods for conducting this assessment in PMTCT sites can be 
found in WHO guidelines for assessing the utility of data from PMTCT programmes for 
surveillance among pregnant women (192). Detailed guidance on conducting ANC 
surveillance using PMTCT data can be found in Conducting HIV surveillance among 
pregnant women attending antenatal clinics based on routine prevention of mother-to-
child transmission of HIV (PMTCT) programme data (289).
Advantages of using PMTCT programme data for biological surveillance include: 
•	 Ideally, HIV-testing is undertaken as part of routine clinical practice.
•	 Participants have the choice and opportunity to opt out of testing.
•	 Participants receive their HIV status.
•	 HIV testing is conducted in a setting where the infrastructure and resources for pre-test 
information and post-test counselling already exist.
•	 Ideally, HIV-positive participants can be linked to HIV treatment and care services.
•	 HIV-negative participants with ongoing high risk of infection can be linked to HIV 
prevention services. 
•	 HIV testing and the collection of demographic data are already being performed at 
these sites. 
•	 Geographical coverage is broader, sample sizes are larger, and the surveillance period is 
longer. 
•	 Data are collected annually.
Limitations of using PMTCT programme data for biological surveillance include: 
•	 There is potential participation bias:
– People obtaining HTS may not be representative of the larger population. For 
example, key groups may be underrepresented or overrepresented depending on the 
setting, or certain groups may not use health-care services.
– People may opt out of HIV testing in a non-random pattern.
•	 Data quality is lower or varies among sites. 
•	 The quality of HIV testing may differ among sites. 
•	 Historical trend data are lacking.
The records of people testing as part of HIV programmes contain personally identifiable 
information (for example, client/patient identifier, name, date of birth, place or area of 
residence, clinic number) and sensitive medical data (for example, the results of medical 
testing, including HIV testing). Thus, to ensure confidentiality, the information needed 
for surveillance should be recorded onto specific surveillance forms without any 
identifiers. Unique study codes can be used to index surveillance participants’ details 
(see section 9.3). In some instances, however, personally identifiable information may be 
needed for surveillance data processing, for example, to identify duplicates or to match 
records to other data (such as an HIV laboratory logbook or testing register) in order to 
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complete the surveillance dataset. In these circumstances the personally identifiable 
information should be permanently removed once the final dataset has been created. 
Data from HIV testing records may be transferred to surveillance forms either manually 
or electronically. When it is done manually, a person on site copies data from routine 
data tools (for example, registers) onto paper or electronic forms (for example, using 
computers, tablets or other digital devices). When it is done electronically, the site may 
elect to send a digital image of the data (such as a scan or photo) to a central location 
for data management. If routine data are captured as a digital image, personally 
identifying information can be excluded by physically covering this information before 
making the digital image. Data security and confidentiality must be ensured throughout 
this process. 
WHO provides further guidance on data confidentiality in Guiding principles on ethical 
issues in HIV surveillance (276). UNAIDS provides guidance on maintaining health 
identifiers and confidentiality in Considerations and guidance for countries adopting 
national health identifiers (290).
9.6 HIV case reporting
WHO recommends that HIV case reporting form part of a comprehensive national HIV 
surveillance system (274). HIV case-based surveillance entails reporting all new HIV 
diagnoses (including those diagnosed at death) to a designated central monitoring body. 
Information collected for case reporting should include the clinical stage of the infection, 
demographic characteristics of the client (for example, sex, age, risk group), date of 
diagnosis, place of diagnosis and the date and source of the report. Other information 
collected may include results of routine baseline testing, such as measures of CD4 cell 
count and viral load, or the results of a biomarker test for recent HIV infection. 
Programmes must use the validated national testing algorithm for all HIV case reports 
(see Chapter 7).
Countries that undertake case reporting should provide HTS with protocols detailing how 
and where to report a diagnosis. Requirements for the confidentiality and security of 
case reporting data are the same as described in section 9.3. Where case reporting 
systems retain identifiers to aid in deduplication, enhanced data security may be needed. 
Deduplication is essential to any case reporting system. Systems that do not 
collect names must use a client/patient identification system, which will allow 
deduplication. Using a Soundex code, which is created by an indexing system for names, 
wHo recommendation
HIV case reporting should form part of a comprehensive national HIV 
surveillance system. This entails the reporting of all new HIV diagnoses to a 
designated central monitoring body by HTS providers. Deduplication of case 
reports is essential to any case reporting system.  
Sources: WHO, 2006 (292); UNAIDS/WHO, 2011 (293); UNAIDS/WHO, 2013 (274).
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may be an alternative to using a name (291). A Soundex code can be used alongside 
other demographic information to generate unique identifiers of records. 
Further guidance on the definition of a case and on clinical staging for surveillance 
purposes can be found in WHO case definitions of HIV for surveillance and revised 
clinical staging and immunological classification of HIV-related disease in adults and 
children (292).
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       Key PoINTS 
•	Monitoring and evaluation of HTS has expanded from measuring numbers such as the 
number of people tested to measure HTS effectiveness and outcomes. The focus is 
on the proportion of people with HIV who know their status, particularly among those at 
highest risk, including people from key populations. 
•	 In most settings key population-specific data cannot be collected from routine 
programme monitoring; therefore, WHO recommends investing in special surveys in 
addition to strengthening routine surveillance. 
•	Analysing the proportion of people diagnosed HIV-positive by type of site is critical for 
determining where national programmes should allocate resources. HTS programmes 
should ensure a good balance between facility and community outreach testing 
strategies.
•	 In addition to attaining high coverage rates and identifying a high proportion of HIV-
positive cases, the quality of HTS depends on accurate diagnosis and effective linkage 
to HIV prevention, treatment and care services. It is important to document SOPs, QC 
results and results of EQA (such as proficiency testing) and to monitor and measure 
linkage to prevention, treatment and care. Linkage of clients to HIV prevention, treatment 
and care services is a key measure of HTS. 
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10.1 Background and key issues
Depending on epidemiological and social context, as well as available resources, 
countries can utilize multiple HTS approaches. Using strategic information, programmes 
can tailor service delivery approaches to maximize HTS coverage and uptake and so 
diagnose more people with HIV. Disaggregating 
service statistics by HIV diagnosis, by service 
delivery point and/or by population subgroups 
can help countries set targets for HTS and better 
link and align HTS with enrolment in prevention, 
treatment, care and support services (44). 
Adjusting for retesting in HTS coverage estimates. There are three different type of 
retesting that WHO recommends within HIV programmes: (1) retesting people at 
on-going risk for HIV infection (for example, retesting pregnant women in settings of 
high HIV incidence/prevalence in their third trimester and in the breastfeeding/postnatal 
period, and retesting among populations at high ongoing risk for HIV infection, for 
example, key populations, at least annually); (2) retesting people with HIV-inconclusive 
test results; and (3) retesting to verify HIV-positive diagnosis before initiating care 
and/or ART (10, 12). Several HTS indicators are more meaningful as measures of access 
and coverage if they count the number of individuals who have been tested rather than 
the number of tests performed. When using routinely collected programme data to 
determine coverage, counting unique individuals over the period of a year as well as 
across many potential HTS sites can be challenging. Using unique client identifiers for 
individuals is one way to keep track of retesting and avoid double reporting, if electronic 
systems are available to easily link data through these unique client identifiers. Another 
approach is to record information about prior testing in the HIV testing register. Then, 
repeat testing and retesting can be counted and subtracted from the total number of 
tests performed for the same individual. Population-based surveys asking if a person has 
ever tested for HIV are another method that minimizes risk of double-counting people 
who retest. Surveys are particularly helpful to determine testing coverage among 
hard-to-reach populations. For most settings WHO recommends investing in surveys to 
estimate service use that are representative and appropriately powered (277). 
Handling disaggregation by several variables. Disaggregation of HTS data at the 
national level is important to ensure that critical populations are accessing HTS (see 
box). The optimal examination of HTS strategic information requires simultaneously 
disaggregating service statistics by multiple dimensions, such as numbers of individuals 
tested by age, sex, test result, diagnosis (HIV-positive or HIV-negative), service delivery 
point and key population status. Computers can make such multiple disaggregations 
fairly easy, but tabulating these figures from paper-based registers is time-consuming. 
Disaggregating service statistics can 
help countries set targets for HTS 
and better link and align HTS with 
enrolment in prevention, treatment, 
care and support services.
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Special efforts are needed to design paper-based tools that support disaggregation of 
these data without placing an undue burden on those responsible for collecting and 
analysing the information. 
Categories to consider for disaggregation of variables
Below is a list of variables to be considered for disaggregating HTS data 
depending on strategic information analysis and intended use of the information: 
•	 Age: <1, 1−9, 10−14, 15–19, 20−24, 25−49, 50+
•	 Sex: male, female, transgender
•	 Test result: HIV-positive, HIV-negative, inconclusive, unknown (not confirmed)
•	 Population: pregnant or breastfeeding women, partners, key populations (men 
who have sex with men, people in prisons and other closed settings, people who 
inject drugs, sex workers, transgender people), serodiscordant couples, infants 
and children, adolescents, TB clients/patients, hepatitis patients
•	 Geographic area: district, region, province, facility, other
•	 Service delivery point: 
– facility-based, for example, ANC clinics, outpatient care, inpatient care, TB 
clinics, STI clinics, HTS clinics, integrated HTS
– community-based, for example, home-based, door-to-door, mobile outreach
– other, for example, HIV self-testing 
•	 Retesting status: new testers, type of retesters (HIV-negative at on-going risk; 
retester after discrepant result (HIV-inconclusive); retester (HIV-positive) to 
verify diagnosis before starting ART)
•	 CD4 count at diagnosis, where CD4 testing is routinely available: <200; 
200−349; 350−500; >500 cells/mm3.
10.2 Selection and use of indicators
Monitoring and evaluation of HTS has expanded and evolved from measuring coverage 
in terms of the number of tests performed to measuring knowledge of HIV status among 
different populations and estimating the proportion of people with HIV who know their 
status. There is increasing focus on determining what populations are underserved by 
HTS as well as how programmes can engage people from populations at highest risk 
who do not know their HIV status. 
Thus, the increased effectiveness of HTS is measured not only in terms of the number of 
people tested for HIV but also more people knowing their status, particularly those with 
HIV and those at highest risk. The most critical outcome indicator is the number and 
proportion of people with HIV who are aware of their status (indicator HTS.1; see Table 
10.1). This indicator reports on the first 90 of the 90–90–90 programme target – that is, 
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that 90% of people with HIV are diagnosed. This information might be obtained from 
representative sample surveys. Other indicators, based on programme data or special 
surveys, also can help assess and guide a country’s testing strategy by measuring the 
proportion who know their status among specific priority groups – pregnant women and 
key populations, for example. More efforts to measure these populations are needed, 
especially where new HIV infections are common in these groups. 
As for priority populations, people with HIV who are already receiving services for other 
reasons (for example, pregnancy or TB) are more accessible for HIV testing, and their 
data are relatively easily captured. In contrast, data are scarce on the proportions of key 
populations and adolescents with HIV who are aware of their status. More efforts to 
measure these populations are needed, especially where new HIV infections are common 
in these groups. It may also be useful to track knowledge of HIV status in populations 
that are eligible for ART regardless of CD4 count, as recommended in WHO’s 
consolidated ART guidelines (13). 
HIV testing is the gateway to the 
HIV services cascade. Thus, the 
strength of linkages to prevention 
and care services should be 
measured.
In addition to attaining high coverage rates, the 
quality of HTS depends on accurate diagnosis and 
effective linkage to HIV prevention, treatment and 
care services. The monitoring of HTS quality starts 
with the review of national testing policies and 
standards, the quality of test kits and testing 
strategies/testing algorithms being used, the 
accuracy of diagnoses and the quality of counselling and referrals provided. Also, the 
laboratory-based aspects of HTS need to demonstrate quality, as measured through 
documentation, SOPs, QC results, and the results of external quality assessments (such 
as proficiency testing). As HIV testing is the gateway to the HIV services cascade, the 
strength of linkages to prevention and care services should be measured (95). Finally, 
monitoring should assess the alignment of HTS policies, programmes and practices with 
human rights norms and standards, especially in HTS services for key populations.
Analysing HTS coverage and quality data further, by type of site, is critical for 
determining where national programmes should allocate resources. As described in 
Chapter 6, site-specific coverage data can be compared with epidemiologic information 
about the site’s catchment area or intended clientele to gauge how resources might need 
to be reallocated to match coverage with need. 
A full listing and descriptions of WHO-recommended indicators for HTS appear in 
Consolidated strategic information guidelines for HIV in the health sector (www.who.int/
hiv/topics/me/en/). Reference sheets for these indicators appear in Annex 13.
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Case example: Testing changes to strengthen linkage to care, ministry of 
Health uganda 
Quality improvement requires the identification of relevant and specific 
interventions followed by a tracking period to determine which are most 
successful at resolving the issues identified. Uganda adopted this approach to 
improve linkage and enrolment from HTS into care and treatment. 
In Uganda people diagnosed HIV-positive are linked to care and treatment within 
the facility or at other facilities based on clients’ preferences. Staff members who 
conduct PITC at three health facilities in Uganda proposed several interventions 
that could be implemented in facilities to improve linkage to care. These included: 
(1) changing the HIV testing point from the laboratory to a designated room, 
(2) visual reminders for staff to update HTS registers, (3) slips to refer newly 
diagnosed clients to the ART clinic, (4) providing HIV-positive peer escorts to the 
ART clinic, (5) enrolling HIV-positive clients into care on the same day.
When assessed, two of the five interventions – peer escorts and same-day 
enrolment – proved to significantly improve linkage. When these improvements 
were introduced, the percentage of HIV-positive clients linked to care rose from 
58% in August 2013 to 89% in April 2014. 
Source: Annex 3.
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